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Abstract 
Enhanced Antibody and Glycomics-Based Approaches for the Detection of Prostate 
Cancer 
Sarah Gilgunn 
 
Prostate Cancer (PCa) is one of the leading medical issues faced by men worldwide and is the 
most prevalent cancer diagnosed in men in both Europe and the United States. The vast 
majority of current literature concerning PCa diagnosis concludes that better PCa markers are 
needed to reduce over-diagnosis of low risk disease and widespread over-treatment.  
The primary objective of this research entails the generation and characterisation of anti-
prostate specific antigen (PSA) isoform-specific recombinant antibody fragments. Selective 
screening of avian single chain antibody fragment (scFv) libraries was carried out for the 
isolation of high-affinity, anti-fPSA and anti-cPSA specific antibody fragments. These antibodies 
were kinetically evaluated using surface plasmon resonance-based instrumentation and 
incorporated into an enzyme-linked immunosorbent assay (ELISA) that can detect PSA in the 
ng/mL range. Anti-fPSA scFvB8 is a nanomolar affinity antibody fragment that contains highly 
conserved cysteine residues. High resolution X-ray crystallography of this antibody fragment 
and mutant variants was successfully carried out and revealed interesting structural attributes 
of avian antibody fragments.    
Glycan expression patterns change with the cellular modifications that accompany the onset of 
tumourigenesis. Hence, as a secondary objective, whole serum N-glycan profiling was carried 
out on 117 prostate cancer patient’s serum using a robotised, high-throughput analysis 
platform for glyco-profiling which utilises ultra-performance liquid chromatography (UPLC) to 
obtain high resolution separation of N-linked glycans released from serum. A specific glycomic 
signature identified from this analysis can distinguish between indolent and aggressive 
prostate cancer with high accuracy.  
The reagents generated and the results obtained from this body of work provide significant 
insight into antibody and glycomic-approaches that can potentially deliver the much sought 
after cancer-specific biomarker analysis for improved PCa diagnosis. 
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Chapter One 
Introduction 
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1.1 Thesis outline 
 
This body of work endeavours to address the clinically relevant issue of prostate cancer (PCa) 
diagnosis through antibody and glycomics-based techniques. There is an unmet need for better 
biomarkers to stratify patients into the most appropriate treatment option for their individual 
prostatic disease. While using prostate cancer as a target for the development of recombinant 
antibodies, the structural and glycomic attributes the avian immunoglobulin repertoire was 
explored, with the ultimate aim generating highly specific, sensitive antibodies for improved 
prostate cancer detection. It is anticipated that antibodies developed from this research will 
ultimately be transferred to a microfluidic-based platform for rapid, sensitive and specific 
diagnosis of prostate cancer.  In addition, an insight into glycomic-approaches that can 
potentially deliver the much sought after cancer-specific biomarker analysis for improved PCa 
diagnosis is critically assessed.  
1.2 Prostate cancer (PCa) 
 
Prostate cancer (PCa) is one of the leading medical issues faced by men worldwide and is the 
most prevalent cancer diagnosed in men in both Europe and the United States (Ferlay et al., 
2010; Siegal et al., 2012). Approximately 1 in 7 men will be diagnosed with PCa within their 
lifetime and this high prevalence brings with it health-related costs and mortality (American 
Cancer Society, 2015; Van der Broeck, 2014). Various risk factors for developing PCa include: 
age (risk increases with aging), family history (5% to 10% of PCa cases are believed to be 
primarily caused by inherited genetic factors or PCa susceptibility genes), race (African-
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American and African-Caribbean men are more at risk than other ethnic groups) and diet (high 
consumption of red meat and high-fat dairy products with low consumption of green 
vegetables may have a slightly higher chance of developing PCa) (Irish Cancer Society, 2015).   
More than 1.1 million cases of PCa were recorded worldwide in 2012, with a total of 68% of 
PCa cases occurring in more developed countries.  Ireland is ranked 10th in the world for PCa 
incidence, with over 3, 300 men diagnosed in Ireland each year (Irish Cancer Society, 2015; 
World Cancer Research Fund, 2015).   
PCa is generally considered as an adenocarcinoma or glandular cancer of the prostate gland 
which is located beneath the bladder near the rectal wall. This walnut-sized structure 
surrounds the urethra and plays an integral role in the male reproductive system (Figure 1.1). 
One of its principal functions is the production of prostate specific antigen (PSA), a protein 
which liquefies semen in the coagulum, permitting sperm motility. The development of solid 
tumours is a multi-step process in which successive genetic insults occur in a normal healthy 
cell, rendering it increasingly malignant over an extended period of time (Loeb et al., 1974). 
The tumour penetrates the capsule via the perineural and lymphatic channels to reach the 
periprostatic tissues of the gland (Tabares et al., 2006). However, the exact aetiology of the 
disease is unknown and the genetic and epigenetic modifications that lead to tumor 
development remain poorly understood (Holland, 2003). Some prostatic cancers present as an 
indolent disease with no clinical symptoms during the life-time of the patient, and in many 
cases, men die with the disease rather than from the disease. Autopsy results have suggested 
that 30% of men age >50 years and 70% of men >70 years have PCa (Kirk et al., 1997; Hoffman, 
2011). However, for some PCa patients the disease takes a much more aggressive route 
spreading into the seminal vesicles, bladder, and rectum and further metastasising to the 
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lymph nodes, bone and other organs (Bott, 2003). PCa is a heterogeneous disease and 
regardless of the manifestation, severely impacts a patient’s life.  
 
 
Figure 1.1: The prostate gland. The normal prostate (A) architecture becomes disrupted in prostate 
cancer (B) causing enlargement of the gland, in turn causing pain, difficulty in urinating and/or 
erectile dysfunction. A malignant tumor of the prostate is characterised by uncontrollable cell 
division and rapid growth of cancerous cells, which can invade nearby tissues. Figure adapted from 
Georgia Urology, 2015.  
1.3 Prostate cancer diagnosis 
 
The two principal methods used for detection of possible cancerous abnormalities of the 
prostate are the Digital Rectal Examination (DRE) and serum concentration of PSA (Heidenreich 
et al., 2011). Disruption of the prostate gland can cause PSA to escape into the blood stream 
and thus elevated levels of PSA are an indicator for the presence of PCa. Measurement of PSA 
levels in serum is routinely used for PCa diagnosis and monitoring disease progression (Lilja et 
al., 1987). Conversely, PSA levels can also rise as a result of Benign Prostate Hyperplasia (BPH) 
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and, hence, provides little or no insight into the biology of an individual’s prostatic disorder 
(Pinsky et al., 2006). Due to the lack of sensitivity and specificity (20% and 93%, respectively) 
the use of PSA alone as a biomarker for PCa remains a very controversial topic amongst 
clinicians and researchers (Thompson et al., 2005). The use of the PSA test in a routine, 
national prostate screening programme is not currently carried out in Ireland. The current 
costs of unregulated PSA testing in Ireland (and elsewhere) are poorly understood, but are 
likely to be substantial. The PICTure study is currently estimating the cost-effectiveness of PSA 
testing in Ireland (National Cancer Registry, 2015).  PSA levels circulating in blood range from 
<0.1 ng/mL in a normal healthy individual to 104 ng/mL in a PCa patient with advanced 
metastasised disease. Traditionally, a PSA level of 4 ng/mL or greater indicates the requirement 
for a biopsy (Lilja et al., 2008). Transrectal ultrasonography-guided biopsy is the preferred 
method to obtain prostate tissue for analysis (Heidenreich et al., 2011). Once detected, the 
tumor is clinically staged using the internationally recognised tumor-nodes-metastasis (TNM) 
staging system which endeavours to identify if the primary tumor remains confined to or has 
spread beyond the prostate. Another fundamental part of PCa diagnosis and classification is 
the use of the Gleason Grading system which describes the aggressiveness of the tumour 
(Gleason and Mellinger, 1974). The Gleason score is based on the glandular architecture of the 
tumour biopsy sample which is analysed by histopathologists and divided into 5 different 
patterns of growth and differentiation. The two most common patterns are given a grade in 
the range of 1 to 5, one being most differentiated or low grade and 5 being least differentiated 
or high grade. The grades are summed and given as the Gleason score, generally represented 
as 6 (3+3), where a higher score indicates a more aggressive tumour. To be counted, a pattern 
(grade) needs to occupy more than 5% of the tissue section, (Heidenreich et al., 2011; Gleason 
and Mellinger, 1974).  However, a biopsy sample represents only a proportion of the pathology 
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of the tissue of the prostate, and a Gleason score is an inaccurate measure of the level of 
aggressiveness across the entire tumour.   
Many prostate cancers are clinically insignificant, that is, the pathogenicity of the disease is 
insufficient to threaten the survival of the patient (Johnstone et al., 2007). The common 
occurrence of these cancers is one of the main challenges in PCa diagnosis and the clinical 
intervention taken. There is currently no methodology to allow a clinician to specifically 
distinguish between a potentially fatal and insignificant PCa. It is widely thought that PSA 
screening can lead to increased detection of insignificant diseases and over-diagnosis. PSA was 
approved by the Food and Drug Administration (FDA) in 1986, initially to monitor disease 
progression in men with PCa and later in 1994 for PCa detection and diagnosis (Mikolajczyk et 
al., 2004). The threshold of 4 ng/mL is frequently subjected to criticism, and lower 'cut-offs’ 
have subsequently been considered. Patients with a PSA level of between 4-10 ng/mL are said 
to be in the diagnostic grey zone, of which only 25% are found to have PCa. However, 
approximately 15% of patients with a serum PSA level of between 2-4 ng/mL and negative DRE 
have PCa (Hoffman, 2011). Conversely, reducing the 'cut-off' level, while detecting more cases 
of cancer (sensitivity), may result in a higher rate of false positives (specificity) (Thompson et 
al., 2005). Abnormal PSA tests lead to biopsies which result in pain, discomfort and stress to 
the patient. It is increasingly evident that a balance must be struck to weigh the harm from 
over-diagnosis against the benefit from early detection and treatment of potentially fatal PCa  
(Lilja et al., 2008; Vickers et al., 2012; Morgan et al., 2015).  
 
7 
 
1.4 Current approaches in PCa detection 
1.4.1 Biology of PSA 
 
Physiologically, PSA is synthesised by the prostate ductal and acinal epithelium. Upon secretion 
into the lumen, PSA proteolyses gel proteins of the seminal fluid such as semenogelin 1 and 
semenogelin 2 (SMEG 1 and SMEG 2) (Lilja 1985; Lilja et al., 1987). The normal prostate 
architecture confines PSA to the gland and only a minor fraction leaks into circulation. 
Elevation of serum PSA in PCa patients is not due to an increased expression of PSA but is 
considered to be as a result of disruption to the ductal lumen architecture and disordering of 
the basement membrane (Lilja et al., 2008). PSA is an androgen-regulated serine protease and 
is also known as hK3, as it is a member of the tissue kallikrein family (Young et al., 1992). 
Fifteen kallikrein members have been identified in humans and the encoding genes reside 
within 280kb of genomic DNA at chromosome 19q133-4 (Yousef et al., 1999). Within this 
family, PSA (hK3) is not the only prostate-specific kallikrein as hK2 and hK4 are also expressed 
in the prostate and appear to be androgen-regulated (Nelson et al., 1999; Yousef and 
Diamandis 2001).   
Circulating total PSA (tPSA) consists of many molecular forms, of which the most abundant 
form is complexed PSA (cPSA), which accounts for approximately 84% of tPSA (Lilja et al., 1991; 
Ozen and Sozen, 2006). Free PSA (fPSA) makes up the remaining 16% of circulating tPSA and 
includes various precursor isoforms of PSA (proPSA), benign PSA (BPSA) and inactive PSA (iPSA) 
(Nurmikko et al., 2001; Peter et al., 2001). The different isoforms of PSA and their synthesis are 
outlined in Figure 1.2.  PSA is initially translated as a pre-pro-polypeptide with a 17 amino acid 
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leader sequence that is co-translationally cleaved during passage through the secretory 
pathway (Lundwall and Lilja, 1987). This results in removal of the leader sequence yielding an 
enzymatically inactive 244 amino acid proPSA precursor protein, [-7]proPSA. Cleavage of 7 
amino acids at the N-terminal of proPSA generates the mature active protease consisting of 5 
intra-chain disulphide bonds, a single N-linked glycan, and has a molecular mass of 33kDa 
(Armbruster, 1993; Kumar et al., 1997). PSA is activated by hK2 as it cleaves proPSA between 
the arginine at position 7 and isoleucine at position 8, resulting in isoleucine as the N-terminal 
amino acid of the mature active PSA protein. Another member of the kallikrein family, hK4, 
was also shown to activate PSA (Lundwall and Lilja, 1987; Takayama et al., 1997; Balk et al., 
2003). Truncated forms of proPSA are also generated by cleavage within the propeptide. 
Isoforms with leader peptide variants of 1, 2, 4 and 5 amino acids, ([-1]proPSA, [-2]proPSA, [-
4]proPSA and [-5]proPSA, respectively) have been identified (Peter et al., 2001; Mikolajczyk et 
al., 1997).  
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Figure 1.2: Biosynthesis of PSA. PSA is synthesised as a 261 amino acid prepropeptide, that is co-
translationally cleaved in the cell to generate [-7]proPSA, an inactive precursor protein. Cleavage 
within the propeptide yields inactive truncated variants. In the lumen, hK2 acts as the major activating 
enzyme, cleaving the propeptide into a 237 amino acid active protein. Additional isoforms are cleaved 
at specific sites generating BPSA and iPSA. The majority of mature active PSA that enters into 
circulation rapidly binds to protease inhibitors, primarily α1-antichymotrypsin (ACT) and the rest of the 
unbound forms circulate as free PSA. cPSA = complexed prostate specific antigen; iPSA = inactive 
prostate specific antigen, BPSA = benign prostate specific antigen (Taken from Gilgunn et al., 2013).  
1.4.2 Improving PSA specificity for PCa diagnosis 
 
From its initial introduction in 1986 PSA revolutionised oncology testing, yet its clinical 
specificity is questionable. Currently the gold standard PSA test is complemented with 
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parameters such as PSA-isoform specific tests, PSA kinetics and PSA density. From an 
increased, comprehensive, understanding of the molecular subforms of PSA, the specificity and 
sensitivity of PSA as a diagnostic tool has improved markedly. 
1.4.2.1 Exploring the ratio of free PSA (fPSA) to total PSA (tPSA) 
 
Early investigations examined molecular forms of PSA to enhance specificity of the test. 
Christensson and co-workers (1993) demonstrated that in proportion to tPSA, fPSA is 
significantly lower in PCa than in BPH patients (Christensson et al., 1993). In current clinical 
practice, patients in the ‘diagnostic grey zone’ are screened for percentage fPSA. A cut-off of 
≤25% fPSA can detect 95% of PCa cases, reducing the number of unnecessary biopsies for 
patients in the 4-10 ng/mL range, and is now established as the criterion for biopsy (Catalona 
et al., 1998). However, diagnostic use of % fPSA is prone to false negatives and many other 
factors influence its reliability including prostate volume, assay variation and specimen 
handling (Ozen and Sozen, 2006). The fPSA assay measures all forms of fPSA, thus further 
investigations into molecular subforms of fPSA were explored to ascertain if different isoforms 
are more significantly correlated with specific aspects of either PCa or BPH (Nurmikko et al., 
2001; Mikolajczyk et al., 2002).   
1.4.2.2 proPSA – The cancer-specific isoform 
 
Mikolajczyk and co-workers (1997) identified proPSA as the major constituent of fPSA. The 
propeptide contains 4 amino acids instead of the normally expressed 7 amino acids and was 
the first of the truncated variants identified in serum (Mikolajczyk et al., 1997). Later, Peter and 
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colleagues (2001) demonstrated that there is a mixture of pro-PSA forms in PCa sera, namely [-
1], [-2], [-4], [-5] and [-7] proPSA, all of which are truncated at various points at the N-terminus 
(Peter et al., 2001). Several studies have illustrated proPSA as a cancer-specific isoform and 
highlighted the proPSA forms [-2] and [-4] as particularly relevant for detection of PCa. In fact [-
2] proPSA was correlated with more aggressive cancer (Mikolajczyk et al., 2001; Catalona et al., 
2004; Sokoll et al., 2010). The distinct biochemical properties of [-2] and [-4] proPSA resulted in 
both being considered  as more stable in cancerous tissues as they cannot be converted to 
mature PSA by hK2 (Mikolajczyk and Rittenhouse, 2003). In a recent large clinical study, 
Catalona and co-workers (2011) evaluated [-2] proPSA in combination with fPSA and PSA for 
PCa detection in the 2-10 ng/mL PSA range for men over 50 years old. They developed a 
mathematical formula, the prostate health index, phi = [-2]proPSA/fPSA ×PSA1/2 to enhance 
specificity for detecting aggressive disease. The results showed greater sensitivity and 
specificity for the phi test than PSA and %fPSA. This test is FDA approved and is now 
commercially available in the U.S., Europe and Australia (Catalona et al., 2011; Loeb et al., 
2015). 
The U.S. Preventive Services Task Force (USPSTF) published a report in 2012 illustrating the 
urgent need to identify novel screening tools that can better identify indolent vs aggressive 
disease. In an attempt to address this issue, Loeb and colleagues (2015) included 658 men in a 
study to determine if phi improves the detection of clinically significant PCa.  The authors 
compared the performance of PSA, %fPSA, [-2]proPSA and phi to predict biopsy results and the 
presence of clinically significant PCa. The results showed that the use of a phi score with a cut-
off of 28.6 could potentially avoid approximately 30% of biopsies in men with benign or 
insignificant disease. The conclusion reached from this study was the phi test may be useful as 
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part of a multivariable approach to reduce prostate biopsies, thus limiting over diagnosis (Loeb 
et al., 2015). 
1.4.2.3 BPSA- specific for BPH diagnosis 
 
Benign PSA is a distinct inactive form of PSA in which internal degradation at residues Arg85-
Phe86, Lys145-Lys146 and Lys182-Ser183 occurs (Zhang and Leinonen, 1995). BPSA is found 
predominantly in the transition zone of patients with BPH (Mikolajczyk et al., 2000) hence 
BPSA and proPSA are often said to be the ‘yin and yang’ forms of fPSA (Mikolajczyk and 
Rittenhouse, 2003).  BPSA is postulated to arise from post translational cleavages by specific 
proteases in the hyperplasic tissue of BPH patients (Mikolajczyk et al., 2004). Linton and co-
workers (2003) developed an immunoassay that employed anti-BPSA antibodies specific for 
the internal Lys182 cleavage site. Results from this study showed that BPSA was a significant 
percentage of fPSA in the sera of biopsy-negative BPH patients with elevated PSA levels but not 
in control sera, illustrating its potential as a marker for BPH (Linton et al., 2003). In combination 
with other makers this immunoassay may provide additional information to discriminate BPH 
from PCa. However, as with the other fPSA isoforms, the BPSA test has its limitations. Notably, 
although BPSA is generally lower in PCa patients, this correlation is weak as the vast majority of 
elderly men with PCa also have BPH (Mikolajczyk et al., 2004).   
1.4.2.4 Ratio of cPSA to fPSA 
 
cPSA is the major component of tPSA and circulates as mature active PSA complexed with 
protease inhibitors, predominantly α1-antichymotrypsin (ACT), a SERPIN type inhibitor (Lilja et 
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al., 1991). Complexes with α2-macroglobulin (A2M) and α1-protease inhibitor (API) are less 
common and are estimated to account for 1-2% of cPSA (Lilja et al., 2008). As with the ratio of 
fPSA to tPSA, the ratio of cPSA to tPSA was shown to improve the specificity of PCa detection. 
Several studies have demonstrated that the cPSA immunoassay, which is an FDA approved test 
for PCa detection, provides better specificity over tPSA, particularly in patients with PSA serum 
levels of >4 ng/mL (Jung et al., 2000; Okihara et al., 2002,). Partin and co-workers (2003) 
conducted  a large clinical trial which concluded that cPSA had increased specificity in detecting 
PCa over tPSA, however, it was noted that % fPSA and % cPSA offer no additional benefit in 
differentiating between indolent and malignant disease (Partin et al., 2003).  
1.5. Glycomics and PCa 
 
Although unravelling the molecular subforms of PSA has enhanced the PSA test for PCa 
detection, there is still no outright test that can distinguish between significant and 
insignificant disease.  
Recent advances in the field of glycobiology show aberrant glycosylation patterns as a 
fundamental characteristic of tumourgenesis. These observations suggest that modifications of 
glycoproteins with tumor-specific glycan moieties are viable diagnostic targets for cancer 
(Meany et al., 2011). This has spurred extensive research exploring the changes in PSA 
glycosylation and the propensity to improve the cancer specificity of the PSA test, hence, the 
glycomic era could potentially revolutionise PCa diagnosis. 
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 1.5.1 An introduction to glycans 
 
The entire collection of sugar chains (glycans) synthesized by a cell under specific conditions 
(the “Glycome”) is at the top of the hierarchy in terms of size and complexity when compared 
to the genome, transcriptome and proteome (Freeze, 2006; Varki et al., 2009). Many factors 
influence the glycome creating a highly diverse environment. Given that the glycome can 
change dramatically in response to subtle changes in the cellular surroundings it is becoming 
increasingly clear that extensive alterations of these specific glycosylation patterns are present 
in many diseases (Arnold et al., 2008; Varki et al., 2009). Changes to cellular pathways in 
cancerous tissue can affect glycan processing and these changes can be monitored by analyzing 
the individual sugar chains of the glycoprotein (Arnold et al., 2008). It is essential to understand 
the structure and function of these important glycans to exploit their aberrant expression 
patterns for the discovery of potential new disease biomarkers. The structural complexity of 
glycoproteins arises from the huge diversity generated due to the presence of more than one 
glycosylation site, the sequence in which monosaccharide subunits are linked together, the 
anomeric position of the linkage (α or β configurations), the presence and degree of branching 
and also modifications made by non-carbohydrate substituents (for example sulfate, 
phosphate and acetate) (Varki et al., 2009; Tharmalingam et al., 2010). Glycosylation is the 
most common post translational modification (PTM) of secreted proteins (Lauc et al., 2010). 
The process of protein glycosylation involves a series of glycotransferases and glycosidases 
(glycoenzymes) that act upon a protein as it is processed from the endoplasmic reticulum (ER) 
through to the Golgi apparatus. The structural modifications made by these glycoenzymes 
allow for the generation of cell-specific glycan expression patterns (Kattla et al., 2011). Glycans 
have numerous functions and can be involved in correct conformation and folding of the 
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protein, effect the stability and activity of the protein, protect the protein from proteases and 
serve as recognition motifs for lectins (carbohydrate binding proteins) (Varki et al., 2009; 
Mariño et al., 2010). 
The two most commonly understood mechanisms in which glycans may be linked to a protein 
are (i) N-Linked glycans, which are a preassembled block of 14 sugars transferred 
cotranslationally via the amide group of an asparagine residue. The sequence for N-Linked 
glycosylation sites is Asn-Xaa-Ser/Thr, where X is any amino acid but proline (Varki et al., 2009) 
N-linked glycosylation is essential for multi-cellular life and its complete absence is 
embryonically lethal (Marek et al., 1999). N-Linked glycans are classified into three general 
types, oligomannose, complex and hybrid, as shown in Figure 1.3. (ii) O-Linked glycosylation 
occurs in a stepwise fashion where sugars are added incrementally to the hydroxyl oxygen of 
Ser and Thr residues, and to a lesser extent, to hydroxylproline side chains. O-linked glycans 
play important roles in protein localization and trafficking, solubility, antigenicity and cell to cell 
interactions (Varki et al., 2009; Hansen et al., 1996). 
Other common types of protein glycosylation include phosphoserine glycans, C-linked glycans, 
a rare form of glycans added to a carbon on the Trp side chain and glypiatedglycans, a 
glycosylphosphatidylinositol (GPI) anchor that links proteins to lipids through glycan linkages 
(Kattla et al., 2011). 
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Figure 1.3: Symbolic diagrams to depict N‑linked monosaccharides and linkages of the three general N
‑linked glycan structures (as devised by Harvey and co-workers) (Harvey et al., 2009). All N‑linked 
glycans share the common sugar core sequence Manα1‑6(Manα1‑3) Manβ1-4GlcNAcβ1-4GlcNAcβ1-
Asn‑X-Ser/Thr. (A) Oligomannose glycan. Only mannose residues are attached to the core. (B) 
Complex glycan. ‘Antennae’ initiated by N‑acetylglucosaminyltransferases are attached to the core. 
(C)  Hybrid glycan. Only mannose residues are attached to the Manα1‑6 arm of the core and one or 
two antennae are on the Manα1‑3 arm (Taken from Gilgunn et al., 2013).  
1.5.2 Recent advances in the analysis of glycoproteins  
 
Given the heterogeneity of glycoforms, the characterisation of glycosylation patterns in serum 
glycoproteins can be problematic. The development of glycoanalytical techniques is to some 
extent lagging in comparison to the huge technological advances in the areas of genomics and 
proteomics. However, as our ever expanding knowledge of the biological significance of 
glycans grows, so does the development of glycoanalytical tools.  Techniques employed in 
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glycan analysis include capillary zone electrophoresis (CZE), mass spectrometry (MS), High 
Performance Liquid Chromatography (HPLC), Ultra Performance Liquid Chromatography 
(UPLC), enzyme-linked immunosorbent lectin assay (ELLA) and combinatorial methodologies. 
Analysis of intact glycoproteins allows elucidation of the glycan structures at individual sites. 
CZE coupled with MS is commonly used and although efficient for characterization of 
oligosaccharide structure, detailed information on individual glycans and their site specificities 
can be difficult to obtain (Kattla et al., 2011). 
Lectins, a family of naturally occurring glycan-binding proteins, can discriminate between 
different glycan structures and are very useful tools for glycoanalysis in assays similar to 
standard ELISA (Wu et al., 2009). Lectins are grouped based on their specificity for individual 
monosaccharide units, for example Aleuriaaurentia lectin (AAL) preferentially binds α1-2,-3 or -
6 linked fucose whereas Galanthusnivalis agglutinin (GNA) specifically binds terminal α1-3 
linked mannose (Varki et al., 2009). Lectins can be conveniently used in ELLAs for glycan 
analysis but do have some limitations including low affinity (generally in the millimolar range) 
and high background signals with many blocking agents. Thompson and co-workers (2011) 
recently described an optimized ELLA method that examined the suitability of a number of 
blocking agents for a wide number of commonly used lectins and identified the synthetic 
polymer polyvinyl alcohol (PVA) as the optimal blocking agent for performing ELLAs (Thompson 
et al., 2011). 
The analysis of free glycans (N- and O-linked structures released from the glycoprotein) is 
essential for biomarker discovery. The initial step of liberating the glycans is generally based on 
chemical (e.g. Hydrazinolysis) or enzymatic deglycosylation (e.g. PNGaseF treatment) strategies 
(Kattla et al., 2011). Once released, glycans with a free reducing end are labelled with 
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fluorescent molecules such as 2-AB (2-aminobenzamide), 2-AA (anthranilic acid), and APTS (8-
aminopyrene-1,3,6-trisulfonate) (Varki et al., 2009). The glycan profile can be elucidated by a 
variety of glycoanalytical techniques including weak anion exchange (WAX) HPLC, MS, CE, and 
UPLC-hydrophilic interaction liquid chromatography (HILIC). In combination with such 
techniques, exoglycosidase digestions can be used to reveal specific sequences and linkages 
(Royle et al., 2006). The Dublin-Oxford Glycobiology group describe a HPLC-based analysis of 
serum N-glycans on a 96-well plate format. This fully automated technology platform, 
employing the software GlycoBase, which allows for detailed analysis of femtomolar quantities 
of N-linked sugars released from the glycoprotein (Royle et al., 2008; Campbell et al., 2008). 
This approach was designed specifically for the identification and screening for disease 
biomarkers (Figure 1.4). 
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 Figure 1.4: Methodology for glycan release, fluorescent labeling, NPHPLC profiling, structure assignment and quantitation. Briefly, the process includes (i) 
sample immobilization on PVDF membranes or in-gel blocks, sample washing and N-glycan release following treatment with PNGaseF, fluorescent labeling 
of released glycans with 2-aminobenzamide (2-AB) and (ii) glycan profiling by quantitative HPLC analysis preliminary structural assignment using the 
GlycoBase database of more than 350 N-linked glycan structures (iii) exoglycosidase digestions providing highly specific monosaccharide sequence, linkage 
and arm-specific details with further HPLC profiling to produce a refined list of glycan structures (Taken from Gilgunn et al., 2013). 
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A recent study by Lauc and co-workers (2010) employed this methodology in the first genome-
wide association study (GWAS) of the human N-glycome, comparing different glycosylation 
patterns in the plasma of 2, 705 patients. This comprehensive study of genetic polymorphisms 
that affect protein glycosylation, identified HIF1α as a master regulator of plasma protein 
fucosylation (Lauc et al., 2010). Further development of such techniques focusing on reducing 
separation times and increasing resolution has enhanced the ability to analyze glycosylation 
patterns. Bones and colleagues (2010) significantly improved the efficiency and selectivity of 
Ultra Performance Liquid Chromatography (UPLC) profiling of 2-AB labeled N-Linked glycans by 
introducing a sub-2 μm hydrophilic interaction-based stationary phase (Bones et al., 2010). This 
study demonstrated the speed and selectivity of this technique for identification of altered 
glycosylation in the serum N-glycome of stomach cancer patients for possible markers for 
cancer progression.  
1.5.3 Altered glycosylation patterns in PCa 
 
Alterations to certain glycan structures are now considered a universal feature of malignant 
transformation and tumor progression. Aberrant expression can manifest in many forms in 
malignant cells, including loss of expression or excessive expression of particular structures and 
patterns (Varki et al., 2009). Many studies have looked at altered glycosylation patterns in 
whole serum of PCa patients and of the PSA protein itself to discriminate between PCa and 
BPH, and to develop a more reliable diagnostic than the current PSA test (Tabarés et al., 2006)  
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The PSA protein is a biantennary N-linked oligosaccharide of N-acetlyllactosamine type 
(Peracaula et al., 2003; Ohyama et al., 2004). A noted increase in α2-3 linked sialic acid in PCa 
patients has been highlighted in several studies. Ohyama et al., (2004) utilized lectin affinity 
chromatography to analyse the binding affinity of numerous lectins to total and free serum 
PSA. Maackia amurensis agglutinin (MAA), which identifies α2-3 linked sialic acids, bound to 
fPSA serum significantly more in PCa patients versus BPH patients (Ohyama et al., 2004). Tajiri 
and co-workers (2008) also suggested that identification of α2-3 linked sialic acids on PSA could 
potentially discriminate between malignant and benign disease when comparing 
oligosaccharide profiles of both fPSA and cPSA in PCa serum and in seminal plasma PSA (Tajiri 
et al., 2008). 
Over 10 years ago, Chandrasekaran  and co-workers reported that α1, 2- L- fucosyltransferase 
exhibits increased activity in the PCa cell line, LNCaP,  and malignancy has been shown to be 
associated with increased fucosylation (Chandrasekaran et al., 2002). Changes in fucosylation 
pathways could affect the level of core-fucosylation, as increase in fucosyltransferases results 
in higher core-fucosylation of Epidermal Growth Factor Receptor (EGFR), which is commonly 
overexpressed in carcinomas and correlates to a poor prognosis (Matsumoto et al., 2008). High 
expression levels of the fucosyltransferases FUT2, FUT5, FUT6, FUT8 and FUT11 lead to an 
increased level of α1,3- outer arm and α1,6-linked  core-fucosylated glycans  in the lung cancer 
cell line CL1 (Liu et al., 2011). In comparing 24 metastatic PCa patients with 10 healthy controls 
Kyselova  et al., (2007) demonstrated that the fucosylation of glycan structures was 
significantly higher in the serum of the PCa patients (Kyselova et al., 2007).   
Saldova and colleagues (2011) examined if differential glycosylation patterns could distinguish 
between different stages of PCa and BPH by exploiting high-throughput N-glycan analysis 
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techniques (Figure 1.4) to analyze a cohort of 13 BPH patients and 34 PCa patients, of which 17 
patients were Gleason score 5 and 17 were Gleason score 7. This study found an increase in 
both core-fucosylated biantennary glycans and α2-3 linked sialic acids in the serum N-glycome 
of the PCa patients compared to the BPH patients. A notable decrease in triantennary 
trigalactosylated glycans (A3G3, A3G3S2, A3G3S3), and in tetraantennary tetrasialylated outer-
arm fucosylated glycans (A4F1G4S4) and increases in tetraantennary tetrasialylated glycans 
(A4G4S4) in patients with Gleason score 7 in comparison to Gleason score 5 patients was also 
established. Using these altered expression patterns the authors were able to predict the 
Gleason score at higher sensitivity and specificity than the current PSA test (Saldova et al., 
2011). Patients with a Gleason score of 7 are generally positive for perineural invasion (PNI), 
found to be at a more advanced stage of metastasis and have an increased chance of re-
occurrence. PNI is an important pre-operative indicator of the pathological stage of the tumor. 
Here, the authors showed that decreases in triantennary trigalactosylated glycans (A3G3) 
and/or bisected core-fucosylated biantennary monosialylated glycans (FA2BG2S1) and 
increases in tetraantennary tetrasialylated glycans (A4G4S4) correlate with PNI (Saldova et al., 
2011). 
Collectively these studies show that the use of glycan patterns has significant potential in 
discriminating between significant and insignificant disease, and could help diagnose tumor 
spread and predict patients’ survival, increasing confidence in PCa diagnosis. 
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1.6  Introduction to the immune system 
 
The immune system is a highly adaptable defence mechanism that has evolved to protect 
multicellular organisms from invading pathogens. Two arms of the immune system, namely, 
the innate immune system and the adaptive immune system collaborate together to protect 
our body. Innate immunity is a non-specific genetically derived system that consists of many 
cellular and molecular mechanisms pre-deployed prior to onset of infection (Kindt et al., 2007). 
Innate defences encompass surface barriers (e.g. skin) and are characterised by rapid 
assimilation, which is particularly valued in an emergency situation, and non-specific response, 
of a limited duration. Adaptive immunity, also referred to as acquired immunity, is highly 
specific and capable of selectively recognising and eliminating foreign microorganism and 
antigens. This arm of the immune system involves a cascade of events involving T- and B- 
lymphocytes. B lymphocytes (B-cells) are derived from the stem cells of the bone marrow and 
produce antibodies. T lymphocytes (also known as T cells) are produced in the bone marrow 
but processed in the thymus and constitute the basis of cell-mediated immunity (McCullough 
and Summerfield, 2005; Kindt et al., 2007). Table 1.1 details the major differences between 
innate and acquired immunity.  
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Table 1.1: Comparison of innate and acquired immunity (Taken from Kindt et al., 2007). 
 Innate Acquired 
Response time Minutes- hours Days 
Specificity Limited and fixed Vast diversity; improves 
during the course of immune 
response 
Response to repeat infection Identical to primary response Much more rapid than 
primary response 
Major components Barriers: e.g., skin, mucosal 
membranes and cellular 
components; Mast cells, 
natural killer cells, 
phagocytes, neutrophils and 
dendritic cells. 
Lymphocytes (B - and T- 
cells), antigen specific 
receptors, antibodies 
 
The key difference between the acquired and innate immunity is the acquired immunity’s 
ability to improve and refine its response following exposure to antigens. When a naïve B-cell 
(one that has not previously encountered an antigen) first encounters an antigen, the antigen 
binds to the membrane bound antibody located on the surface of the B-cell. This causes the 
cell to rapidly divide, giving rise to both memory B-cells that immediately recognise an antigen 
post primary exposure and plasma cells, which are responsible for the secretion of antigen-
specific antibodies. The capability of the body to generate a diverse range of antigen-specific 
antibodies accounts for the remarkable nature of the adaptive immune system (Kindt et al., 
2007). Our natural immune repertoire is highly dynamic, with the capacity to generate a 
repertoire of 108 by affinity maturation in vivo, which is substantiated by continual exposure or 
sensitisation to antigens from the environment or by immunisation (Conroy et al., 2014).  
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1.6 .1 Antibody structure 
 
Antibodies are glycoproteins and are the major secretory products of the adaptive immune 
system. The terms immunoglobulin and antibody are used widely and interchangeably. The 
term “antibody” refers to a molecule that binds a known antigen while the term 
“immunoglobulin” describes a family of antibody proteins that have common structure 
features. All antibodies are constructed in the same way from paired heavy and light 
polypeptide chains. There are 5 major classes of immunoglobulins, denoted IgG, IgM, IgA, IgD 
and IgE; the differences in these lie in their heavy chains (termed γ, μ, α, δ, and ε respectively) 
which lead to differences in their effector functions (Barbas et al., 2001). IgG is by far the most 
abundant immunoglobulin in humans and exists as many subforms (IgG1, IgG2, IgG3, IgG4).  
The basic structure of an IgG antibody molecule (approximately 150 kDa) contains four 
polypeptides- two identical heavy chains (50 kDa each) and two identical light chains (25 kDa 
each) joined to form a "Y" shaped molecule (Figure 1.5). The heavy chains are linked to each 
other and to a light chain each by disulphide bonds, these form the arms of the ‘Y’ and each 
arm is known as a  fragment antigen binding (Fab). Each Fab arm is composed of 2 variable 
domains (indicated as VH for the heavy chain and VL for the light chain) and 2 constant domains 
(CH1 and CL) (Barbas et al., 2001; Sela-Culang et al., 2013). Domain pairing leads to close 
interaction of the heavy and light arms of the Fab, known as the Fv region, which makes 
antigen contact. The specificity of antibodies is dictated by the hypervariable loops- HVL or 
complementary determining regions – CDRs which forms the sites in the Fv region for contact 
with its cognate antigen. There are 6 hypervariable loops in the variable domain, 3 in the light 
chain (L1, L2, L3) and 3 in the heavy (H1, H2, H3, which are supported by a conserved 
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framework region (FWR) of β-sheets (Wu and Kabat, 1970; Chothia and Lesk, 1987).  The FWR 
provides a structural scaffold for the antigen-binding site and are important for structural 
diversity and in some instances may make direct antigen contacts (Sela-Culang et al., 2013).  
The stem of the ‘Y’ comes in the form of 2 additional chains of the heavy chain, CH2 and CH3, 
(called the Fc region) which is responsible for mediating the biological activity of the antibody 
molecule (Sela-Culang et al., 2013). The hinge region is a flexible amino acid stretch, rich in 
cysteine and proline amino acids, in the central part (top) of these heavy chains, which links 
the 2 chains by disulfide bonds (Adlersberg, 1976). Disulfide bonds are an important 
component of the IgG structure, with intrachain disulfide bonds stabilising domain folding and 
interchain disulfide bonds stabilising both the interaction of heavy and light chains and the 
interaction of heavy chains (Barbas et al., 2001).   
The CH2 domain of the Fc region also contains a conserved asparagine (N) 297-linked 
glycosylation site which plays a crucial role in modulating the structural stability and functional 
activity of the antibody (Millán Martín et al., 2015). The linked carbohydrate moieties in the Fc 
region of therapeutic antibodies can affect both their thermal stability and physicochemical 
properties, along with other crucial features like receptor-binding activity, circulating half-life 
and immunogenicity. Hence, it is unsurprising that the structural characterisation of N-glycans 
present on antibody therapeutics is required under regulatory guidelines (Millán Martín et al., 
2015; Venetz et al., 2015).   
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Figure 1.5: (A) Basic structure of the Immunoglobulin G (IgG) molecule and (B) Ribbon diagram of IgG, illustrating the Fv, Fab and Fc regions. The 
immunoglobulin is composed of two identical heavy chains consisting of constant (CH1, CH2, and CH3) and variable (VH) domains, associated by a disulphide 
bond at the hinge region of the molecule. The light chain consist of a constant (CL) and a variable (VL) domain that are linked with the heavy chain via a 
disulphide bond. The molecule has three distinct regions. The variable fragment (Fv) determines the antigen-binding specificity of the antibody. The antigen 
binding fragment (Fab) contains the Fv and is separated by the hinge region from the crystallisable fragment (Fc). The Fc domain confers effector functions 
on the antibody and contains a single N-glycosylation site at Asn297 (indicated by a purple star). 
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It was over 100 years ago when Paul Ehrlich realised that antibodies were cruical 
elements of the immune system and would play a key role in the development of 
immunotherapies  “antibodies are in a way magic bullets that identify their target 
themselves without harming the organism” (Strebhardt and Ullrich, 2008). Today, 
antibodies are at the forefront of the field of targeted therapeutics and 
diagnostics due to their natural high affinity and excellent half-life properties that 
are well established. These molecules can be readily manipulated using standard 
molecular biology techniques into customised antibodies that are tailored to 
perform efficiently in their chosen end-point application. The biopharmaceutical 
industry has heavily invested in antibody-based diagnostics and therapeutics, 
which currently represents the largest and fastest growing class of 
biopharmaceuticals (Finlay and Almagro, 2012; Conroy et al., 2014).  
Antibodies are generally represented in three forms (i) Polyclonal (produced from 
a mixture of various B lymphocyte clones) (ii) Monoclonal (secreted from a single 
clone of B lymphocytes) and (iii) recombinant antibodies (are the product of 
genetic manipulation of antibody genes) (Leenaars and Hendriksen, 2005; Zhu et 
al., 2014).  In making the choice between monoclonal, polyclonal or recombinant 
antibody production, cost, production and time need to be considered. However, 
the desired end point application is the deciding factor and each form has its own 
advantages and disadvantages.  
 
1.6.2 Recombinant Antibodies 
Recombinant antibodies are ideal biological reagents for diagnostic assays as they 
are highly specific for a chosen analyte and genetic manipulations can be easily 
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employed to precisely tailor their specificity and biophysical properties (Conroy et 
al., 2009; Hayes et al., 2012). The ability to readily generate bulk quantities of 
recombinant proteins with low production costs in Escherichia coli has fuelled the 
emergence of an assortment of distinct antibody constructs that can be employed 
in a wide variety of applications within the life sciences, particularly in the field of 
diagnostics.  Some common recombinant antibody constructs are illustrated in 
Figure 1.6.   
The smallest antibody fragment that retains the full monovalent antigen binding 
capabilities of a human IgG is the Fv, which comprises of the VH and VL domains 
held together by non-covalent interactions. However, these molecules cannot be 
produced with ease by proteolysis of the intact IgG and recombinant single-chain 
Fv (~28kDa) constructs, in which the variable heavy (VH) and variable light (VL) 
domains are associated via a polypeptide linker, are commonly used to mimic Fv 
fragments (Hudson, 1998; Hollinger and Hudson, 2005). The scFv is more stable 
than the Fv (which is more aggregation prone than the scFv) and typically, a 
flexible 15 residue (Gly4Ser)3 linker is incorporated as it aids in antibody folding 
and stability for bacterial expression (Barbas et al., 2001). 
The antigen-binding fragment (Fab) is a well characterised, larger, more stable 
fragment of approximately 50kDa. The Fab fragment consists of the variable 
heavy and light chains and the constant heavy and light chains (VH & CH1 and VL & 
CL).  An interchain disulphide bond exists between the CH1 and CL (Joosten et al., 
2003). 
There are various advantages and disadvantages of the different types of 
recombinant antibody structures that can be engineered as it is necessary to take 
the end point into consideration. It should also be noted that antibody fragments 
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can be relatively easily reformatted for improved characteristics such as 
expression (Hayhurst et al., 2003), reduction in non-specific binding (Birtalan et 
al., 2008) and enhanced specificity (Stura et al., 2011).  The selection of 
superlative antigen-specific recombinant fragments can be achieved using a 
process known as phage display technology.  
Figure 1.6: Recombinant antibody fragment constructs. The mammalian IgG construct 
(150kDa) is secreted by B cells of the immune system and consists of two heavy and two 
light chains linked together by disulphide bonds. The chains have constant (C) and 
variable regions (V). Diversity in antibody–antigen interactions is achieved through the 
‘hyper-variable region’ in the variable light (VL) and variable heavy (VH) chains, of 
approximately 3–25 amino acids, which is known as the complementarity determining 
regions (CDRs). The scFv consists of the VH and VL chains joined together by a flexible 
linker. A scAb fragment comprises of a scFv with an additional constant light chain 
added to the end of VL. Fab contains the full light chain with VH and CH1. F(ab’)2 is 
comprised of two fab fragments held together by disulphide bond.  
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1.7 Phage display technology 
 
When George P. Smith first demonstrated, in 1985 that the link between 
phenotype and genotype could be established in filamentous bacteriophage the 
advent of phage display technology emerged (Smith, 1985). Over the last few 
decades an increased understanding of antibody structure and function has 
allowed phage display to become the most powerful tool in the controlled 
selection of unique antibodies with properties unattainable from conventional 
hybridoma methods.  Some five years later McCafferty et al., (1990) identified a 
novel method in which a functional scFv was successfully expressed on the surface 
of bacteriophage, providing a way to select antibodies from libraries based on the 
antigen specificity for the individual clones (McCafferty et al., 1990; Hoogenboom, 
2005). Phage display can be used with naïve, immunised or synthetic repertories 
(Bradbury et al., 2011) and  allows for the controlled selection and screening of 
antibodies against defined antigen conformations from a highly diverse 
combinatorial library of antibody fragments (Bradbury and Marks, 2004). 
Selection involves subjecting the phage library to successive rounds of exposure 
to antigen, allowing for antigen-specific phage-displayed antibodies to bind to 
their targets, in a process known as panning. The antigen-specific phage are 
recovered and subsequently infected in bacteria for re-amplification 
(Hoogenboom, 2005). Ideally, a high affinity antibody would be selected for in the 
initial round. However non-specific binding of phage confines the enrichment that 
can be achieved during each round and hence typically 2-5 rounds of panning are 
necessary to identify high affinity binders (Bradbury and Marks, 2004). One round 
of panning is shown in Figure 1.7. 
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The most common method of selection is panning on immobilised antigen coated 
onto a solid support, but many other methods exist (Bradbury and Marks, 2004; 
Conroy et al., 2009). There are many selection considerations that must be taken 
into account when designing phage selection regimes. In pursuance of a high 
affinity antibody, the coating antigen concentration should ideally be decreased in 
each successive panning round. Antigen presentation is also of particular 
significance as some epitopes may be partially denatured when immobilised on 
solid surfaces, leading to the selection of antibodies that will not recognise the 
native antigen. A means of avoiding this issue is by indirect coating, using a 
commercially available antigen specific antibody to capture the target antigen 
(Bradbury and Marks, 2004; Conroy et al., 2009). It is also very important to use a 
suitable blocking agent in order to inhibit some of the non-specific phage binding; 
some commonly employed blocking agents include BSA and semi-skimmed milk 
powder. The addition of a detergent such as Tween 20 also helps reduce non-
specific phage binding (Bradbury and Marks, 2004).  
The washing step is typically performed by rinsing with PBS and/or PBS containing 
Tween 20 (0.05-0.05%, v/v) between 10-30 times (Barbas et al., 2001). After the 
first cycle it is very important to recover all phage-binding antigen. Thus, the 
washing conditions should be less severe. However, in subsequent rounds 
washing should be more stringent to allow for enrichment of strong binders 
(Bradbury and Marks, 2004). 
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Figure 1.7: Selection of antibodies by phage display (panning). The process of ‘panning’ 
is a means of selection of defined clones through binding of the phage library to the 
target, washing unbound phage and elution of the target-specific phage. This process is 
repeated for a number of ‘rounds’ to enrich for a high affinity binder.   
 
1.7.1 Filamentous bacteriophage biology 
 
Filamentous bacteriophage (Ff) are a structurally and genetically diverse group of 
viruses capable of infecting E. coli. The Ff class of filamentous bacteriophages (f1, 
fd and M13) are the main tools utilised in phage display technology and are also 
the most extensively understood (Barbas et al., 2001; Qi et al., 2012). Ff phages, 
illustrated in Figure 1.8A, are a rod-like shape with a circular single stranded DNA 
(ssDNA) genome that infect E. coli cells and do not kill the host during productive 
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infection. The ‘tube-like’ capsid consists of approximately 2, 700 helically arranged 
molecules of the major coat protein pVIII (~ 50 amino acids), while the ends are 
composed of two pairs of proteins – pVI & pIX and pIII & pVI. At one end there is 
approximately 5 molecules of both pVII (33 amino acids) and pIX (32 amino acids), 
whereas the opposite end is capped by 3-5 copies of the 112 residue long pVI and 
the 406 amino acid pIII (Barbas et al., 2001; Bratkovic, 2010).  
 
Figure 1.8: Filamentous bacteriophage. (A) Schematic representation of the phage 
particle showing each of the coat proteins. Ff phages are rod-like viruses with a circular 
ssDNA genome. (B) The minor coat protein pIII is essential for phage infectivity and is 
comprised of 3 domains separated by glycine-rich regions.  
 
pIII mediates entry of the phage into the cell. It consists of 3 domains, designated 
N1, N2 and CT, which are separated by glycine rich areas (Figure 1.8B). The N-
terminal domains are essential for infectivity – N1 is 68 amino acids in length and 
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interacts with the bacterial membrane protein TolA, facilitating translocation of 
the phage DNA into the cytoplasm and insertion of the phage coat proteins into 
the cytoplasmic membrane (Kehoe and Kay, 2005). The N2 domain (residues 87-
217) is in close proximity to the N1 domain, forming a horseshoe structure. 
Infection begins when the N2 domain of pIII attaches to the F pillus of E .coli. The 
third domain of pIII is the 150 residue carboxy-terminus (CT) which is essential for 
forming a stable phage particle (Figure 1.9) (Barbas et al., 2001).  
Phage display libraries have been successfully generated using the major coat 
protein pVIII, however, in direct comparison between pIII and PVIII, pIII was 
shown to be far more efficient, thus is widely accepted as the coat protein of 
choice for the display of recombinant antibody fragments (Kretzschmar and 
Geiser, 1995; Bradbury and Marks, 2004). The clear advantage pIII has over the 
other coat proteins is its ability to package large insertions without interfering 
with phage integrity and infectivity, its ability to display monovalent copies of 
phage antibody particles and, also, the wide availability of suitable vectors (Barbas 
et al., 2001).  
Both phage (Cwirla et al., 1990) and phagemid vectors (Barbas et al., 1991) have 
been used to display recombinant antibody fragments and other proteins 
successfully. Phage display vectors will readily support presentation of short 
peptides on all copies of the minor coat protein (pIII), as the gene encoding the 
recombinant protein is included in the phage genome, leading to polyvalent 
display. Polyvalent display tends to allow for the selection of lower affinity 
variants after the panning (selection) process (Bradbury and Marks, 2004; 
Bratkovic, 2010).  
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The development of phage-based plasmid vectors, known as phagemid vectors, 
allows for monovalent display and thus the selection of high affinity antigen-
specific antibodies (Barbas et al., 1991). Phagemids bring together features of 
plasmids (replication of dsDNA) with features of phage vectors (production and 
packaging of ssDNA into virons) (Bratkovic, 2010). Phagemids contain both an E. 
coli origin of replication and phage origin of replication. They are specifically 
engineered to express recombinant pIII-fused phage under controlled conditions. 
However, they are unable to make phage unless the bacterial host is super-
infected with helper phage. Helper phage are essentially defective Ff phage. They 
carry mutations in their packaging signal and also carry antibiotic resistance 
genes.  The packaging signal is flawed, and hence the helper phage cannot make 
phage when alone in the bacterium. However, in the presence of a phagemid, 
which contains an optimal packaging signal, the phagemid is preferentially 
packaged over helper phage. Thus, phagemid preparations are both 
phenotypically and genotypically heterogeneous (Bradbury and Marks, 2004).  
The three domains of pIII have important functions in infectivity; therefore, when 
using phagemid vectors that express pIII-fusion proteins, it is important to 
consider to which end of pIII the fragment will be fused. In order to introduce the 
phagemid DNA into F’E. Coli hosts, the amino terminal domain is required (Figure 
1.9). 
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Figure 1.9: Model for the early events in the phage infection of E. coli. (A) The phage pIII 
second N-terminal domain (N2) interacts with the F-pilus on the outside of the bacteria. 
The outer membrane proteins OmpF (blue cylinders) and Pal lipoprotein (green) are also 
included, as there have been reports of TolA interacting with these proteins prior to 
infection. (B) After F-pilus retraction, the first N-terminal domain of pIII (N1) binds to the 
C-terminal domain of bacterial TolA (TolAIII). (C) The retracting pilus brings phage pIII 
domains in closer contact with TolA domains, allowing the TolA to assume a more 
compact state of assembly, bringing the outer and inner membranes of the bacteria 
closer together. At this stage, the central domain of TolA (TolAII) has the possibility to 
interact with the N2 domain of phage pIII. (D) The phage pII is inserted into the inner 
membrane, and the cap of the phage head is opened to allow phage DNA to enter the 
bacteria. Taken from Karlsson et al., 2003.  
 
This step is followed by infection with helper phage, which is required for phage 
production (including packaging of the phagemid genome) and the display of 
fusion proteins that constitute the library. To allow for infection with helper 
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phage, the amino terminal of pIII in the fusion expressed by the phagemid should 
be deleted. Truncation of pIII, leaving residues 198-406, serves as the fusion 
partner for the displayed recombinant antibody fragment. The resulting packaged 
phagemid carries both native 406 amino acids long pIII (necessary for infection) 
and the protein-fused truncated pIII, which is displayed for selection (Barbas et 
al., 1991; Radar and Barbas, 1997; Barbas et al., 2001). 
The pComb series of phagemid vectors control expression under a single lac 
promoter with ompA and pelB leader sequences to direct expression of the 
recombinant antibody fragment-pIII fusion into the periplasmic space (Barbas et 
al., 2001). The pComb3X vector series has several features that make it very 
attractive for display of antibody fragments (See Chapter Four, Figure 4.8 for 
schematic representation of pComb3xSS phagemid vector).  
This vector facilitates the soluble expression of recombinant antibodies through 
the addition of an amber (TAG) stop codon at the junction between the gene III 
and the region encoding the antibody fragment. Propagation of phage during 
selection in suppressor strains of E. coli such as XL1 blue or ERB2537 allows for 
transcription of gene III fusion antibody for display. However, by incorporating 
phage into a male non-suppressor strain such as TOP10F’, the stop codon is read 
and soluble expression of the recombinant antibody fragment into the 
periplasmic space, without continued fusion to the phage particle, is produced 
(Barbas et al., 2001; Bradbury and Marks, 2004). This vector also includes two 
peptide tags at the carboxyl terminus of the displayed protein. The hexa-histidine 
(His6) tag facilitates purification by immobilised metal affinity chromatography 
(IMAC) and the influenza haemaggluttinin (HA) epitope (YPYDVPDYAS) tag, which 
facilitates for simple detection (Barbas et al., 2001).  
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1.8 Antibody characterisation by surface plasmon resonance 
 
Classical methods for characterisation of antibody interactions such as ELISA 
demonstrate that a binding interaction is taking place. This provides evidence for 
the formation of the complex (i.e. antibody and antigen). When specific molecular 
interactions such as this occur, the principles of thermodynamics and 
biomolecular structure and recognition come into play (Wilson, 2002).   
Within the last few decades, surface plasmon resonance (SPR)-based optical 
biosensors are at the forefront of instruments for the study of biomolecular 
interactions (deCresenzo et al., 2008). SPR-based methods are favourable as the 
binding events can be monitored in real-time and without the requirement of 
ancillary labels. These key attributes facilitate accurate kinetic measurements, 
rapid analysis times, reduced additional costs and potential heterogeneities or 
other complications that can arise when using labelled interactants (Wilson, 2002; 
Leonard et al., 2011). 
SPR is an optical phenomenon that occurs when polarised light is passed through 
a prism and undergoes total internal reflection at a metal surface (of a sensor 
chip) and liquid interface. The light energy excites plasmons in the metal surface 
causing them to resonate and emit electromagnetic waves. A decrease in the 
intensity of the reflected light is observed by an optical detection unit as these 
plasmons absorb incident light (Wilson, 2002; Leonard et al., 2011) (Figure 1.10). 
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Figure 1.10: Schematic representation of a Surface Plasmon Resonance (SPR)-based 
system. (A) SPR occurs on a thin layer of gold, which is sandwiched between a glass slide 
and the sample solution flowing through a specially designed microfluidic cartridge. 
Polarized light from a light source is passed through the prism at an angle of incidence 
greater than the critical angle causing total internal reflection to occur. When the light 
hits the gold at the critical angle (θc), not only does it internally reflect, but it also leaks 
an electromagnetic energy called an evanescent wave which moves exponentially across 
the gold interface exciting plasmons, this is seen as a drop in the intensity in the 
reflected light and is measured the detector. When analyte binds to the sensor surface a 
mass change occurs near the surface of the sensor chip. The refractive index near the 
sensor chip surface changes, this in turn changes the angle at which the SPR occurs. The 
photo diode array detector detects the change in SPR angle and displays the change in 
real-time on a sensogram. (B) Association and dissociation are measured in arbitrary 
units and displayed in a graph called a sensorgram. The example shown consists of an 
association, steady state and dissociation phase of an exponential molecular 
interaction.  
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Over 40 years ago, seminal work by Otto, Krestschmann and Raether established 
that the SPR phenomenon occurs when surface plasmon waves, related to 
collective excitations of electrons in metal, are excited by light at a metal/liquid 
interface (deCresenzo et al., 2008). The vast majority of SPR biosensors that are 
commercially available today still utilise the geometry proposed by Krestschmann 
and Raether to direct polarised light through a prism and the reflect it from a gold 
film, of approximately 50 nm, deposited on its surface (deCresenzo et al., 2008). 
BiacoreTM (GE healthcare) developed one of the first instruments that utilises SPR 
for ‘real-time’ analysis of biomolecular interactions in a ‘label-free’ environment. 
Biacore technology exploits SPR methodology by using a gold sensor chip 
immobilised with ligand and passing over analyte in solution. As analyte binds to 
the immobilised ligand a change in mass at the metal surface occurs. This binding 
interaction perturbs the resonating plasmons and this change is recognised by the 
optical detection unit as a decrease in the intensity of reflected light. This binding 
profile is then reported as a sensogram (Wilson, 2002; Leonard et al., 2011).  
The key application of Biacore in antibody characterisation is determination of 
affinity and kinetics characteristics of a biomolecular interaction, which in turn is 
determined by a number of biophysical parameters (Table 1.2). The simplest 
interaction is the 1:1 binding event, which can be described for immobilised ligand 
(A) binding to cognate analyte (B) forming a complex (AB) as illustrated by the 
equation in Figure 1.11 (Leonard et al., 2011).  
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Figure 1.11: Binding interaction for analytes A and B forming the complex AB 
 
Table 1.2: Definitions of biophysical determinants for biomolecular interactions (Taken 
from Hearty et al., 2010) 
Constant Definition Description Proportionality Unit 
ka Association rate 
constant (also 
referred to as ‘on-
rate’ 
No. of AB complexes 
formed per unit time at 
unit concentration of A 
and B 
Affinity ∝ Ka M
-1s-1 
kd Dissociation rate 
constant (also 
referred to as ‘off-
rate’ 
No of AB complexes 
dissociating per unit time 
Affinity ∝ 1/ Kd s
-1 
KA Equilibrium 
association 
constant 
Affinity propensity to 
association of A + B 
KA =Ka/Ka = 
[AB]/[A]+[B] 
M-1 
KD Equilibrium 
dissociation 
constant 
Affinity contribution to 
stability of AB complex 
KD=Kd/Ka = 
{[A]+[B]}/[AB] 
M 
 
 
BiacoreTM instruments use surfaces with carboxymethylated dextran layers that 
form a hydrogel-like polysaccharide matrix. These carboxymethylated dextran 
chains are tethered to a gold substrate via a nanometric-thin self-assembled alkyl 
monolayer. Stable anchorage is mediated through a sulphur atom present at one 
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end of the alkyl chain (deCrescenzo et al., 2008).  Ligands can be covalently 
immobilized via primary amine groups after activation of the carboxymethyl 
groups on the sensor surface with a mixture of N-hydroxysuccinimide and N-ethyl-
N'-(dimethylaminopropyl) carbodiimide (deCrescenzo et al., 2008).   
The BiacoreTM 3000 provides comprehensive characterisation of binding events. 
Furthermore kinetic analysis and epitope mapping can be easily conducted using 
the 3000 system (Biacore, 2015). The BiacoreTM 4000 is a powerful tool for larger 
scale, high through put screening. This system allows 60 hour automated runs and 
parallel analysis of up to 16 targets or 4800 interactions in 24 hours. The Biacore 
4000 is particularly useful for screening and ranking large libraries of antibodies 
direct from crude E. coli extracts whilst also characterising antibody specificity and 
selectivity (Biacore, 2015).  
Yu and co-workers (2004) reported the use of a CM5 Biacore chip as a dextran 
surface on which a sandwich assay for free PSA was conducted (Yu et al., 2004). 
The assay combined SPR and fluorescent labelling, i.e. surface plasmon field-
enhanced fluorescence spectroscopy (SPFS). This technology used surface 
plasmons to excite the fluorescent label and produce the signal. The limit of 
detection observed was 80 fM for a 40 minute contact time, which is many orders 
of magnitude lower than detection limits of third generation PSA assays 
commercially available today. 
1.9 Antibody characterisation by X-ray crystallography 
 
Understanding protein structure and its relationship to function is of paramount 
concern to scientists to elucidate the interactions between proteins, for example 
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between an antibody and an antigen. X-ray crystallography is a powerful, robust 
method for obtaining high resolution structural information about biological 
macromolecules. The history of protein crystallography started at the beginning of 
the 19th century when W.C Roentgen discovered X-rays and since then the major 
contributions X-ray crystallography has made to the scientific community have 
been recognised with the awarding of 14 Nobel prizes (Shi, 2014) (Figure 1.12).  
 
Figure 1.12: History of X-ray crystallography in Nobel prizes (Adapted from Shi, 2014) 
 
Some of the key milestones highlighted in Figure 1.12 only tip the iceberg in terms 
of the immeasurable impact the field of structural biology has had  on science and 
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medicine. The discovery of the structure of the DNA double helix model is likely 
the famous development (Watson and Crick, 1953). However, owing to 
crystallography we have also revolutionised the concepts of vaccine design 
through insights gained from viral structures (Rossmann et al., 1985; Doores et al., 
2015), gained significant insights into the understanding of membrane proteins 
(Lyons et al., 2012) and developed  what is now one of the central paradigms in 
immunology from determination of the crystal structure of the class 1 Major 
Histocompatibility Complex (MHC) molecule HLA-A2 (Bjorkman et al., 1987).  
Protein crystallisation has advanced significantly since the determination of the 
first protein structure of myoglobin in 1957 (at 6 Å) (Kendrew et al., 1958). 
Information sourced from X-ray diffraction studies can uncover considerable 
details regarding the dynamics and heterogeneity of protein structure and 
function (Acharya and Lloyd, 2005). Much research focuses around the three 
dimensional structure of proteins and the protein data bank (PDB) was 
established in 1971. To date 10, 9661 biological macromolecule structures have 
been archived (as of June 2015). The majority (approximately 89%) of structures 
housed in the PDB were determined by X-ray crystallography.  
1.9.1 Crystal structure determination X-ray diffraction 
 
The three dimensional molecular structure of a protein can be obtained from a 
crystal that is exposed to an X-ray beam.  A protein crystal is a solid composed of 
repeated structural motifs in a 3-dimensional lattice and the building blocks of a 
crystal (asymmetric units) are arranged, according to well defined symmetries, 
(forming 230 space groups) into unit cells that are repeated in 3-dimesions. Due 
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to their chirality, biological macromolecules do not crystallise in all space groups 
reducing the number of available space groups to 65 (Wukovitz and Yeates, 1995).  
The precise positions/arrangements of atoms in a protein crystal can be 
determined. When a crystal is exposed to an X-ray beam, diffraction occurs, 
resulting in the scattering of the X-ray beam in a predictable pattern based on the 
crystal lattice structure. X-ray diffraction is a reflection of the architecture of the 
crystal lattice; hence any imperfections in the crystal generally result in a poor 
diffraction pattern (Acharya and Lloyd, 2005).   
In a diffraction pattern, each spot is defined by 3 parameters, (1) amplitude (can 
be measured from the intensity of the spot), (2)  wavelength (set by X-ray source) 
and (3) ‘phase’, which all need to be known for all the spots in order to determine 
the position of the atoms that give rise to the diffracted beams. As ‘phases’ are 
not directly measurable (the ‘phase-problem’ is further discussed in section 
1.9.3.1), reasonable estimates for the phases of all diffracted beams can be 
obtained through indirect methods. Once these three parameters are known, 
they can be combined to produce an electron-density map. A model can then be 
progressively built into the observed electron density, producing a relatively 
accurate protein structure model (Figure 1. 13) (Acharya and Lloyd, 2005).  
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Figure 1.13: Overview of protein crystallography by X-ray diffraction. There are many 
stages involved in determination of protein structure (A) X-ray diffraction; the scattering 
of X-rays when they hit a crystal lattice (B) typical X-ray diffraction pattern: The 
diffraction pattern is a map of the arrangement of the molecules or atoms in the crystal. 
The pattern of spots (reflections) and the relative strength of each spot (intensities) can 
be used to generate (C) an electron density map; the electron density map is interpreted 
in terms of a set of atomic coordinates. This generates the preliminary model which 
needs to be refined (D) Ribbon diagram of the structure of myoglobin. Amino acid 
residues are fitted into the electron density map to produce the protein model. The final 
model is refined using methods such as molecular replacement. Figure adapted from 
(Acharya and Lloyd, 2005). 
1.9.2 Data collection: 
 
Protein crystallography relies almost entirely on the scattering of X-rays by the 
electrons in the molecules that constitute the sample under investigation. It was 
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more than a century ago when Roentgen discovered X-rays and in the recent 
decades the sources of X-rays used for crystallographic experiments and the 
methods of their detection have undergone dramatic changes and improvements.  
Traditional laboratory X-ray sources have a rotating anode X-ray generator, 
(predominantly with a copper target) which gives a peak of CuKα radiation of 1.54 
Å. However, data is now more commonly collected using synchrotron radiation 
sources. Synchrotrons have existed since the 1940’s. However, in 1980 the world's 
first synchrotron dedicated to producing synchrotron light for experiments was 
built. Synchrotrons are now considered the single most powerful tool available to 
X-ray crystallographers (Wlodawer et al., 2013, Diamond Light Source, 2015). 
Synchrotron radiation is emitted when electrons, travelling close to the speed of 
light, are forced to move in a circular orbit under the action of a magnet. Unlike 
conventional lab sources, this type of X-ray beam has much higher intensity and 
data can be collected at any wavelength approximately in the range 0.5-3 Å. 
Synchrotrons are very large facilities (roughly the size of a football field) and 
contain several dedicated beamlines with charged-coupled detectors (CCDs), 
making data collection exceptionally accurate and fast (Wlodawer et al., 2013, 
Diamond Light Source, 2015). 
1.9.3 Data analysis 
 
Once protein crystals that diffract X-rays to a reasonable resolution have been 
obtained, the obstacle to overcome is to obtain an interpretable electron density 
map. The dataset which is built from many different images contains spots 
relating to the electron density calculated by Fourier transforming the diffraction 
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intensities. The data is indexed (matching electron density variations to spots), 
merged and scaled (matching relative strengths of the spots in various images) 
and combined to give the total electron density (phasing). 
1.9.3.1 The phase problem 
 
The ‘phase problem’ arises from the lack of ability to directly measure the phases 
of individual diffracted X-ray waves. Intensities (amplitude) are directly measured 
during data collection; however, phases must be obtained by other means  
(Scapin, 2013). There are numerous experimental methods for the determination 
of phase including multiple isomorphous replacement (MIR), multi-wavelength 
anomalous dispersion (MAD) and the molecular replacement method (MR). 
Markedly, it is not just determination of crystal structures that will earn one a 
Nobel prize; The Nobel Prize in Chemistry 1985 was awarded jointly to Herbert A. 
Hauptman and Jerome Karle "for their outstanding achievements in the 
development of direct methods for the determination of crystal structures”- i.e. 
the development of MAD for gathering phase information. Soulimane and 
colleagues (2000) used MAD phasing techniques to determine the crystal 
structure of the ba3-cytochrome c oxidase from Thermus thermophilus to 2.4 Å 
and revealed the presence of a novel subunit IIa spanning the membrane. This 
was the first intrinsic membrane protein to be solved by MAD phasing (Soulimane 
et al., 2000).  
Generally, in the absence of any previous phase information the MIR method is 
the most important method for solving the phase problem, that said, the most 
popular method is MR. When the structure of the protein is expected to be 
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closely related to another known protein structure (e.g. high sequence homology) 
this similarity may be used to obtain preliminary phase information about the 
unknown structure, which can then be refined (Smyth and Martin, 2000).  
MR involves finding out how to orient and position the known structure such that 
it corresponds with the unknown structure in the crystal by using rotation and 
translation functions.  Using the rotation function the approximate orientation of 
the two molecules is calculated and secondly, the translation function generates a 
superimposition of the two molecules. If more than one molecule is present in the 
unit cell, another rotation-translation function is performed until all molecules are 
placed into the unit cell.  MR operates on the idea of ‘borrowing’ phases from 
known structures to determine structure factor of the unknown and calculate the 
electron density map. There are numerous well established software packages 
and program suits available for carrying out MR and the dramatic evolution of 
both computer hardware and software has resulted in  faster, more flexible, and, 
in many cases, fully automated methodologies (Smyth and Martin, 2000; Scapin, 
2013).  
1.9.3.2 Assessing the quality of the diffracted data 
 
Once an electron density map is prepared, this can be refined to generate the 
final protein structure. High quality protein structures arise from properly refined, 
good quality data.  It is vital to correctly assign the space group symmetry during 
collection of the diffracted data as this dictates how much data is needed to solve 
the structure. In three dimensions, there are seven lattice systems: cubic, 
hexagonal, tetragonal, rhombohedral, orthorhombic, monoclinic and triclinic, 
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which are subdivided into 230 space groups, of which proteins can crystallise in 65 
(Acharya and Lloyd, 2005). With a high symmetry crystal such as a cubic system, 
one needs only to collect diffraction data through as little as 35°. Conversely, in a 
monoclinic lattice, a lower symmetry crystal, data might need to be collected 
through 180°. That said, generally as much diffractable data as possible is 
collected to aid in structure determination (Smyth and Martin, 2000).  
Final structure model analysis should ideally include analysis of the geometry 
(chirality, bond lengths and angles) and folding of the main-chain (Ramachandran 
plot), accompanied by important quality indicators such as resolution, 
completeness, signal-to-noise ratio (I/σ) and Rmerge (Wlodawer et al., 2008; Evans 
et al., 2011). A glossary of the various parameters/quality measures for 
determination of the quality of diffraction data is detailed in Appendix One. It 
should be noted that if a structure contains outliers from ‘ideal’ conformations, it 
is not necessarily an indicator that the structure is wrong as sometimes unfamiliar 
conformations are associated with some biological functions (Acharya and Lloyd, 
2005).  
1.9.4 Crystal structure of antibodies 
 
The three dimensional structure of antibodies has played a central role in 
elucidating humoral immune response mechanisms, evolution of the antibody 
repertoire and optimisation of in vitro-generated antibodies. Information 
generated from knowing the structure of antibodies can be exploited for the 
design of novel diagnostic and therapeutic reagents as well as for development of 
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immunogens for improved vaccines with greater breadth and efficacy (Lee and 
Wilson, 2015).  
Mutational hotspots and structure-guided mutation strategies can maximise the 
diagnostic performance of recombinant antibody fragments (Muller et al., 2011; 
Stura et al., 2011). Muller and colleagues (2011) specifically mutated an anti-fPSA 
antibody (Fab – 5D3D11) and the results from this study, showed improved  
diagnostic performance for patients in the ‘diagnostic grey zone’, allowing for 
better discrimination between prostate cancer and BPH (Muller et al., 2011).  
Recent exploitation of the avian immune system has highlighted its use for the 
generation of high-quality, high-affinity antibodies to a wide range of antigens for 
a number of therapeutic and biotechnological applications. The principle 
mechanisms in which chickens generate antibody diversity and the advantages of 
using chickens for the development of recombinant antibodies is discussed in 
detail in Chapter three of this thesis.  There is however a limited knowledge of the 
structural attributes of avian antibodies. During a search of the PBD, using the key 
words ‘single chain fragment, with the refinement of ‘Gallus gallus’ (chicken), the 
vast majority of the structures relate to avian lysozyme predominantly in complex 
with antibodies from human sources. As of July 2015, there are three chicken scFv 
fragment crystal structures in the PBD, one of which was deposited from this body 
of work (Conroy et al., 2014).   
Basic knowledge of chicken antibody structures would be of benefit to the 
scientific community and would enhance our knowledge of antibody structures, 
allowing for the development of antibodies with unique binding specificities 
targeting human proteins that can ultimately address various clinically relevant 
medical issues, such as prostate cancer diagnostics.  
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1.10 Thesis aims 
 
The costs of unregulated PSA testing in Ireland are considered to be extensive. 
These include the economic burden of testing, diagnosis and PCa treatment, 
which fall not only on the health services, but on patients themselves as lost time 
and out-of-pocket expenses, and on society in the form of lost productivity. Over-
diagnosis and over-treatment are widely recognised consequences of inadequate 
PSA testing (National Cancer Registry, 2015). The vast majority of current 
literature concerning PCa diagnosis conclude the article with the same statement- 
better PCa markers are needed that will reduce diagnosis of low risk disease and 
widespread overtreatment. The aims of this body of work are to use both 
antibody and glycomic-based approaches to address this research gap through: 
 Generation of recombinant avian anti-fPSA and anti-cPSA-specific 
antibody fragments using phage display technologies. 
 Investigation of the kinetic and structural attributes of these avian 
antibody fragments to enhance their diagnostic capabilities by SPR and X-
ray crystallographic methodologies. 
 Development of a further understanding the avian immunoglobulin 
structure by investigating the detailed N-glycan profile of IgY polyclonal 
antibodies using high-throughput N-glycan analysis, based on ultra-
performance liquid chromatography (UPLC) separation of released 
glycans. 
 Analysis of the N-glycome of PCa patient’s sera for the identification of a 
glycomics based signature that can distinguish between indolent and 
aggressive prostate cancer with high accuracy. 
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Chapter Two 
Materials and Methods 
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2.1 Materials 
2.1.1 Equipment list  
 
Instrument Supplier 
 
Tecan SafireTM 2 plate reader 
Tecan Group Ltd., Seestrasse 103, 8708 
Männedorf, Switzerland. 
 
NanoDropTM ND1000 NanoDrop Technologies, Inc.,3411 
Silverside Road, Wilmington, DE 19810, 
USA. 
Gene Pulser XcellTM electroporator 
Bio-rad PowerPac Basic 
Trans-Blot SD semi-dry transfer cell 
Bio-rad Min-Protean electrophoresis 
system 
Gel Doc™ EZ system and Image Lab™ 
 
Bio-Rad Laboratories Inc., 1000 Alfred 
Nobel Drive, Hercules, California 9454, 
USA. 
Balances (Chyo JK-180, Mettler PJ300) 
Orion 3 Star pH meter 
Medical Supply Company Ltd., 
Damastown, Mulhuddart, Dublin 15, 
Ireland. 
Heraeus Hera-safe laminar flow 
cabinet 
Thermo Scientific, 12-16 Sedgeway 
Business Park, Witchford, 
Cambridgeshire CB6 2HY, UK. 
Eppendorf refrigerated centrifuge 
5810 R 
Rotors: 
Fixed angle rotor: F45-30-11 (max. 
speed 14,000 rpm/ 18, 500 x g) 
Swing-bucket rotor: A-4-62 (max. 
speed: 4,000 rpm/3,220 x g) 
Eppendorf UK Ltd., Endurance House, 
Vision Park Histon, Cambridge CB24 
9ZR, UK. 
Homogeniser (Ultra- Turrax) IKA-Werke GmbH & Co. KG, 10 Janke & 
Kunkel-Str., 79219, Staufen, Germany. 
HermLe Z233 MK-2 refirigerated 
centrifuge 
Rotar- Hermle 220.87 V05 (15,000 
rpm/21, 380 x g, 1.5/2 mL tubes) 
HermLe Labortechnik GmbH, 
Siemensstrasse, Wehingen, 78564, 
Ireland. 
Biacore 3000 and A100 (4000) GE Healthcare Bio-Sciences AB, 
Danmarksgatan 41, M5, 75184 Uppsala, 
Sweden. 
Stuart Roller Mixer – SRTI Lennox Laboratory Supplies Ltd., John 
F. Kennedy Drive, Naas Road, Dublin 12, 
Ireland. 
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Instrument  Supplier 
37oC static incubator Sanyo Europe Ltd., 18 Colonial Way, 
Watford WD24 4PT, UK. 
Waters Acquity UPLC H-Class Waters, Milford, MA, USA. 
Waters Ethylene Bridged Hybrid (BEH) 
Glycan Column 
Waters, Milford, MA, USA. 
Vydac 301VHP575 7.5 x 50 mm 
Column 
Anachem Ltd., Anachem House, 1 & 2 
Titan Court, Laporte Way, Luton, 
Bedfordshire, LU4 8EF, UK. 
2695 Alliance separations module with 
a 2475 fluorescence detector (For 
HPLC) 
Waters, Milford, MA, USA. 
Waters Xevo G2 QTof (YCA 219) with 
Acquity® UPLC 
Waters, Milford, MA, USA. 
Hamilton Robotics StarLet liquid-
handling platform 
Hamilton Medical AG, Bonaduz, Via 
Crusch 8, CH-7402 Bonaduz, GR, 
Switzerland. 
AKTA FPLC system GE Healthcare, Silverwater NSW 1811, 
Australia. 
S75 (16/60) analytical gel filtration 
column 
GE Healthcare, Silverwater NSW 1811, 
Australia. 
Clifton stirred water bath Nickel – Electro Ltd., Oldmixon 
Crescent, Weston-super-Mare, North 
Somerset BS24 9BL, UK. 
 
2.1.2 Reagents  
 
All reagents were of the highest quality (analytical grade) available and purchased 
from Sigma-Aldrich Ireland Ltd., Vale Road, Arklow, Wicklow, Ireland or Fisher 
Scientific Ireland., Suite 3, Plaza 212, Blanchardstown Corporate Park 2, 
Ballycoolin, Dublin 15 Ireland, except where otherwise stated.  
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Reagent Supplier 
Bacteriological Agar 
Yeast Extract 
Tryptone 
Cruinn Diagnostics Ltd., Hume Centre, 
Parkwest Business Park, Nangor Road, 
Dublin 12, Ireland. 
DNA Ligase 
M13K07 helper phage 
Restriction enzymes 
dNTP’s 
Brennan and Company, 61 Birch 
Avenue, Stillorgan Industrial Park, 
Stillorgan, Co. Dublin, Ireland. 
GoTaq DNA polymerase Medical Supply Company Ltd., 
Damastown, Mulhuddart , Dublin 15, 
Ireland. 
 
 
Reagent Supplier 
RNALater 
RNase Free Tubes 
RNase Free Tubes 
Glycogen 
3M Sodium Acetate 
Ambion/Bio-sciences, 3 Charlemont 
Terrace, Crofton Road, Dun Laoghaire, 
Co Dublin, Ireland. 
1Kb DNA Hyperladder 
InstantBlue Protein stain 
Amintra Ni-NTA 
MyBio, Hebron Business Park, Kilkenny, 
Ireland. 
PCR Primers Integrated DNA Technologies, BVBA, 
Interleuvenlaan 12A, B-3001 Leuven, 
Belgium. 
fPSA 
cPSA 
ACT 
SCIPAC/BBI Solutions, Broad Oak Road, 
Sittingbourne, Kent, ME9 8AQ, UK. 
HRP-labelled donkey anti-chicken- IgY-
Fab 
Donkey anti-chicken- IgY-Fab 
HRP-labelled donkey anti-chicken-IgY-
H+L 
Gallus Immunotech, 6570 1st Line West 
Garafraxa, Fergus, ON N1M 2W4, 
Canada. 
Goat anti-PSA pAb 
Goat- anti-HA tag pAb 
 
Abcam, 330 Cambridge Science Park, 
Cambridge, CB4 0F, UK. 
Platinum Taq High Fidelity DNA 
polymerase 
Trizol 
SYBRTMSafe DNA gel stain 
Bio-sciences, 3 Charlemont Terrace, 
Crofton Road, Dun Laoghaire, Co 
Dublin, Ireland. 
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2.1.3 Commercial Kits 
 
Kit Supplier 
NucleoSpin Plasmid  DNA purification 
kit 
NucleoSpin Gel and PCR Clean-up kit 
NucleoBond Xtra Midi Plasmid DNA 
purification kit 
Macherey-Nagel GmbH & Co. KG., 
Neumann Neander Str. 6-8, D-52355 
Düren,  Germany. 
Pierce Thiophilic Adsorption Kit Thermofisher /Fisher Scientific Ireland, 
Suite 3, Plaza 212, Blanchardstown 
Corporate Park 2, Ballycoolin, Dublin 15, 
Ireland. 
Superscript III RT-PCR Kit Bio-sciences, 3 Charlemont Terrace, 
Crofton Road, Dun Laoghaire, Co Dublin, 
Ireland. 
Amine Coupling Kit GE Healthcare Life Sciences, Amersham 
Place, Little Chalfont, Buckinghamshire, 
HP7 9NA, UK. 
 
2.1.4 Bacterial Strains 
 
Strain Genotype Supplier 
XL1Blue 
E. coli 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 
lac [F ́proAB lacIqZΔM15Tn10(Tetr)] 
Agilent Technologies 
Ireland Ltd., Unit 3, Euro, 
House, Euro Business, 
Park, Little Island, Cork, 
Ireland. 
TOP10F’ 
E. coli 
F ́{lacIqTn10(TetR)}mcrA∆(mrr-hsdRMS-
mcrBC)Φ80lacZ∆M15∆lacX74recA1araD139∆(ar
a-leu)7697galUgalKrpsLendA1nupG 
Invitrogen/ Bio-sciences, 3 
Charlemont Terrace, 
Crofton Road, Dun 
Laoghaire, Co Dublin, 
Ireland. 
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2.1.5 Media Compositions 
 
Media Components/1L 
Luria Broth (LB) Tryptone 10 g 
Yeast Extract 5 g 
NaCl 10 g 
Super Broth (SB) MOPS 10 g 
Tryptone 30 g 
Yeast Extract 20 g 
2xTryptone Yeast (2xTY) Tryptone 16 g 
Yeast Extract 10 g 
NaCl 5 g 
Super Optimal Carbolite (SOC) Tryptone 20 g 
Yeast Extract 5 g 
KCL 2.5 mM 
NaCl 0.5 g 
MgCl2 20 mM 
Glucose 20 mM 
 
2.1.6 Media Additives 
2.1.6.1 Antibiotics 
 
Antibiotics used for bacterial cell culture were prepared as described below and 
sterile filtered through 0.2μm filter before use. Antibiotic stocks were stored at -
20oC in aliquots to reduce the risk of contamination. 
Antibiotic Component Composition 
Carbenicillin 100 mg/mL 
(w/v) 
Carbenicillin salt 
MG H2O 
500 mg 
5 mL 
Kanamycin 70 mg/mL 
(w/v) 
Kanamycin 
MG H2O 
700 mg 
10 mL 
Tetracycline 5 mg/mL 
(w/v) 
Tetracycline 
MG Ethanol 
50 mg 
10 ml 
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2.1.6.2 Additivies 
 
Media Additive Component Compostion 
1M MgSO4 Magnesium Sulfate 
MG H20 
12.036 g 
100 mL 
100x 505 Glycerol 
Glucose 
dH20 (Autoclaved) 
50% (v/v) 
5% (w/v) 
Up to 50 mL 
 
2.1.7 Buffers 
 
Buffer Component Composition 
1x  Phosphate Buffered 
Saline (PBS) 
NaCl 
Na2HPO4 
NaH2PO4 
 
5.84 g/1L 
4.72 g/1L 
2.64 g/1L 
Final pH 7.2 
PBS-Tween 0.05% (PBST) PBS 
Tween 20 
1x 
0.05% (v/v) 
PBS-Milk 5% (PBSM) PBS 
Milk Marvel 
1x 
5% (w/v) 
PBST-Milk 1% (PBSTM) PBST 
Milk Marvel 
1x 
1% (w/v) 
 
2.1.8 Buffers for sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) 
 
10x Electrophoresis Buffer  
50mM Tris (pH 8.3) 
196mM Glycine 
0.1% (w/v) SDS 
dH20 
30 g 
144 g 
10 g 
Up to 1L 
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Preparation of 12.5% Separating Gel 1 gel 
1M TrisHCl, pH 8.8 
30% (w/v) acrylamide (AcrylaGel) 
2% (w/v) methylamine bisacrylamide (Bis-AcrylaGel) 
dH2O 
10% (w/v) SDS 
10% (w/v) Ammonium persulfate  (APS) 
N, N, N', N'-tetramethylethylenediamine (TEMED) 
1.5 mL 
2.5 mL 
1.0 mL 
934 μL 
30 μL 
30 μL 
6 μL 
 
Preparation of 4.5% Stacking Gel 1 gel 
1M TrisHCl, pH 8.8 
30% (w/v) acrylamide (AcrylaGel) 
2% (w/v) methylamine bisacrylamide (Bis-AcrylaGel) 
dH2O 
10% (w/v) SDS 
10% (w/v) Ammonium persulphate  (APS) 
N, N, N’, N’-tetramethylethylenediamine (TEMED) 
300 μL 
375 μL 
150 μL 
1.74 mL 
24 μL 
24 μL 
2.5 μL 
 
Transfer Buffer 500 mL 
Trizma Base 
Glycine 
Methanol 
dH2O 
2.4 g 
7.2 g 
100 mL 
Adjust to 500 mL 
 
4x Loading Buffer dye  
0.5M Tris, pH 8.3 
Glycerol 
2-mecaptoethanol 
20% (w/v) SDS 
Bromophenol blue 
dH2O 
2.5 mL 
2.0 mL 
0.5 mL 
2.5 mL 
20 ppm 
2.5 mL 
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2.1.9 Protein Purification Buffers 
 
Buffer Composition/200mL 
Osmotic Shock Buffer A 
(OSB-A) 
1XPBS + 150 mM NaCl, pH 8.0 
Osmotic Shock Buffer B 
(OSB-B) 
1XPBS + 150 mM NaCl + 1 M Sucrose + 2 mM EDTA, 
pH 8.0 
Periplasmic Buffer 5 mM MgSO4 (prepared in dH2O) 
Wash # 1 1XPBS + 150 mM NaCl + 10 mM Imidazole, pH 8.0 
Wash # 2 1XPBS + 150 mM NaCl + 15 mM Imidazole, pH 8.0 
Elution Buffer 250 mM Imidazole in 0.3 M NaCl and 50 mM Sodium 
Phosphate, pH 8.0 
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2.2 Methods 
2.2.1 General molecular methods 
2.2.1.1 Agarose gel electrophoresis 
  
Gels were prepared by weighing out the desired amount to give you the require 
percentage gel in grams of agarose (i.e. for 1.5% (w/v) gel, 1.5 g agarose is 
needed). The weighed agarose was added to 100 mL 1X Tris-acetate-EDTA (TAE) 
buffer and heated in a conical flask in the microwave for 2-3 minutes until 
completely dissolved. This was left to cool before adding 10 μL SYBRTM safe DNA 
gel stain. This was then poured into a gel box containing a comb and allowed to 
cool.  Once set, the comb was removed and gel electrophoresis was carried out 
using the Bio-Rad PowerPacTM in 1x TAE running buffer at 90V for approximately 
50 minutes.  
2.2.1.2 Ethanol precipitation of DNA 
 
Ethanol precipitation was used to remove any contaminants, to concentrate the 
nucleic acid and to change the solution in which a DNA sample was suspended. 
Recommended temperatures and times for ethanol precipitation with sodium 
acetate range from -80oC to RT, and times range from 10 minutes to overnight. 
Ethanol precipitation was carried out at -20oC overnight (o/n) or at -80oC for two 
hours. To a 1.5 mL tube containing DNA the following was added: 0.1x volume of 
3 M sodium acetate (NaOAc), pH 5.2, 2x volumes of ice cold absolute ethanol and 
1 μL glycogen (5 mg/mL). The tubes were mixed gently by inverting several times 
and then placing at the desired temperature for the required period of time.  The 
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precipitates were centrifuged at 19,500 x g for 30 minutes at 4oC and the pellet 
was washed with 200 μL ice cold 70% (v/v) EtOH and again centrifuged at 19,500 x 
g for 5 minutes at 4oC. The pellet was then air dried and resuspended in an 
appropriate volume of MG H2O.  
2.2.1.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) 
 
The separation of macromolecules in an electric field is called electrophoresis. The 
most commonly used method for separating proteins by electrophoresis uses a 
polyacrylamide gel as a support medium and sodium dodecyl sulfate (SDS) to 
denature the proteins, and  was originally described in 1970 (Laemmli, 1970). SDS 
is an anionic detergent and has a net negative charge within a wide pH range. A 
polypeptide chain binds amounts of SDS in proportion to its relative molecular 
mass. The protein sample is mixed with SDS which destroys the complex structure 
of proteins (secondary and non-disulphide linked tertiary strutures) and is strongly 
attracted toward an anode (positively-charged electrode) in an electric field. 
Heating the protein sample to 95oC further promotes denaturation, allowing SDS 
to bind.  
Polyacrylamide gels restrict larger molecules from migrating as fast as smaller 
molecules. As the charge-to-mass ratio is approximately the same amongst SDS-
denatured polypeptides, the final separation of proteins is dependent almost 
entirely on the mass differences. If proteins of known mass are run 
simultaneously with an unknown sample the, masses of unknown proteins can be 
estimated (Schägger and von Jagow, 1987).  
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Assessment of protein quality and protein purifications were routinely assessed 
by SDS-PAGE and Western Blot (WB) analysis using the buffers described in 
section 2.1.8.  
Initially, the casting apparatus was set up as per the manufacturer’s guidelines. 
The mixture for the 12.5% separation gel and 4.5% stacking gel were prepared as 
detailed in section 2.1.8. Polymerisation occurs on addition of APS and TEMED, 
hence is not added until the gel was ready to be cast. The 12.5% gel is responsible 
for separating the polypeptides and was cast first by adding the APS and TEMED 
and immediately pouring the mixture between two clean glass plates and 
covering with a layer of isopropanol to promote more rapid polymerisation of the 
gel. Once the gel polymerises, the isopropanol layer was removed by inverting the 
apparatus. APS and TEMED was then added to the 4.5% stacking gel gently poured 
on top of the polymerised 12.5% gel, and a comb was inserted to make wells in 
preparation for loading of the protein samples.  
Once this gel fully polymerised, the plates were placed into the electrophoretic 
chamber, the chamber was filled with 1x electrophoresis buffer and the comb was 
removed. The samples to be assessed were prepared by adding 4x loading buffer 
dye and/or dH2O to a final concentration of 1x and heating for 5 minutes at 95
oC, 
to further promote denaturation. A volume of 10 μL sample was added to each 
well and 6 μL PageRulerTM prestained protein ladder was added to the first well. 
The gels were resolved at 160V until the tracker dye (bromophenol blue) almost 
reached the bottom of the gel, typically taking 55 minutes. The gels are then 
removed from the casting apparatus and stained with InstantBlueTM for 10-30 
minutes and washed with dH20.  
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2.2.1.4 Western Blotting 
 
Western blotting is a commonly used technique in cell and molecular biology that 
allows for the identification of specific proteins from a complex mixture of 
proteins extracted from cells or tissue homogenate. There are three key steps 
involved in western blotting, namely (1) separation by size (SDS-PAGE), (2) 
transfer to a solid support, and (3) marking target protein using a specific primary 
and labelled secondary antibody for visualisation (Mahmood and Yang, 2012).  
Initially, proteins were separated by SDS-PAGE as described above (section  
2.2.1.3) and once the gel was resolved, it was left to soak in transfer buffer, along 
with adsorbent tissue paper (4 pieces cut to gel dimensions) and a nitrocellulose 
membrane (also cut to gel dimensions), for 10 minutes. A sandwich consisting of 2 
layers of adsorbent tissue paper, nitrocellulose membrane, SDS-PAGE gel and 2 
further layers of adsorbent tissue paper was prepared as shown in Figure 2.1. Air 
bubbles were removed by carefully rolling each of the layers with a plate 
spreader. The separated proteins were then transferred to the nitrocellulose 
membrane using the Trans-Blot® SD Semi-Dry Transfer System (Bio-rad) at 15V for 
21 minutes. 
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Figure 2.1: Semi-Dry transfer system. This system allows for rapid transfer of separated 
proteins from an SDS-PAGE gel to a nitrocellulose membrane which can then be probed 
for detection of specific protein. (Figure adapted from Biorad, 2015.) 
The nitrocellulose membrane was then blocked for non-specific binding in 20 mL 
PBSM in a large weigh boat for 2 hours at room temperature (RT) or overnight at 
4oC with agitation. The membrane was washed briefly three times with PBST and 
three times with PBS. The membrane was then incubated with 10 mL of 1 in 2,000 
dilution of a primary antibody diluted in PBSTM for 1 hour at RT in a large weigh 
boat with gentle agitation. The antibody solution was discarded and the 
membrane washed as before. Next, the membrane was incubated with a specific 
relevant enzyme labelled secondary antibody (1 in 2,000 dilution), prepared in 10 
mL PBSTM, for 1 hour at RT, with gently agitation. The antibody solution was 
discarded and the membrane was washed as before. The development of the 
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specific reaction was achieved by adding (5-10 mL) of the liquid enzyme substrate, 
3, 3', 5, 5' -tetramethylbenzidine (TMB) and was stopped by washing with dH2O 
(20-30 mL).  
2.2.1.5 Preparation of bacterial cell stocks 
 
Cell stocks were prepared in either 1.5 mL tubes or 96-well culture plates and 
stored at -80oC.  
96-well plates: Individual colonies were picked and grown in SB media 
supplemented with the appropriate antibiotic(s) overnight at 220 rpm at 37oC in a 
sterile 96 well plate. A sample of 30 μL was taken from each well of the overnight 
cultures and was inoculated into 370 μL fresh 2xTY media for expression. The 30 
μL sample taken was replaced with 30 μL 80% (v/v) glycerol and the plates kept at 
-80oC for storage. 
1.5 mL tubes: An overnight culture was prepared by inoculating 5 mL SB 
(supplemented with the relevant antibiotic(s)) with 5 μL clone. The cultures were 
grown overnight at 37oC while shaking at 220 rpm. The cells were collected by 
centrifugation at 5,500 x g for 30 minutes at 4oC. The supernatant was discarded 
and the cells were resuspended in SB containing 20% (v/v) glycerol and snap 
frozen in liquid nitrogen and stored at -80oC.  
2.2.1.6 Buffer exchange and protein concentration 
 
Protein samples sometimes need to be buffer exchanged to a solution more 
suitable for long-term storage. Proteins were concentrated and buffer exchanged 
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using Vivaspin columns (GE healthcare) with an appropriate molecular weight 
'cut-off' (Mr 3,000 to 100,000, depending on protein size). A 5 mL sample was 
concentrated and buffer exchanged against PBS/0.02% (w/v) NaN3 using a 
Vivaspin column with a 10,000 molecular weight 'cut-off'. The 6 mL concentrator 
was washed with 5 mL water by centrifugation at 5,500 x g 4oC for ~5 minutes and 
then washed twice more in the same manner with 5 mL sterile PBS. The protein 
sample was added to the column and buffer exchanged by centrifuging the 
sample (5,500 x g, 4oC) until the volume reached ~0.5 mL. It was then refilled with 
sterile PBS/0.02% (w/v) NaN3 to 5 mL and centrifuged as above until the volume 
reached ~0.5 mL. This process was repeated 3 times. On the last spin, the volume 
was brought to 1 mL and the concentrated protein was pipetted from the surface 
of the Vivaspin column and stored at -20oC in aliquots of 20 μL.  Protein was 
quantified using the NanoDrop (A280nm).   
2.2.2 Screening and analysis of an existing avian anti-fPSA library 
 
Anti-fPSA scFv and Fab clones from a previously built avian anti-fPSA library 
(generated by Dr. Conor Hayes) were screened for the identification of a high 
affinity anti-fPSA antibody. Briefly, an adult leghorn chicken was immunised with 
the fPSA molecule according to protocols described by Barbas et al. (2001). The 
animal was sacrificed, the spleen harvested and the RNA extracted with Trizol 
reagent using a well established protocol (see section 2.2.3.3). 
The amplified antibody variable genes were assembled by splice by overlap 
extension polymerase chain reaction and cloned  into the pComb3X vector for 
subsequent panning (Barbas et al., 2001). Anti-fPSA specific clones were isolated 
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from a large library (3.10 x 108 cfu/mL) following three rounds of selection from 
the antibody repertoire displayed on the surface of filamentous phage by 
immobilised panning against fPSA.  
2.2.2.1 Identification of anti-fPSA specific antibody fragments by 
monoclonal ELISA and Biacore 4000 
 
Glycerol stocks plates of anti-fPSA scFv and Fab clones were used for inoculation 
in 150 μL SB supplemented with 50 μg/mL carbenicillin in sterile 96-well culture 
plates. The plates were cultured overnight at 37oC while shaking at 220 rpm. The 
following day, 30 μL of this overnight culture was infected into 370 μL fresh SB 
media supplemented with 50 μg/mL carbenicillin, 1 mM MgS04 (and 1x505 (0.5% 
(v/v) glycerol & 0.05% (v/v) glucose), in sterile deep-well 96-well plate. The plates 
were shaken at 220 rpm at 37oC, until an optical density (OD600) of ~0.600 was 
reached. A final concentration of 0.1 mM IPTG was added to each well and the 
plate was left shaking at 220 rpm overnight at 30oC. An ELISA plate was coated 
overnight at 4oC with 100 μL/well 0.5 μg/mL fPSA and subsequently blocked at 
37oC for 1 hour with 200 μL/well PBSM. The plate was then washed three times 
with 200 μL/well PBST, followed by three times with PBS.   
The antibodies were extracted from the periplasmic space of the cell by placing 
the plates at -80oC for 10 minutes and then thawing at 37oC for 20 minutes. One 
hundred microliters/well of 1 mg/mL lysozyme/PBS was added to disrupt the cell 
wall. The plate was then subject to two successive freeze-thaw cycles. This 
commonly used method releases periplasmic proteins by bursting the E. coli cells. 
The cell extracts were cleared by centrifugation at 5,500 x g for 30 minutes and 
the resultant lysate was diluted 1 in 2 in PBSTM and 100 μL of this lysate was then 
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added to the wells of the ELISA plate and incubated for 1 hour at 37oC. The plate 
was washed as before and the fPSA-specific scFv/Fab clones were then detected 
with 100 μL/well with a HRP-labelled goat anti-hemagglutinin tag antibody (anti-
HA) diluted (1 in 2,000) in PBSTM for 1 hour at 37oC. The plate was washed as 
before and 100 μL/well TMB substrate enzyme solution added to each well. The 
plate was incubated at RT for approximately 5 minutes to allow chromophore 
development, after which the reaction was stopped by addition of 50 μL/well 10% 
(v/v) HCl. The absorbance was read at 450 nm using the Tecan SafireTM plate 
reader. 
Clones with an absorbance value greater than 0.3 were taken further for kinetic 
analysis using the BiacoreTM 4000, this work was carried out in collaboration with 
Dr. Paul Conroy.  Briefly, the clones were screened using a previously immobilised 
CM5 dextran chip (Conroy et al., 2012) functionalised with approximately 6,000 
RU of anti-HA epitope by EDC-NHS coupling chemistry over spots 1, 2,4 and 5. 
Anti-fPSA scFv and Fab lysates were diluted 1:3 (in duplicate) in HBPS-EP+ and 
analysed in a capture approach over the anti-HA surface at 25oC. The diluted 
lysates were captured on spots 1, 2, 4 and 5 and two concentrations of fPSA (10 
nM and 50 nM diluted in HBS-EP+) were then passed over the captured antibody 
fragments and referenced against the unmodified surface on spot 3. The data was 
evaluated with BiaEvaluation software using the ‘2 over 2’ template and curves 
were fitted with a 1:1 Langmuir binding equation.  
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2.2.2.2 Optimisation of expression of scFv B8 
 
The gram negative bacterium Escherichia coli is the most widely used host for the 
expression of recombinant proteins.  It is fast and inexpensive to test a wide 
variety of possible strategies in E. coli, its genetics are well characterised and 
numerous mutant strains are available. Expression in E. coli requires 4 key 
elements; (1) protein of interest (2) a bacterial expression vector (3) an expression 
cell line, and (4) equipment/materials (i.e. Shaking Incubator, media, etc.).  Within 
these fundamental elements however, there are multiple questions that must be 
answered – which expression vector should be used? What strain(s) should be 
chosen? Should the protein of interest be tagged? What affinity tag is the best? 
What temperature is optimal for induction? Many steps in the production of 
recombinant proteins must be optimised and there is no ‘right’ answer to any of 
the above questions, as every protein is different and the ‘right’ expression 
strategies and purification protocols must be worked out for each individual 
protein (Francis and Page, 2010).  
An overview of the optimisation of expression of the anti-fPSA scFv clone B8 is 
detailed in Figure 2.2.  Briefly, inoculation was carried out in 5 mL SB 
supplemented with 50 μg/mL carbenicillin with 2 μL of a glycerol stock of scFv B8 
and the culture was then grown overnight at 37oC while shaking at 220 rpm. This 
was then sub-cultured into 50 mL fresh SB media supplemented with 50 μg/mL 
carbenicillin, 1 mM MgS04 and 1x 505 in a 250 mL flask and grown at 37
oC until 
OD600 of 0.600 was reached. The culture was then induced. Various 
concentrations of IPTG were assessed at both 25oC and 30oC. Over different time 
points (ranging from 2 hours to overnight), 1 mL samples were taken and 
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centrifuged and the pellet was retained at -80oC for further analysis. The pellets 
were lysed, as previously described, and loaded onto SDS-PAGE gels for analysis.  
 
Figure 2.2: Overview of optimisation of expression of recombinant proteins in E. coil. 
Optimal conditions must be assessed for expression of each individual recombinant 
antibody clone to identify the best expression strategies. There are 3 basic steps 
involved in expression of recombinant proteins. A small overnight culture was prepared 
and grown o/n at 37
o
C. This was then used to inoculate a fresh starter culture which was 
cultured until mid-log phase when it was induced. Expressions studies must be carried 
out where temperature, time and inducer concentration are rigorously optimised.   
2.2.2.3 Purification of scFv B8 by Immobilised Metal Affinity 
Chromatraphy (IMAC) 
 
The DNA sequence specifying a string of six to nine histidine residues is frequently 
used in vectors for production of recombinant proteins. Recombinantly expressed 
His-tagged proteins can be purified by a single-step affinity chromatography called 
immobilized metal ion affinity chromatography (IMAC), which is commercially 
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available in different kinds of formats, Ni-NTA matrices being the most widely 
used (Spriestersbach et al., 2015). 
 
Supports such as beaded agarose or magnetic particles can be derivatized with 
chelating groups to immobilize the desired metal ions, which then function as 
ligands for binding and purification of biomolecules of interest. This forms the 
basis IMAC. The chelator most commonly used as ligands for IMAC is 
nitrilotriacetic acid (NTA). Once the NTA-agarose resin is prepared, it can be 
"loaded" with the desired divalent metal (e.g., Ni, Co, Cu, Fe). Using nickel as the 
example metal, the resulting affinity support is usually called Ni-chelate or Ni-NTA 
resin. IMAC has many advantages including strong, specific binding, mild elution 
conditions and the ability to control selectivity by including low concentrations of 
imidazole in chromatography buffers (Sulkowski, 1985; Gräslund  et al., 2008).  
 
An overnight culture of scFv was prepared by inoculating 2 μL glycerol stock scFv 
into 1 mL SB media with 50 μg/mL carbenicillin, with shaking at 220 rpm at 37oC. 
This culture was sub-cultured into five 1 L flasks, each containing 200 mL SB, 50 
μg/mL carbenicillin, 1 mM MgS04 and 1x505. The culture was grown at 37
oC until 
an OD600 of 0.600 was reached and it was subsequently induced with 0.1 mM IPTG 
at 25oC for 4 hours. The expressed cultures were centrifuged at 5,500 x g for 45 
minutes 4oC (four 250 mL bottles) and the supernatant was discarded and the 
pellets frozen at -80oC.  
 
The following day, the pellets were thawed at 37oC for 10 minutes (in the water 
bath) and each pellet was then resuspend thoroughly in 7.5 mL OSB-A and 
transferred to two 85 mL Oakridge tubes (i.e. 15 mL in each bottle). OSB-B (15 mL) 
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was added and the tubes were incubated for 10 minutes at RT on a roller. The 
shocked cells were collected by centrifugation at 14,000 x g (4oC) for 20 minutes. 
The supernatant was discarded and pellets resuspended in 15 mL periplasmic 
buffer. Samples were place on ice for 10 minutes, with gently mixing by inverting 
the tubes every 2 minutes to ensure the solution was homogenous.  
 
The cell debris was collected by centrifugation at 14,000 x g (4oC) for 20 minutes. 
The supernatant was pooled in a 50 mL tube and the protein was sequentially 
filtered through a 0.45 μm and 0.2 μm filters. A 100 μL sample of the filtered 
lysate was taken to use for SDS-PAGE analysis.  Ni-NTA nickel resin slurry (2 mL) 
was added to a chromatography column and allowed to settle. The resin bed was 
washed with 10 mL PBS twice (20 mL total) followed by 10 mL of OSB-A buffer. 
The lysate was then applied to the column, collecting the 'flow-through' in a 50 
mL tube (collecting a 100 μL sample and labelling it F1- i.e. ‘flow through’ 1). This 
process was repeated (collecting a 100 µL sample again-FT2). The column was 
then washed with 10 mL of wash buffer #1 (1XPBS + 150 mM NaCl + 10 mM 
Imidazole, pH 8.0) collecting in a 50 mL tube and again sampling (100 μL- W1). The 
retained protein was then eluted by adding 5 mL elution buffer (250 mM 
Imidazole in 0.3 M NaCl and 50 mM Sodium Phosphate, pH 8.0) to the column and 
collecting (taking 100 µL sample – EP (eluted protein)). The eluted sample (5 mL) 
was then concentrated and buffer exchanged against PBS/0.02 % (w/v) NaN3 using 
a Vivaspin column with a 10,000 molecular weight 'cut-off' level, as described in 
section 2.2.1.6. 
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2.2.2.4 Anti-fPSA scFv B8 Sandwich ELISA Limit of Detection (LOD) Assay 
 
The anti-fPSA scFv B8 Limit of Detection (LOD) was determined in accordance with 
the Clinical and Laboratory Standards Institute’s (CLSI) published guidelines “EP17, 
Protocols for Determination of Limits of Detection and Limits of Quantification” 
(Armbruster and Pry, 2008). This ELISA was carried out 24 times to ensure the 
accuracy of the result. 
 
A 96 well Maxisorb plate was coated with 100 μl/well 1 μg/mL goat anti-PSA 
polyclonal antibody diluted in PBS and incubated for 1 hour at 37°C. The plate was 
the blocked with PBSM (200 μl/well) and incubated for 1 hour at 37°C. The wells 
were then washed three times with PBST and three times with PBS (200 μl/well). 
One hundred microliters per well of fPSA in varying dilutions (serial dilutions from  
32 to 0 ng/mL) was then added to the plate and again incubated at 37°C for 1 
hour. The plate was washed as before and anti fPSA scFv B8 was then added in 
PBSTM (100 μl/well) at a 1:1000 dilution and incubated for 1 hour at 37°C. The 
plate was then washed as before. A 1 in 2,000 dilution of the secondary antibody, 
HRP-labelled anti-HA, diluted in PBSTM (100 μl/well) was added and incubated as 
before. The plate was washed as before and 100 μL/well TMB substrate solution 
was added to each well. The plate was incubated at RT for approximately 5 
minutes to allow chromophore development, after which the reaction was 
stopped with 50 μL/well 10% (v/v) HCl. The absorbance was read at 450 nm using 
the Tecan SafireTM plate reader. 
 
 
 
77 
 
2.2.2.5 Kinetic analysis of scFv B8 using Biacore 3000 
 
In the past decade surface plasmon resonance (SPR)-based optical biosensors, 
such as Biacore systems have evolved as standard tools for antibody 
characterisation and binding interaction studies. The Biacore 3000 instrument 
uses SPR technology for biomolecular interaction analysis in ‘real-time’ without 
the need for labels. This instrument provides a comprehensive characterisation of 
binding events and kinetics analysis can also be conducted with relative ease 
(Wilson, 2002; Leonard et al., 2011). 
2.2.2.5.1 Instrument /Chip preparation 
 
The Biacore 3000 was cleaned prior to the study using a ‘super desorb’ program at 
25oC. This is carried out to ensure that the instrument is completely free of any 
residual proteins, for optimal performance. A maintenance chip was docked and 
the instrument was primed five times with 0.05% (w/v) SDS, followed by priming 
once with ultrapure water, and, finally,  five times with 50 mM glycine-NaOH, pH 
9.5. The maintenance chip was replaced with a research-grade carboxymethylated 
(CM) dextran sensor chip CM5 sensor chip, and primed three times with running 
buffer. For this study sterile filtered and degassed HEPES-buffered saline (HBS, pH 
7.4: 10 mM 4-(2-hydroxyethly) piperazine 1 ethanesulfonic acid N-(2-
hydroxyethyl) piperazine N’-(2-ethanesulfonic acid)(HEPES), 150 mM NaCl, 3 mM 
EDTA (ethylenediaminetetraacetic acid) and 0.05% [v/v] Tween 20 ) as both 
running and sample preparation buffer. The CM5 chip was then preconditioned 
with two consecutive injections each of 50 mM NaOH and 0.05% (w/v) SDS for 10 
seconds at a flow rate of 100 μL/minute.  
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A preconcentration study was carried out by passing over 25 μg/mL anti-HA 
polyclonal antibody in 10 mM NaOAc over a range of pH values to determine the 
optimal pH to promote efficient immobilisation. The pH which demonstrates the 
highest RU level of antibody onto the underivatised surface was employed for the 
immobilisation of the polyclonal antibody to the surface, using amine-coupling 
chemistry.  The surface chip was activated by passing over equal volumes of 400 
mM EDC (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride) and 
100 mM NHS (N-hydroxysuccinimide) at a flow rate of 10 μL/minute for 7 
minutes. Anti-HA polyclonal antibody was diluted in 10 mM NaOAc to 25 μg/mL, 
pH 4.4 was passed over the activated surface at a flow rate of 10 μL/minute for 15 
minutes. Unreactive NHS groups were capped and deactivated and non-covalently 
bound antibody was removed by addition of 1 M ethanolamine-hydrochloride 
solution at a flow rate of 10 μL/minute for 7 minutes. Post-conditioning of the 
surface was then carried out by pulsing the surface 5 times with 15 μL injections 
of 20 mM NaOH.  
2.2.2.5.2 Kinetics analysis of anti-PSA scFv B8 using Biacore 3000 
 
Kinetic analysis of avian anti-PSA clone B8 was performed using the kinetic wizard 
functionality and data analysis was evaluated using BIAevaluation 4.1.1 software.  
Initially, the appropriate dilution for capture of approximately 100 RU of scFv B8 
was assessed. Purified scFv B8 was diluted 1 in 3,000 in running buffer and passed 
over the anti-HA surface at a flow rate of 30 μL/minute for 3 minutes. After 
capturing the scFv, fPSA was passed over the surface in varying concentrations 
(12.5, 6.25, 3.12 (in duplicate), 1.6, 0.8, 0.4 and 0 nM) for 3 minutes, and allowed 
to dissociate for 12 minutes.  Regeneration of the surface was carried out by 
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passing over 20 mM NaOH for 10 seconds at a flow rate of 30 μL/minute. The data 
obtained was evaluated using the kinetic evaluation model of BiaEvaluation 
software version 4.1.1. The dataset from the reference flow cell (underivatised 
surface) was subtracted to remove any systemic effects, and the 0 nM fPSA 
concentration binding response (buffer only) was subtracted from each antigen 
response, thus double referencing subtracting the dataset.  Kinetic constants were 
modelled on the curves with 1:1 Langmuir binding model.  
2.2.2.6 Crystal Structure of scFv B8  
 
The interaction of antibodies with their congante antigen involes a multidude of 
non-covalent interactions between the epitope (binding site on the antigen) and 
the paratope (binding site on the antigen). An indepth understanding of the 
molecular structure of antibodies and antigens can provide insight into the 
mechanisms of molecular recognition and therefore assist in the rational design of 
antibodies (Finlay and Almagro, 2012; Sela-Culang et al., 2013).  
Through a collaboration with Dr Paul Conroy and Prof. James Whisstock (Monash 
University, Melbourne, Australia), the crystal structure of scFv B8 was solved, as 
descibed  by Conroy et al., (2014). Briefly, scFv B8 was expressed, purified and 
subsequently concentrated to 5.8 mg/ml, with a 3-kDa concentrator (Merck-
Millipore). Crystallization was carried out by the hanging drop method with a 1:1 
mixture of protein and mother liquor at 4 °C, where crystals formed in 3–7 days. 
Initial crystal forming conditions were identified from the Basic Crystallization kit 
for Proteins (Sigma). Crystals of scFv B8 were obtained in 0.1 M NaOAc, pH 4.6, 
0.2 M ammonium sulphate. The crystals were flash-cooled in liquid nitrogen using 
25% (v/v) glycerol as the cryoprotectant.  
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Data sets were collected at the Australian Synchrotron MX2 beamline at 100K. 
The data was merged and processed using XDS , POINTLESS, and SCALA. 
Molecular Modelling and replacement was carried as described (Conroy et al., 
2014). 
2.2.2.7 Site-Directed Mutagenesis of scFv B8 
 
Mutant variants of scFv B8 were generated in order to develop a greater 
understanding of the structural and binding properties of this antibody fragment. 
Plasmid DNA was prepared by inoculation of scFv B8 in 10 mL SB media 
supplemented with 50 μg/mL carbenicillin. The culture was grown o/n at 37oC 
with shaking at 220 rpm. The overnight culture was centrifuged at 5,500 x g for 30 
minutes at 4oC, the supernatant was discarded and the plasmid was purified using 
the Nucleospin plasmid prep, as per the manufacturer’s guidelines.  Plasmid DNA 
was eluted in 40μL MG H2O and quantified with the NanoDrop 
spectrophotometer. 
scFv B8 plasmid DNA was then used as a template to introduce a cysteine to 
serine double mutant at C97 and C100 in CDRH3 (C97/100S; scFv B8 Ser MT) and a 
cysteine to alanine double mutant at C97 and C100 in CDRH3 (C97/100A; scFv B8 
Ala MT). These site specific mutations were generated by polymerase chain 
reaction (PCR) site directed mutagenesis (SDM) using KOD Hot Start DNA 
polymerase (Quickchange mutagenesis), with the following forward and reverse 
primers; 
scFv B8 Ser MT(C97/100S) Forward: 
5’GATCTCATAGCAGTGGTAGCCGGAATGCTGCTCTCATC3’ 
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scFv B8 Ser MT(C97/100S) Reverse: 
5’GATGAGAGCAGCATTCCGGCTACCACTGCTATGAGATC3’ 
scFv B8 Ala MT(C97/100A) Forward: 
5’GATCTCATGCCAGTGGTGCCCGGAATGCTGCTCTCATC3’ 
scFv B8 Ala MT(C97/100A Reverse: 
5’GATGAGAGCAGCATTCCGGGCACCACTGGCATGAGATC3’ 
The PCR reaction was set up according to Table 2.1 under the conditions outlined 
in Table 2.2 
Table 2.1: Reaction set up for site-directed mutagenesis of scFv B8  
Component Test (μl) Control (μl) 
Buffer 5 5 
MgCl2 3 3 
dNTP’s 1 1 
Fwd 1 NA 
Rev 1 NA 
DNA (50 ng) 1 1 
Polymerase 0.2 0.2 
dH20 37.8 39.8 
Final Volume 50μL 
 
Table 2.2: PCR conditions for site-directed mutagenesis of scFv B8 
Stage Step Temp (⁰C) Time (sec) Number of 
Cycles 
1.  Initial 
Denature 
95 30 1 
2.  Denature 
Annealing 
Extension 
95 
56 
72 
30 
60 
420 
 
16 
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Before transformation the original plasmid, which served as a template must be 
removed from the reaction to minimise background. This was carried out using 
the restriction digestion enzyme Dpn I. To the PCR product, 1 μL of Cut Smart 
Buffer (10x) and 1 μL Dpn I restriction enzyme (10 U/μL) was added and incubated 
at 37oC for approx. 6 hours. The reaction was then deactivated following 
incubation at 65oC for 10 minutes. PCR clean-up was performed as per 
manufacturer’s guidelines: Promega, Wizard® SV Gel and PCR Clean-Up System 
and the DNA was eluted in 20 μL MG H2O. 
Transformation of E. coli. was carried out using  XL1 blue competent cells for 
uptake of the PCR product. Two microliters of DNA was added to 50 μL XL1 blue 
competent cells and this mix was left on ice for 30 minutes. The cells and DNA 
were then subjected to heat shock for 45 seconds at 42oC followed by cooling on 
ice for 5 minutes. The transformed material was then added to 100 μL pre-
warmed 2xTY media to the tube and and allowed to outgrow by incubating for 1 
hour at 37oC while shaking at 220 rpm.  This mix (150 μL) was then plated out on 
LB/Carb plates and incubated o/n at 37oC. The control sample was treated in the 
same manner.  
Four clones were picked and grow o/n in 3 mL 2xTY supplemented with 1:1,000 
dilution of carbenicillin. The overnight culture was centrifuged at 5,500 x g for 30 
minutes at 4oC, the supernatant was discarded and the plasmid was purified using 
the Nucleospin plasmid prep as per the manufacturer’s guidelines.  Plasmid DNA 
was eluted in 40 μL MG H2O and subsequently sent for sequencing to ensure that 
the correct mutations were introduced. Sequence analysis was carried out by 
Source Bioscience Ltd, Dublin, Ireland. The DNA sequences obtained were 
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translated using the translate tool from Expasy (http://web.expasy.org/translate/) 
and the amino acid sequences were then exported to PowerPoint. 
2.2.2.8 Expression and Purification of scFvB8 Ser MT by Immobilised 
Metal Affinity Chromatraphy (IMAC) and Gel Filtration 
 
Anti-fPSA scFv B8 Ser MT was expressed and purified according to methods 
described in Conroy et al., (2014). Briefly, single colonies were selected from LB-
Agar supplemented with 25 μg/mL carbenecillin and grown overnight in 5 mL  SB 
supplemented with 25 μg/mL carbenecillin and 1% (w/v) glucose at 37oC, with 
shaking at 220 rpm. This starter culture was used to inoculate 100 mL SB with 25 
μg/mL carbenicillin and was grown to O.D600 = 0.6-0.8 before sub-culturing into 10 
x 500 mL SB with 25 μg/mL carbenicillin (2 L flasks). At O.D600 = 0.6-08 the cultures 
were induced with 0.2 mM IPTG, at 30oC with shaking at 230 rpm o/n.  
The bacteria were harvested by centrifugation (3, 220 x g) at 4oC for 20 minutes. 
Soluble scFv were released from the periplasmic space by osmotic shock in a two-
step process. The pellet was first thoroughly resuspended in 1X TBS (25 mM Tris, 
pH 8.0, 150 mM NaCl) and an equal volume of 2X shock buffer (50 mM Tris, pH 
8.0, 300 mM NaCl, 1 M sucrose and 2 mM EDTA) was added before incubation at 
RT for 15 minutes. Shocked cells were recovered by centrifugation at 12, 400 x g, 
4oC for 20 minutes, followed by resuspension in ice-cold 5 mM MgSO4 and 
incubation on ice for 15 minutes.  
The periplasmic-stripped cells were collected by centrifugation (27, 200 x g at 4oC 
for 20 minutes) and 0.2 times the volume of 5X binding buffer (125 mM Tris, pH 
8.0, 750 mM NaCl, 50 mM imidazole, 0.02% (w/v) NaN3) was added to the 
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supernatant. HisBind (Novagen) resin (1 mL equilibrated in 30 mL 1X binding 
buffer) was added and scFv recovered by batch binding overnight at 4oC on an 
end-over-end roller. The resin was collected by gravity flow and washed with 30 
mL binding buffer followed by a second wash with 30 mL wash buffer (25 mM Tris, 
pH 8.0, 150 mM NaCl, 20 mM imidazole, 0.05% (v/v) Tween® 20, 0.02% (w/v) 
NaN3). Bound protein was eluted with 10 mL elution buffer (1X running buffer 
with 300 mM Imidazole) in 1 mL fractions.  
Eluted protein fractions from the IMAC purification were further purified by 
chromatography on a size exclusion column. Gel filtration (also referred to as size 
exclusion chromatography) is a basic chromatography technique that separates 
proteins based on differences in molecular size and shape as they pass through a 
gel filtration medium in a packed column, and it is often used as a final polishing 
step following IMAC purification for isolation of highly pure protein (Kim et al., 
2011).  
An S75 (16/60) gel filtration column (GE Healthcare) was equilibrated with 25 mM 
Tris pH 7.4, 150 mM NaCl, 0.02% (w/v) NaN3 (1CV = 50 mL). Protein-containing 
fractions (eluates 2-6) of scFv B8 Ser MT (26 mg/mL) previously purified by IMAC 
were applied to the column at a flow rate of 1 mL/minute. Fractions were 
collected after 0.4CV until 1CV was reached. Protein was monitored online by A280 
using the dedicated Unicorn control and evaluation software (GE Healthcare). 
Protein peaks were analysed by SDS-PAGE. 
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2.2.2.9 Determination of the crystal structure of scFv B8 Ser MT 
 
Binding capabilities of antibodies are highly diverse given the structural 
similarities between most antibodies (Sela-Culang et al., 2013). However, in 
contrast to the mechanism employed by humans, mice and primates, the V-gene 
repertoire of the chicken does not utilise highly diverse sequences resulting in the 
generation of unique canonical classes (Finlay and Almagro, 2012).  A limited 
number of avian antibody crystal structures are available in the Protein Data Bank 
(PBD) which has restricted our understanding of the structural consequences of 
uniquely chicken features. Investigation of the structural properties of mutant 
variants of scFv B8 by X-ray crystallography will aid in the understanding of the 
binding mechanisms employed by chicken antibodies.  
2.2.2.9.1 Coarse screening for optimal crystal formation conditions  
 
The process of growing protein crystals has been carried out for well over 150 
years. Initially, identification of crystal-forming conditions occurred empirically. 
However, this has now moved towards more rationality as a result of a better 
understanding of the physical chemistry of protein crystal growth. Factors such as 
the solubility of the protein, source and amount of protein,  the type of salts used 
to induce super-saturation, temperature and need for additives are of great 
importance for identification of conditions that will sustain crystal growth (Giegé, 
2013). Screening is now simplified and made easier through the use of 
commercially available screening kits. These kits provide crystallisation conditions 
that included buffers with pHs ranging from pH 4.2 to pH 10.5, polymers (PEG 400 
to PEG 8,000), salts (such as sodium chloride, ammonium sulphate, calcium, zinc, 
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and magnesium), alcohols (such as ethanol, isopropanol, 1,4-butanediol, 
pentaerythritol propoxylate, and 2-methyl-2,4-pentanediol), organics (such as 
dioxane, polyacrylic acid, and Jeffamine), and many other additives that promote 
crystal growth (Kim et al., 2011).  
Coarse  screening was carried out in a 24-well plate format. The antibody 
fragment was concentrated to 16.12 mg/mL, since a very high protein 
concentration is necessary for setting crystallization trials. A total of 240 
conditions were set using the following kits; Crystal Screen, 2 x 24-well plates  
(Hampton Research), Crystal Screen II, 2 x 24-well plates  (Hampton Research), 
PEG/Ion, 2 x 24-well plates  (Hampton Research), and The JCSG Suite, 4 x 24-well 
plates  (Qiagen).  The 24-well plates were prepared by application of a ring of 
petroleum jelly to the circumference of each well and  adding 500 μL of mother 
liquor (one condition per well) from each kit. A 1 μL drop of mother liquor was 
placed in the centre of the siliconised glass slides (Hampton Research) and 1 μL of 
anti-PSA scfvB8 Ser MT (at 16.12 mg/mL) was mixed into the mother liquor drop. 
A control drop was included for each condition in which a 1 μL drop of mother 
liquor was mixed with 1 μL buffer and placed in the centre of the siliconised glass 
slides below the protein drop. The slide was then carefully inverted and sealed. All 
plates were then placed in a vibration excluded temperature controlled 
environment at both 20oC and 4oC and monitored daily for crystal formation. 
2.2.2.9.2 Fine-Screening to refine optimal crystal formation conditions  
 
Once initial crystal forming conditions were identified refinement of these 
conditions was carried out in order to increase the size and number of crystalline 
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outcomes. Fine screening conditions were prepared for the Crystal Screen II 
condition number 13 and condition number 5. Each buffer was mixed thoroughly 
by vortexing for 1-2 minutes before setting up the trays for crystallisation.   
Refinement of Crystal Screen number 13 (0.2 M ammonium sulphate, 0.1 M 
sodium acetate trihydrate, pH 4.6, 30 % (w/v) polyethylene glycol monomethyl 
ether (PEG MME) 2,000)  
Variations to the pH of this condition with the amount of PEG MME were assessed 
to see if crystal growth formation was improved. Investigation for the optimal pH 
of this condition was performed by adding 50 μL sodium acetate (pH range 4.3-
4.8) according to the plate map (Figure 2.3). Stock solutions of PEG MME 2000 
(50% (w/v)) and ammonium sulphate (NH4)2SO4 (2M) were used to make up the 
individual buffers; the amounts added are detailed in Table 2.3. Once the buffers 
were prepared, 450 μL of each condition was added to the appropriate well 
(Figure 2.3). Once buffers were prepared and thoroughly mixed, trays were set as 
for the coarse screen (section 2.2.2.9.1)   
Table 2.3: Preparation of buffers for fine screening for scFv B8 Ser MT crystal formation 
% PEG MME 
2000 
Amount of 
Stock to Add 
(mL) 
Ammonium 
Sulphate (M) 
concentration 
Amount of 
Stock to Add 
(mL) 
MG H2O 
(mL) 
28% (w/v) 3.53 0.2 M 0.63 1.51 
29% (w/v) 3.65 0.2 M 0.63 1.39 
30% (w/v) 3.78 0.2 M 0.63 1.26 
31% (w/v) 3.91 0.2 M 0.63 1.13 
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Figure 2.3 Plate map detailing the layout of the fine screening of condition number 13 
for scFv B8 Ser MT crystal formation. To see if variations in pH could improve on crystal 
formation a variety of different pH’s (pH 4.3-pH 4.8) was assessed (across-red), as was 
the % PEG MME (28-31%) (down-purple). Drops (1 μ) were set with a 1:1 ratio of mother 
liquor: protein. 
Refinement of Crystal Screen number 5 (2 M ammonium sulphate, 5% (v/v) 2-
propanol) 
Varying high pH was performed by adding 50 μL Bis-Tris pH buffers (pH range 5.3-
6.0) whilst varying low pH was carried out with acetate pH buffers (pH range 4.3-
4.8) according to the plate map in Figure 2.4. Stock solutions of IPA (25% (v/v)) 
and (NH4)2SO4 (2 M) were used to make up the individual buffers as detailed in 
Table 2.4. Original conditions were also repeated, using freshly prepared 2 M 
(NH4)2SO4 and varying % IPA, according to Figure 2.4.  Four hundred and fifty 
microliters of each buffer was added to the appropriate well according to the 
plate maps (Figure 2.4). Once buffers were prepared and thoroughly mixed, trays 
were set as for the coarse screen (section 2.2.2.9.1). 
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Table 2.4: Preparation of buffers for fine screening for scFv B8 Ser MT crystal formation 
% 2 Propanol Amount of 
Stock to 
Add (mL) 
Ammonium 
Sulphate (M) 
concentration 
Amount of 
Stock to Add 
(mL) 
MG H2O 
(mL) 
5% (v/v) 1.26 2 M 3.71 0.704 
4% (v/v) 1.01 2 M 3.71 0.954 
3% (v/v) 0.76 2 M 3.71 1.204 
2% (v/v) 0.5 2 M 3.71 1.464 
 
 
Figure 2.4: Plate map detailing the layout of the fine screening of condition number 5 for 
scFv B8 Ser MT crystal formation. Fine screening was carried out to see if variations in 
pH could improve on crystal formation at a variety of different pH’s (A) pH 4.3-pH 4.8, 
using NaOAc buffers), (B) pH 5.3-pH 6.0) was assessed (across-red), (C) The original 
condition was also repeated and the percentage 2-propanol (5%-2% [v/v]) was also 
investigated for each new condition (down-purple). Drops (1 μ) were set with a 1:1 ratio 
of mother liquor: protein. 
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2.2.2.9.3 X-ray diffraction of crystals of scFv B8 Ser MT 
 
Individual crystals were collected in a gionometer loop (allows the crystal to be 
positioned accurately within the X-ray beam and rotated) of an appropriate size 
(decided visually under a microscope) and flash-cooled in liquid nitrogen using 
25% (v/v) glycerol as a cryoprotectant. X-ray diffraction data-sets were collected 
at the Australian Synchrotron MX2 beamline. The data was merged and processed 
using XDS , POINTLESS, and SCALA. Molecular Modelling and replacement was 
carried out by Dr. Paul Conroy, as previously described (Conroy et al., 2014). 
2.2.2.10 Kinetic analysis of scFv B8 Ser MT using Biacore 3000 
 
Kinetic analysis was performed in a similar manner to the wild type (2.2.2.5). 
However, fPSA was immobilised to the CM5 chip. The instrument was prepared as 
described in section 2.2.2.5 and a preconcentration study to identify the optimal 
buffer conditions for subsequent immobilisation was carried out by preparation of 
25 µg/mL fPSA, diluted in 10 mM NaOAc over a range of pH values ( 4.0, 4.2, 4.4, 
4.6, 4.8 and 5.0). This was then passed over the underivatised chip surface (flow 
cell 4) and the degree of electrostatic binding monitored. 
Once the optimal pH for immobilisation was identified fPSA was immobilised to 
the surface by passing fPSA diluted in 10 mM NaOAc to 25 μg/mL, pH 4.0 over the 
activated surface at a flow rate of 10 μL/minute for 15 minutes. Following capping 
and deactivation of any unreactive NHS groups, the surface was post conditioned 
with 20 mM NaOH. 
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ScFv B8 Ser MT was kinetically characterised using the kinetic wizard functionality 
on the Biacore 3000 and the subsequent data generated was evaluated using 
BIAevaluation software, version 4.1.1.  Purified scFv B8 Ser MT was passed over 
the fPSA surface in varying concentrations (2.5 μM, 1.25 μM, 0.625 μM (x2), 0.312 
μM, and 0 μM) for 3 minutes, and allowed to dissociate for 12 minutes.  The 
surface was regenerated using a 20 mM solution of NaOH. The dataset from the 
reference flow cell (flow cell 3 - underivatised surface) was subtracted to remove 
any systemic effects, and the zero nM scFv B8 Ser MT concentration binding 
response (buffer only) was subtracted from each antigen response, thus double 
reference subtracting the dataset. Kinetic constants were modelled on the curves 
using a 1:1 Langmuir binding model.  
2.2.2.11 Expression and Purification of scFvB8 Ala MT by Immobilised 
Metal Affinity Chromatraphy (IMAC) and Gel Filtration 
 
Expression and purification of scFv B8 Ala MT was carried out by Dr. Paul Conroy 
as described in section 2.2.2.8 and in Conroy et al., (2014). 
2.2.2.12 Crystal Structure of scFv B8 Ala MT 
 
The crystal structure analysis of scFv B8 Ala MT was carried out by Dr. Paul 
Conroy. Briefly, scFv B8 Ala MT was expressed, purified and concentrated to 6.5 
mg/mL, with a 3 kDa concentrator (Merck Millipore). Crystallisation was carried 
out using the hanging drop method with a 1:1 mixture of protein and mother 
liquor. Screening for crystal forming conditions was carried out using Crystal 
Screen and Crystal Screen II (Hampton Research) at 20oC. Crystals of scFv B8 Ala 
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MT were obtained in 2 M ammonium sulphate.  The crystals were flash-cooled in 
liquid nitrogen using 25% (v/v) glycerol as the cryoprotectant.  
 
Data sets were collected at the Australian Synchrotron MX2 beamline at 100K. 
The data was merged and processed using XDS , POINTLESS, and SCALA. 
Molecular Modelling and replacement was carried as described by Conroy et al., 
(2014). 
2.2.2.13 Mammalian Expression of recombinant PSA 
 
At 24 hours prior to transfection HEK293F cells were seeded to 1-2 x 106 cells/mL 
in Freestyle Media (Gibco) in 125 mL shake flasks, in the following conditions; 5% 
(v/v) carbon dioxide, 37°C atmosphere, at  120 rpm.  Recombinant PSA 
(pSecTag2A/PSA, Invitrogen) was transiently expressed using 1 μg/mL DNA and 
polyethylenimine (PEI) as transfection reagent, with a DNA:PEI ratio of 1:3. 
FreeStyle Media was supplemented with 2 mM glutamine, 5 g/L (w/v) lupin and 
the glucose concentration was adjusted to 33 mmol/L. Six days following 
transfection, the PSA-containing medium was collected for subsequent 
purification.  
2.2.2.14 Purification of recombinant PSA by Immobilised Metal Affinity 
Chromatraphy (IMAC) and Gel Filtration 
 
IMAC purification was carried out by adding the PSA-containing medium to 
HisBind (Novagen) resin (1 mL equilibrated with 1x binding buffer). Batch binding 
was then carried out overnight at 4oC on an end-over-end roller. The resin was 
collected by gravitational flow and washed with 10 mL 1x binding buffer. The 
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recombinant PSA was recovered by eluting in 5 mL elution buffer (300 mM 
Imidizole), in 0.5 mL fractions.  Protein-containing fractions were concentrated to 
1 mL in a 3 kDa concentrator.  A S75 (16/60) gel filtration column (GE Healthcare) 
was equilibrated with 25 mM Tris, pH 7.4, 150 mM NaCl, 0.02% (w/v) NaN3 (1CV = 
50 mL). The concentrated 1 mL sample of PSA (1 mg/mL), previously purified by 
IMAC, was applied to the column at a flow rate of 1 mL/minute. Fractions were 
collected after 0.4 column volumes until 1 column volume was reached. Protein 
was monitored online by A280 using the dedicated Unicorn control and evaluation 
software (GE Healthcare). Protein peaks were analysed by SDS-PAGE. 
2.2.2.15 Formation of recombinant PSA-scFvB8 complex  
 
Anti-PSA scFvB8 was expressed in E. coli and purified by IMAC and gel filtration 
chromatography as previously described in section 2.2.2.8 and in Conroy et al., 
(2014). The antibody-antigen complex was formed by adding 1 mg/mL anti-fPSA 
scFvB8 to 0.4 mg/mL recombinant PSA, mixing gently and leaving static on ice for 
2 hours (excess antibody was added to ensure there would be no free antigen in 
solution). This antibody-antigen complex was then concentrated down to 1 mL 
and resolved on a S75 (16/60) gel filtration column (GE Healthcare) as before. 
Purified complexed protein fractions were collected and analysed by SDS-PAGE. 
2.2.2.16 Determination of the crystal structure of recombinant PSA-
scFvB8 complex by X-ray crystallography 
 
Elucidation of the molecular architecture of antibody-antigen provides a wealth of 
information across a variety of areas, including immunity (understating the 
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mechanisms that underlie antibody-antigen interactions), antibody engineering 
and epitope recognition. Knowledge of the antibody-antigen interface can identify 
residues that are important for antigen recognition and, hence, guide engineering 
of better binders (Sela-Culang et al., 2013). There is currently no protein antigen-
avian antibody structure available in the PDB. Determination of the crystal 
structure of recombinant PSA-scFvB8 complex could aid in our understanding of 
chicken antibody recognition. 
2.2.2.16.1 Coarse screening for optimal crystal formation conditions 
 
Coarse screening was carried out in 24-well plate format. The complex was 
concentrated to 7.3 mg/mL and the plates (24-well) were prepared by application 
of a ring of petroleum jelly to the circumference of each well and adding 500 μL of 
mother from the ProPlex Kit (Molecular Dimensions) for the crystallization of 
protein complexes. Conditions 1 to 96 were placed in the appropriate number of 
wells (4 x 24-well plates, per kit). A 0.5 μL drop of mother liquor was placed in the 
centre of the siliconised glass slides (Hampton Research) and 0.5 μL of anti-PSA 
scfvB8/PSA protein complex (at 7.3 mg/mL) was mixed into the mother liquor 
drop. Two controls were used, firstly to ensure the crystals formed were complex 
crystals a drop was included for each condition in which a 0.5 μL drop of mother 
liquor was mixed with 0.5 μL scFv B8 (at 3.25 mg/mL). The second control  drop 
included (for each condition)  a 0.5 μL drop of mother liquor was mixed with 0.5 
μL buffer and placed in the centre of the siliconised glass slides below the protein 
drop.  The slide was then carefully inverted and sealed. All plates were then 
placed in a vibration excluded temperature controlled environment at 20oC and 
monitored daily for crystal formation. 
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2.2.2.16.2  Fine screen to refine for optimal crystal formation conditions 
  
Fine screeening for condition 2.8 from the identified in Proplex crystallisation kit, 
(0.1 M magnesium acetate, 0.1 M MOPS pH 7.5, 12% (w/v) PEG 8000) was carried 
out by Dr. Paul Conroy by optimising for pH and percentage PEG 8000. 
2.2.2.16.3 X-ray diffraction of crystals of recombinant PSA-scFvB8 
complex  
 
X-ray diffraction of the recombinant PSA-scFvB8 complex was carried out by Dr. 
Paul Conroy. Individual crystals were collected in a goniometer loop of an 
appropriate size (decided visually under a microscope) and flash-cooled in liquid 
nitrogen using 25% (v/v) glycerol as a cryoprotectant. X-ray diffraction data-sets 
were collected at the Australian Synchrotron MX2 beamline. The data was merged 
and processed using XDS, POINTLESS, and SCALA. Molecular Modelling and 
replacement was carried out as previously described (Conroy et al., 2014). 
2.2.3 Generation of an avian scFv antibody library 
2.2.3.1 Immunisation of female Leghorn chickens with cPSA 
 
An adult female Leghorn chicken was administered 1 mL, subcutaneous injections, 
with cPSA for the production of cPSA recombinant antibodies. Namely, on day 
one, the chicken was immunised with 25 μg/mL cPSA in 550 μL PBS emulsified in a 
1:1 ratio with Freund’s complete adjuvant (FCA). The mixture was vigorously 
mixed to ensure a complete homogenous solution. Subsequent ‘booster’ 
injections were performed at 4 week intervals until a sufficient titre was achieved. 
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Booster immunisations were performed with 12.5 μg/mL cPSA mixed in a 1:1 ratio 
with Freund’s incomplete adjuvant (FCIA). One-week post immunisation bleeds 
were taken from the animal to determine antiserum titre. Once the titre reached 
an appropriate level, as determined by ELISA, the animals were given a final boost 
7 days prior to being sacrificed by lethal injection (EUTHASOL® (pentobarbital 
sodium and phenytoin sodium) Solution). Both the bone marrow and the spleen 
were harvested for library building.  
2.2.3.2 Determination of avian serum antibody titres for immune 
response to cPSA  
 
An indirect ELISA was used to determine the serum antibody titres from the 
immunised animal. A Maxisorp plate was coated with equimolar concentrations 
(30 nM) of cPSA/fPSA/ACT diluted in PBS for 1 hour at 37oC (100 μL/well).  The 
plate was then blocked with 200 μL/well PBSM for 1 hour at 37oC and washed 
three times with 200 μL/well PBST, followed by three washes with PBS only.  A 
series of dilutions ranging from 1 in 100 to 1 in 1,100,000 of the chicken serum, 
diluted in PBSTM was added to the plate (100 μL/well) and incubated for 1 hour at 
37oC. The plate was washed as before. Donkey anti-chicken-horse radish 
peroxidase-conjugated secondary antibody (anti-IgY-Fab-HRP) was added at 1 in 
2,000 dilution in PBSTM (100 μL/well) and incubated for 1 hour at 37oC. The plate 
was washed as before and 100 μL/well TMB substrate solution was added to each 
well. The plate was incubated at room temperature for approximately 5 minutes 
to allow chromophore development, after which the reaction was stopped with 
addition of 50 μL/well 10% (v/v) HCl. The absorbance was read at 450 nm using 
the Tecan SafireTM plate reader. 
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 2.2.3.3 Isolation and quantification of total cellular RNA from spleen and 
bone marrow  
Total RNA was recovered from the bone marrow (BM) and spleen (SP) of the 
immunised animals by chloroform-based extraction carried out immediately after 
sacrifice. All reagents used were of molecular grade and all materials were treated 
with RNazeTM Zap where possible. This is a decontamination solution that 
completely removes RNase contamination from glass and plastic surfaces. Minor 
trace quantities of RNase can lead to degradation during the RNA purification 
process and hence it is essential to ensure the method can be carried out in an 
‘RNase-free’ environment (Sigma Aldrich, 2015).  
Prior to use the laminar unit was cleaned with 70% (v/v) isopropanol alcohol (IPA) 
and RNazeTM Zap to ensure an uncontaminated environment. The spleen was 
removed and placed in a 50 mL 'RNAse-free tube' and 10 mL of ice-cold TRIzol® 
reagent was immediately added (TRIzol® reagent is an extremely hazardous 
substance and Personal Protective Equipment must be worn when handling 
TRIzol®. Spills must be cleaned up immediately with great care. Hypochlorite’s 
should not be used to clean up spills and TRIzol® must be kept away from heat or 
any ignition sources at all times).  SP and BM were processed separately.  
The bone-marrow (from the thigh bone) was extracted by cutting away the joint 
knuckles at either end of the bone and flushing out as much marrow as possible 
using a syringe and needle containing 10 mL  TRIzol® reagent. Both SP and BM 
were homogenised using a pre-sterilised (with presept), RNazeTM Zap-washed and 
autoclaved homogeniser probe. A further 20 mL TRIzol® reagent was added to 
each tube when both the SP and BM were completely homogenised and allowed 
to stand at room temperature (RT) for 10 minutes. The mixture was then 
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centrifuged at 5,000 x g for 20 minutes at 4oC (ensuring that the centrifuge was 
cooled prior to centrifugation) and the resultant supernatant carefully transferred 
to a 50 mL Oakridge tube. Six mL chloroform was added and the tube was 
vigorously shaken (by hand) for 15 seconds and then let stand at RT for 15 
minutes. 
The Oakridge tubes were centrifuged at 15,500 x g for 30 minutes at 4oC and the 
upper aqueous layer was removed and transferred to an 85 mL Oakridge tube. 
Hence a small residual portion of the aqueous layer was left rather than risking 
disruption of the interphase. To the aqueous layer, 15 mL IPA was added with 
vigorous shaking for 15 seconds and then let stand at RT 10 minutes, followed by 
centrifugation at 15,500 x g for 30 minutes at 4oC. The resultant supernatant was 
removed carefully ensuring the opaque pellet was undisturbed. The pellet was 
then washed with 30 mL 75% (v/v) MG EtOH and centrifuged at 15,500 x g for 30 
minutes at 4oC and the pellet was left to air dry for 20 minutes. The pellet was 
resuspended in 500 μL 'RNase-Free' water and the RNA quantified using the 
NanoDrop spectrophotometer. A sufficient quantity of RNA was used for cDNA 
synthesis and the remainder was ethanol-precipitated as described in section 
2.2.1.2 and stored at -80oC.  
2.2.3.4 Reverse transcription of total RNA to cDNA 
 
The superscript III first stand synthesis system for RT-PCR was used, as per the 
manufacturer’s guidelines to transcribe the total RNA obtained to cDNA. Once 
successfully synthesised the cDNA was quantified using the NanoDrop 
spectrophotometer and stored in 10 μL aliquots at -80oC. 
 
99 
 
2.2.3.5 ScFv library construction 
 
Antibody library construction was carried out as described by Andris-Widhofp and 
co-workers (Andris-Widhopf et al., 2000; Barbas et al., 2001). The initial steps 
carried out were the amplification of the VH and VL domains from the synthesised 
cDNA from the BM and SP of the chicken. The primers used for library 
construction are detailed in Phage Display: A Laboratory Manual, and are used to 
clone antibody fragments into the pComb3x vector series. Chapter 9 of this book 
details the construction of a chicken scFv library with a short linker (GGSSRSS) or a 
long linker (GGSSRSSSSGGGGSGGGG) (Barbas et al., 2001). The primers were 
commercially synthesised by Integrated DNA Technologies and are listed herein.  
Variable Heavy (VH) 
CSCVHo-FL: (sense - Long linker) 
5’ GGT  CAG  TCC  TCT  AGA TCT  TCC  GGC  GGT  GGT  GGC  AGC  TCC  GGT  GGT  
GGC  GGT  TCC  GCC  GTC  ACG  TTG  GAC  GAG 3’ 
CSCG-B (reverse) 
5’ CTG  GCC  GGC  CTG  GCC  ACT  AGT  GGA  GGA GAC GAT GAC TTC  GGT CC 3’ 
Variable Light (Vλ) 
CSCVK (sense) 
5’ GTG  GCC  CAG  GCG  GCC  CTG  ACT  CAG  CCG  TCC  TCG  GTG  TC 3’ 
CKJo-B (reverse) 
5’ GGA  AGA  TCT  AGA  GGA  CTG  ACC  TAG  GAC  GGT  CAG  G 3’ 
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SOE Overlap  
CSC-F (sense) 
5’ GAG  GAG  GAG  GAG  GAG  GAG  GTG GCC CAG GCG  GCC  CTG  ACT  CAG  3’ 
CSC-B (reverse) 
5’ GAG  GAG  GAG  GAG  GAG  GAG  GAG  CTG  GCC  GGC  CTG  GCC  ACT  AGT  
GGA  GG 3’ 
2.2.3.6 PCR amplification and optimisation of the heavy and light-chain 
variable (VH and VL) coding regions 
 
To amplify the V genes, one VH amplification and one Vλ amplification were carried 
out. Initially magnesium chloride (MgCl2) is optimised for the VH/VL amplifications. 
Identification of the optimal MgCl2 concentration is crucial for successful 
amplifications. Optimisation reactions were carried out at 1x (Table 2.5) and once 
the optimal MgCl2 concentration was determined large-scale reactions (10x) were 
carried out. The PCR reaction(s) were carried out under the following conditions 
outlined in Table 2.6. 
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Table 2.5: Small-scale (1x) reaction for magnesium chloride (MgCl2) optimisation for 
VH/VL amplifications 
 1.5mM 2.0mM 3.0mM 4.0mM 
GoTaq Buffer 
(5x) 
10 μL (1x) 10 μL 10 μL 10 μL 
MgCl2 (25 mM) 3 μL 4 μL 6 μL 8 μL 
MG H2O 33.75 μL 32.75 μL 30.75 μL 28.75 μL 
Fwd. Primer    
(60 pM) 
0.5 μL 0.5 μL 0.5 μL 0.5 μL 
Rev. Primer    
(60 pM) 
0.5 μL 0.5 μL 0.5 μL 0.5 μL 
dNTPs (100 
mM) 
1 μL 1 μL 1 μL 1 μL 
cDNA 1 μL (1 μg) 1 μL (1 μg) 1 μL (1 μg) 1 μL (1 μg) 
Polymerase 
(5U/(μL) 
0.25 μL (1.25 
U) 
0.25 μL (1.25 
U) 
0.25 μL (1.25 
U) 
0.25 μL (1.25 
U) 
Total Vol 50 μL 50 μL 50 μL 50 μL 
 
Table 2.6: PCR conditions for amplification of the VH and VL chain genes 
Stage Step Temp (⁰C) Time 
(seconds) 
Number of 
cycles 
1 Initial 
Denature 
94 120 1 
2 Denature 
Annealing 
Extension 
94 
56 
72 
15 
30 
60 
 
30 
3 Final Extension 72 600 1 
 
In order to ensure there was sufficient PCR product to carry out the second round 
PCR’s, 10x reactions were carried out four times for each of the variable domains 
for both the BM and SP. The products were pooled and ethanol-precipitated 
overnight at -20oC, as described in section 2.2.1.2. The pellet was resuspended in 
36 μL pre-warmed (in the 80oC dryer) MG H2O and 4 μL 10x loading buffer dye (for 
a final concentration of 1x). The products were resolved at 90V for 50 minutes on 
1.5% (w/v) agarose gel and bands at approximately 350bp (VL) and 450bp (VH) 
were excised and gel-purified as per the manufacturer’s guidelines using 
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Nucleospin Extract II – Extraction of DNA from agarose gels kit. The purified 
products were quantified using the NanoDrop spectrophotometer.  
2.2.3.7 Generation of scFv-fragment by splice-by-overlap extension (SOE) 
PCR 
 
For the second round PCR, the purified first round PCR products were mixed in 
equal ratios to generate the final overlap product. The primers used in the first 
round PCR produce identical sequences that serve as the overlap for the 
extension of the full length scFv construct in the VL-VH orientation (Barbas et al., 
2001).  The use of High Fidelity Platinum Taq polymerase was employed for these 
PCR cycles to ensure optimal yield, fidelity and specificity. Initially the magnesium 
sulphate (MgSO4) concentration was optimised at 1x and once the optimal 
concentration was determined large-scale (10x) reactions were carried out. The 
SOE- PCR reactions were carried out under the conditions set out in Table 2.8 
Table 2.7: Small-scale (1x) magnesium sulphate (MgSO4) optimisation for SOE-PCR  
 1.5mM 2.0mM 3.0mM 4.0mM 
High Fidelity 
PCR Buffer 
(10x) 
5 μL 5 μL 5 μL 5 μL 
MgSO4 (50 
mM) 
1.5 μL 2 μL 3 μL 4 μL 
M.G. H2O Up to 50 μL Up to 50 μL Up to 50 μL Up to 50 μL 
Fwd. Primer 
CSC-F 
0.5 μL 0.5 μL 0.5 μL 0.5 μL 
Rev. Primer 
CSC-B 
0.5 μL 0.5 μL 0.5 μL 0.5 μL 
dNTPs 1 μL 1 μL 1 μL 1 μL 
VL 100 ng 100 ng 100 ng 100 ng 
VH 100 ng 100 ng 100 ng 100 ng 
Polymerase 
(5U/μL) 
0.2 (IU) 0.2 (IU) 0.2 (IU) 0.2 (IU) 
Total 50 μL 50 μL 50 μL 50 μL 
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Table 2.8: SOE-PCR reaction conditions 
Stage Step Temp (⁰C) Time 
(seconds) 
Number of 
cycles 
1 Initial 
Denature 
94 120 1 
2 Denature 
Annealing 
Extension 
94 
56 
68 
15 
30 
60 
 
30 
3 Final Extension 68 600 1 
 
The SOE products were pooled and ethanol-precipitated, as described in section 
2.2.1.2 and gel-purified by resolution on 1.5% (w/v) agarose gel at 90V for 50 
minutes. These were then extracted using the Nucleospin Extract II – Extraction of 
DNA from agarose gels kit, as per the manufacturer’s guidelines. The purified scFv 
constructs were eluted in 30 μL MG H2O. 
2.2.3.8 Preparation of pComb3xSS vector  
 
The pComb3xSS vector was kindly supplied by Prof. Carlos Barbas III (Scripps 
Institute, La Jolla, California). An overnight culture (100 mL SB media 
supplemented with 50 μg/mL carbenicillin) was inoculated with 2 μL of glycerol 
stock of pComb3xSS and cultured at 37oC with shaking at 220 rpm. The overnight 
culture was centrifuged at 5,500 x g for 30 minutes at 4oC, the supernatant was 
discarded and the plasmid was purified using the Nucleobond Xtra midi kit, as per 
the manufacturer’s guidelines. Plasmid DNA was eluted in 300 μL MG H2O and 
quantified with the NanoDrop spectrophotometer.  
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2.2.3.9 Restriction digestion of the SOE-PCR and phagemid cloning vector 
pComb3xSS  
 
The PCR products for both the SP and BM and the pComb3xSS vector were 
prepared for cloning by restriction digestions with Sfi I. All reactions were set up 
as detailed in Table 2.5 and incubated at 50oC for 5 hours in the PCR thermocycler. 
The scFv product was ethanol-precipitated @ -20oC overnight, as previously 
described in section 2.2.1.2.  
Table 2.9: Sfi I digest of pComb3xSS vector and scFv inserts 
 SP BM pComb3xSS 
DNA 10 ng 10 ng 20 ng 
Buffer 4 (10x) 1x 1x 1x 
BSA (100x) 1x 1x 1x 
M.G. H20 Up to 200 μL Up to 200 μL Up to 200 μL 
Sfi I (20 U/μL) 36 U/μg 36 U/μg 6 U/μg 
Total 200 μL 200 μL 200 μL 
 
The pComb3xSS vector was then subjected to further digestion with Xho I and Xba 
I by incubation at 37oC for 1 hour followed by 65oC for 30 minutes (Table 2.6). The 
vector was then Antarctic phosphatase-treated (Table 2.10) by incubation at 37oC 
for 30 minutes, followed by deactivation at 65oC for 15 minutes. Post triple 
digestion and Antarctic phosphatase treatment the vector was ethanol-
precipitated, as outlined in section 2.2.1.2. 
 
 
 
 
105 
 
Table 2.10: Xba I and Xho I digestion of pComb3xSS vector 
 pComb3xSS pComb3xSS (vol) 
Xba I 3 U/μg 1.5 μL 
Xho I 3 U/μg 1.5 μL 
 
Table 2.11: Antarctic phosphatase treatment of digested pComb3x vector 
 pComb3x pComb3x (vol) 
Antarctic Phosphatase 
Buffer (10x) 
1x 20 μL 
Antarctic Phosphatase  
(5 U/μL) 
1 U/μg 4 μL 
 
2.2.3.10 Library ligation and transformation 
 
The purified Sfi I digested scFv products for BM and SP were ligated into the 
pComb3x using T4 DNA ligase.  The reaction set up (detailed in Table 2.12) and 
was carried out overnight at RT.  
Table 2.12: Ligation reaction components of scFv insert and pComb3x vector 
 SP BM Control 
Vector 1.4 μg 1.4 μg 1.4 μg 
Insert 0.7 μg 0.7 μg NA 
MG H2O Up to 100 μL Up to 100 μL Up to 100 μL 
Ligase Buffer (10x) 1x 1x 1x 
T4 DNA Ligase    
(500 U/μL) 
10 U/μg 10 U/μg 10 U/μg 
Total 100 μL 100 μL 100 μL 
 
The overnight ligated product was deactivated at 65oC for 20 minutes and then 
ethanol-precipitated at -20oC overnight as described in section 2.2.1.2. The 
overnight precipitates were centrifuged at 19,500 x g for 30 minutes at 4oC, 
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washed with 100 μL ice cold 70% (v/v) EtOH and centrifuged again at 19,500 x g 
for 10 minutes at 4oC. The resultant pellet was resuspended in 15 μL pre-warmed 
(in an 80oC oven) MG H2O 
Electrocompetent XL1 Blue E. coli cells (150 μL) (Agilent technologies, Ireland) 
were placed in pre-chilled 2.5 mm electroporation cuvettes (Bio-rad) and allowed 
to thaw before adding 7.5 μL of the library ligation. The cells and DNA were let 
stand on ice for 1 minute and then the cuvette was gently tapped to ensure the 
suspension was at the base of the cuvette. DNA was electroporated into the cells 
using the Gene Pulser xCell Electroporation system (Bio-rad) with the following 
parameters: 2.5 kV, 25 μF and 200 Ω (τ = 4.0 msec). The cuvette was immediately 
flushed with 1.25 mL of SOC media and transferred to a pre-warmed 50 mL tube. 
All the electroporated samples (x2 BM & x2 SP) were combined in one 50 mL tube 
(approximately 5 mL total volume). To facilitate the recovery of the cells they 
were then incubated at 37oC for 1 hour with shaking at 220 rpm.   
A control ligation (digested pComb3x – no insert) was also electroporated and 
treated in the same fashion. To both the library and the control, 10 mL of pre-
warmed (37oC) SB media and 3 μL carbenicillin (100 mg/mL) and 30 μL 
tetracycline (5 mg/mL) were added and a transformation titre was carried out by 
taking 2 μL of this 15 mL culture and adding to 198 μL SB media. This was then 
plated on LB agar plates supplemented with 100 μg/mL carbenicillin (10 μL and 
100 μL was plated each for control and library). The control was discarded and the 
library was incubated for 1 hour at 37oC, 220 rpm.  
After this incubation, 4.5 μL carbenicillin (100 mg/mL) was added and the culture 
was incubated further for 1 hour at 37oC, while shaking at 220 rpm. Two mL of 
MK1307 (1 x1011 pfu/mL) helper-phage was then added and the library was 
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transferred to a 500 mL baffled flask containing 183 mL pre-warmed SB 
supplemented with 91.5 μL (100 mg/mL) carbenicillin and 370 μL tetracycline (5 
mg/mL). This culture was incubated for 2 hours with shaking, as before.  For the 
final step, 280 μL of 70 mg/mL kanamycin was added and the culture was left to 
shake at 220 rpm o/n at 37oC. At this stage the library was displayed on the phage 
particle and is ready for panning.  
2.2.3.11 Selection of cPSA-specific phage particles by panning against 
immobilised cPSA on an ELISA plate 
2.2.3.11.1 Phage rescue after each round of panning 
 
Phage rescue is the process carried out during each round of panning to recover 
the selected scFv-displaying phage from the culture supernatant. After incubation 
of the transformed library overnight (section 2.2.3.10) the phage are isolated by 
PEG precipitation.  The o/n culture was split into four 50 mL aliquots in (new, 
clean) 85 mL Oakridge tubes and centrifuged at 11,000 x g for 15 minutes, 4oC. 
The supernatant was then transferred to clean (new) 85 mL Oakridge tubes and 
12.5 mL 5x PEG (total volume 62.5 mL) was added. The samples were gently 
inverted several times and left on ice for 30 minutes. The precipitated phage was 
then centrifuged at 16,000 x g for 15 minutes at 4oC, the supernatant discarded 
and the tubes left inverted on paper towel for 10 minutes. The phage-containing 
pellet was resuspended in 2 mL 1% (w/v) BSA/PBS/0.02% (w/v) NaN3 and 
transferred to a 2 mL micro-centrifuge tube. Residual cell debris was then 
removed by centrifugation at 19,500 x g for 5 minutes at 4oC. This supernatant 
was then transferred to fresh 2 mL tube and kept at 4oC until ready to add to the 
ELISA plate for panning (R0). 
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2.2.3.11.2 Library panning on an cPSA immobilised surface 
 
Panning consist of several rounds of binding phage to an antigen immobilised on 
the wells of an ELISA plate, washing, elution of the specifically bound phage and 
reamplification (Figure 1.4). The wells of a 96-well ELISA plate (8 wells) were 
coated with 50 μg/mL ACT (depletion step) (100 μL/well) diluted in PBS and a 
separate plate was coated 50 μg/mL cPSA (100 μL/well) diluted in PBS and both 
were left overnight at 4oC. The ACT/cPSA was removed and the coated wells were 
blocked with PBSM 200 μL/well, for 1 hour at 37oC. The blocking solution was 
removed and the plate was washed 3 times with PBST and 3 times with PBS (200 
μL/well).  The freshly rescued phage (100 μL/well) were then added to each of the 
8 wells of the ACT plate and allowed to interact with the ACT for 2 hours at 37oC.  
Unbound scFv displaying phage were then removed from this plate and 
transferred to the cPSA plate and allowed to interact with the cPSA for 2 hours at 
37oC. Non-specific phage were then removed by washing 5 times with PBST and 5 
times PBS, by pipetting up and down 5 times vigorously followed by leaving static 
for 5 minutes for each wash step. Specifically bound cPSA displaying scFv phage 
were then eluted with 100 μL per well of 10 mg/mL trypsin/PBS by pipetting up 
and down vigorously 10 times and incubating for 30 minutes at 37oC.  
These eluted phage were then infected into 2mL of mid-exponential E. coli XL-1 
blue cells and let stand at RT for 15 minutes. This 2.8 mL was then added to 6 mL 
pre-warmed SB media with 1.6 μL carbenicillin (100 mg/mL) and 12 μL 
tetracycline (5 mg/mL) in a 50 mL tube and incubated for 1 hour at 37oC with 
shaking at 220 rpm. An output titre was performed at this point by taking 2 μL of 
this 8 mL culture and diluting to 200 μL in SB, and subsequently plating out 10 μL 
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and 100 μL of this on LB-carbenicillin (50 μg/mL)-agar plates and incubating  
upside down o/n at 37oC. After the hour incubation, a further 2.4 μL carbenicillin 
(100 mg/mL) was added and the 50 mL tube was incubated for an additional hour 
at 37oC, with shaking at 220 rpm.  
Helper phage (MK13O7: 1x1011 pfu/ml) were then added and the culture was 
transferred to a 500 mL baffled flask containing 91 mL pre-warmed SB,  46 μL 
carbenicillin (100 mg/mL) and 184 μL tetracycline (5 mg/mL) and incubated at 
37oC for 2 hours, while shaking at  230 rpm. The final step was the addition of 140 
μL kanamycin (70 mg/mL), and the culture was left to grow o/n 37 oC, with shaking 
at 230 rpm.  
An input titre was also performed (during the incubation steps) by adding 10 μL of 
the rescued phage to 90 μL SB, mixing gently and then making 10-fold serial 
dilutions to 10-9.  Mid-exponential E. coli XL-1 blue (50 μL) was then infected with 
a 2 μL sample of each of the 10-7 10-8 and 10-9 phage dilutions, and incubated at RT 
for 15 minutes. These were then plated out on LB-carbenicillin (50 μg/mL) agar 
plates and incubated upside down at 37oC overnight.  
 This panning process was repeated for 3 rounds on successive days with 
increasing washes and decreasing antigen concentrations (Table 2.13) to enrich 
for high-affinity cPSA-specific clones.  
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Table 2.13: Panning conditions employed for four successive rounds of panning for 
isolation of cPSA-specific scFv antibody 
 
Round Depletion (ACT) cPSA Number of 
wells 
Washes 
R1  50 µg/mL  50 µg/mL 8 3 + 3 
R2  50 µg/mL   50 µg/mL 4 5 + 5 
R3  50 µg/mL  25 µg/mL 4 5 + 5 
 
2.2.3.12 Polyclonal phage ELISA  
 
After completion of 3 rounds of panning experiments a polyclonal phage ELISA 
was carried out to assess the success of the panning conditions and to identify 
which phage pool shows specific binding to cPSA.  A 96-well ELISA plate was 
coated with 100 nM cPSA in PBS (100 μL/well) o/n at 4oC. The plate was then 
blocked with PBSM (200 μl/well) and incubated for 1 hour at 37°C. The wells were 
then washed three times with PBST and three times with PBS (200 μl/well). 
Dilutions (1 in 5) of each round of phage in PBSTM were prepared and 100 μL per 
well (in duplicate) was added to the plate and incubated for 1 hours at 37 oC.  
The plate was then washed as before and 100 μL/well of a 1 in 2,000 dilution of 
HRP-labelled anti-M13 antibody prepared in PBSTM was added to the plate for 1 
hour at 37oC. The plate was washed as before and 100 μL/well TMB enzyme 
substrate solution was added to each well. The plate was incubated at RT for 
approximately 5 minutes to allow chromophore development, after which the 
reaction was stopped with 50 μL/well of 10% (v/v) HCl. The absorbance of the 
wells was then read at 450 nm using the Tecan SafireTM plate reader. 
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2.2.3.13 Soluble expression of scFv fragments and subsequent 
monoclonal ELISA analysis 
 
To express the avian anti-cPSA scFv clones, the scFv-containing phage were 
directly infected into a non-suppresser strain of E. coli. A growing culture (OD600 
0.6-0.8) of TOP10F’ E. coil was infected with 50 μL phage from each round of 
panning and incubated for 1 hour at 37oC. Dilutions from 10-1 to 10-7 were 
prepared in SB and plated (100 µL) on LB/carbenicillin (100 μg/mL) agar plates and 
incubated o/n at 37oC. Single colonies from each round were picked and grown in 
150 μL SB supplemented with 50 μg/mL carbenicillin in the inner 60 wells of 
sterile 96-well culture plates and cultured overnight at 37oC with shaking at 220 
rpm. Glycerol stocks were made of these plates, as described in section 2.2.1.5.  
To assess the specificity of these scFv clones for cPSA, 30 clones from each round 
of panning were inoculated in 150 μL SB supplemented with 50 μg/mL 
carbenicillin and cultured overnight at 37oC with shaking at 220 rpm in a sterile 
96-well culture plates. The following day, 30 μL of this overnight culture was 
infected into 370 μL fresh SB media supplemented with 50 μg/mL carbenicillin, 1 
mM MgS04 and 1x505 (0.5% (v/v) glycerol & 0.05% (v/v) glucose), in a sterile 
deep-well 96-well plate. The plate was shaken at 220 rpm at 37oC, until an optical 
density (OD600) of ~0.600 was reached. A final concentration of 0.1 mM IPTG was 
added to each well and the plate was left shaking at 220 rpm overnight at 30oC. 
An ELISA plate was coated overnight at 4oC with 100 μL/well 100 nM cPSA and 
subsequently blocked at 37oC for 1 hour with 200 μL/well PBSM. The plate was 
then washed three times with 200 μL/well PBST, followed by three times with 
PBS.   
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The scFv antibodies were extracted from the periplasmic space of the cell by 
placing the plates at -80oC for 10 minutes and then thawing at 37oC for 20 
minutes. One hundred microliters/well of 1 mg/mL lysozyme/PBS were added to 
disrupt the cell wall. The plate was then subjected to two successive freeze-thaw 
cycles. This commonly used method releases periplasmic proteins by bursting the 
E. coli cells. The cell extracts were cleared by centrifugation at 5,500 x g for 30 
minutes and the resultant lysate was diluted 1 in 2 in PBSTM and 100 μL of this 
scFv-lysate was added to the wells of the ELISA plate and incubated for 1 hour at 
37oC. The plate was washed as before and the cPSA-specific scFv clones were then 
detected with 100 μL/well with a HRP tagged anti-IgY (H+L) antibody diluted (1 in 
2,000) in PBSTM for 1 hour at 37oC. The plate was washed as before and 100 
μL/well TMB substrate solution was added to each well. The plate was incubated 
at RT for approximately 5 minutes to allow chromophore development, after 
which the reaction was stopped with 50 μL/well 10% (v/v) HCl. The absorbance 
was read at 450 nm using the Tecan SafireTM plate reader.  
2.2.3.14 Small scale expression and purification of anti-cPSA 2D2SG by 
Immobilised Metal Affinity Chromatraphy (IMAC) 
 
An overnight culture of scFv was prepared by inoculating 2 μL glycerol stock scFv 
2D2SG into 10 mL SB media with 50 μg/mL carbenicillin, with shaking at 220 rpm 
at 37oC. This culture was sub-cultured into a fresh 100 mL culture of SB containing 
50 μg/mL carbenicillin, 1 mM MgS04 and 1x505. The culture was grown at 37
oC 
until an OD600 of 0.6-0.8 was reached and it was subsequently induced with 0.2 
mM IPTG at 30oC for overnight. The expressed culture was then centrifuged at 
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5,500 x g for 45 minutes 4oC (50 mL in two 85 mL Oakridge tubes) and the 
supernatant was discarded.  
Each pellet was then resuspended completely in 7.5 mL OSB-A and transferred to 
a clean 85 mL Oakridge tube (i.e. 15 mL total). OSB-B (15 mL) was then added and 
the incubated for 10 minutes at RT on the roller. The shocked cells were collected 
by centrifugation at 14,000 x g (4oC) for 20 minutes. The supernatant was 
discarded and pellets resuspended in 15 mL periplasmic buffer. Samples were 
place on ice for 10 minutes, with gently mixing by inverting the tubes every 2 
minutes to ensure the solution was homogenous.  
The cell debris was collected by centrifugation at 14,000 x g (4oC) for 20 minutes. 
The supernatant was pooled in a 50 mL tube and the protein was sequentially 
filtered through a 0.45 μm and 0.2 μm filters. Ni-NTA nickel resin slurry (2 mL) was 
added to a chromatography column and allowed to settle. The resin bed was 
washed with 10 mL PBS twice (20 mL total) followed by 10 mL of OSB-A buffer. 
The lysate was then applied to the column, collecting the 'flow-through' in a 50 
mL tube. This process was repeated. The column was then washed with 10 mL of 
wash buffer 1 collecting in a 50 mL tube. This wash step was repeated with 10 mL 
wash buffer 2. The retained protein was then eluted by adding 5 mL elution buffer 
to the column and collecting the flow through. The eluted sample (5 mL) was then 
concentrated and buffer exchanged against PBS/0.02 % (w/v) NaN3 using a 
Vivaspin column with a 10,000 molecular weight 'cut-off' level, as described in 
section 2.2.1.6. Samples were taken throughout and analysed by SDS-PAGE.  
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2.2.3.15 Examination of anti-cPSA 2D2SG cross reactivity  
 
To ensure anti-cPSA 2D2SG was specific for cPSA and not cross reactive with ACT 
or fPSA an indirect ELISA was performed. A 96 well Maxisorb plate was coated 
with 100 μl/well 100 nM cPSA/fPSA/ACT diluted in PBS and incubated for 1 hour 
at 37°C. The plate was the blocked with PBSM (200 μl/well) and incubated for 1 
hour at 37°C. The wells were then washed three times with PBST and three times 
with PBS (200 μl/well). One hundred microliters per well of anti-cPSA scFv 2D2SG 
(1 in 10 dilution in PBSTM was then added to the plate and again incubated at 
37°C for 1 hour. The plate was washed as before. A 1 in 2,000 dilution of anti-HA 
diluted, in PBSTM (100 μl/well) was added and incubated as before. The plate was 
washed as before and 100 μL/well TMB enzyme substrate solution was added to 
each well. The plate was incubated at RT for approximately 5 minutes to allow 
chromophore development, after which the reaction was stopped with 50 μL/well 
10% (v/v) HCl. The absorbance of the wells was read at 450 nm using the Tecan 
SafireTM plate reader. 
2.2.4. N-glycan profiling of avian polyclonal IgY antibodies  
 
IgY is the predominant serum immunoglobulin in birds, reptiles and amphibians 
and is considered to be the evolutionary ancestor of mammalian IgG and IgE 
antibodies.  IgY is more heavily glycosylated than its mammalian counterpart as it 
contains two potential N-glycosylation sites. One is located in the Cv3 domain, 
that is absent in mammalian IgG, and the other is located in the Cv3 domain which 
corresponds to the CH2 (Cγ2) domain of mammalian IgG. Knowledge of the 
carbohydrate moieties present on immunoglobulins is essential as certain glycan 
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structures can adversely impact physicochemical and biological properties (Narat, 
2003; Suzuki and Lee, 2004). Glycoproteins consist of a heterogeneous population 
of glycoforms in which a variety of glycan structures are present at each 
glycosylation site. Hence, the analysis of glycans requires high resolution 
separation techniques that can provide detailed structural analysis, including 
monosaccharide sequence and linkage information (Royle et al., 2006). The 
polyclonal IgY purification approach and subsequent glycan analysis methods used 
are described herein.  
2.2.4.1 Purification polyclonal IgY antibodies from serum 
 
A Pierce® Thiophilic Adsorption Kit was used to purify polyclonal IgY antibodies 
from the serum of the immunised chickens. The manufacturer’s protocol was 
used and the eluates were pooled and concentrated as previously described in 
section 2.2.1.6.  Concentrated purified polyclonal IgY was then analysed by SDS-
PAGE and Western Blotting (WB), as detailed in section 2.2.1.3 and 2.2.1.4, 
respectively. The Western Blots were probed with a 1 in 2,000 dilution of a HRP 
labelled donkey anti-chicken IgY-H+L antibody, diluted in PBSTM.  
2.2.4.2 Glycan release 
 
N-glycans were released from the dissolved samples (1 mg/mL) (lyophilised 
samples were resuspend in water) using PNGase F, (Prozyme, San Leandro, CA, 
USA) in accordance with methods previously described by Royle et al. (2006) and 
Royle et al. (2008). IgY samples were reduced in a  polypropylene 96-well flat-
bottomed microplate by adding 5 μl  sample, 2 μl sample buffer (100 μl 10% SDS + 
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62.5 μl stacking buffer + 337.5 μl water), 2 μl   water, and 1 μl of 0.5 M 
dithiothreitol (DTT) to the well mixing gently using pipette action. The plate was 
then were incubated at 65oC for 15 minutes. The sample was then alkylated by 
adding 1 μl of 100 mM iodoacetamide and incubated for 30 minutes in the dark at 
room temperature. The sample was then set into a gel block by addition of  22.5 
μl of 30% (w/w) acrylamide/0.8% (w/v) bis-acrylamide stock solution (30% 
ProtoGel, National Diagnostics, Hessle, Hull, UK),  11.25 μl of 1.5 M Tris (pH 8.8), 1 
μl of 10% SDS, 1 μl of 10% ammonium peroxodisulfate (APS), and finally, for gel 
polymerisation, 1 μl  of N,N,N,N’-tetramethyl-ethylenediamine (TEMED). Reagents 
were mixed by pipetting and left to set.  
The gel blocks were transferred to a filter plate (Whatman Protein Precipitation FF 
plate) and then washed with 1 ml of acetonitrile with shaking on a plate mixer for 
10 min, followed by removal of the liquid (all wash and elution steps were 
performed on a vacuum manifold). This washing procedure was repeated twice 
with 1 ml of 20 mM NaHCO3 (pH 7.2) followed by 1 ml of acetonitrile (Royle et al., 
2008).  
N- and O- linked glycans utilise different chemistries for protein-sugar attachment 
hence require different approaches for their release. Intact N-glycans can be 
enzymatically released from glycoproteins with an amidase called peptide N-
glycosidase F, PNGase F (Mariño et al., 2010). The N-linked glycans were released 
from IgY using peptide N-glycanase F (Prozyme, San Leandro, CA, USA), as 
previously described (Royle et al., 2008, Küster et al., 1997).  Briefly, after washing 
the gel pieces, the plate on top of a polypropylene 2ml deep 96-well plate 
(collection plate) and 25 μl 100 mU/ml PNGaseF solution was added to each gel. 
This was left for 5 minutes to be soaked up by the gel before adding an additional 
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25 μl PNGaseF.  To the gel pieces   50 μl of 20 mM NaHCO3 was added and the 
plate was sealed (with a SealPlate adhesive film) and incubated at 37oC overnight 
(Royle et al., 2008). The released glycans were collected in the collection plate by 
washing the gel pieces with 3 x 200 μl of water, 200 μl of acetonitrile, 200 μl of 
water, and finally 200 μl of acetonitrile (1200 μl total volume). The release glycans 
were dried completely in vacuum centrifuge (this can take between 5 – 16 hours). 
Once samples were  dry they were subjected to a formic acid treatment by 
addition of  20 μl  1% formic acid (made up fresh) and  incubated at room 
temperature for 40 minutes, and then re-dried. 
2.2.4.3 Labelling of released glycans with 2-aminobenzamide (2AB)  
 
Glycans were then fluorescently labelled with 2-aminobenzamide (2AB) by 
reductive amination (Bigge et al., 1995). Carbohydrates have no significant UV 
absorbing/fluorescent elements hence labelling is essential to achieve sensitive 
detection of the released glycans (Mariño et al., 2010a). Labelling was performed 
by adding 5 μl of 2AB labeling solution (350 mM 2-aminobenzamide, 1 M sodium 
cyanoborohydride in acetic acid/dimethyl sulfoxide (30:70)), vortexing for 10 
minutes, incubation for 30 minutes at 65oC, vortexing for a further 10 minutes, 
and a final incubation for 90 minutes at 65oC.  
Excess 2AB was removed using solid-phase extraction (SPE) with Whatman 3MM 
chromatography paper. Prewashed, dried Whatman 3MM chromatography paper 
(cut into 1-cm square pieces) were folded into quarters and placed into a filter 
plate (Whatman Protein Precipitation FF previously conditioned by washing with 
200 μl of acetonitrile followed by 200 μl of water). The 5 μl of 2AB-labelled 
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samples were applied to the paper and left to dry/bind for 15 minutes. Any excess 
2AB was removed by addition 2 ml of acetonitrile for 15 minutes (with agitation) 
and then removing the acetonitrile using a vacuum manifold; this procedure was 
repeated four times. The labelled glycans were eluted from the chromatography 
paper by paper by addition of 900 μl of water and left to agitate for 30 minutes 
before vacuuming to a collection block. This was repeated with a further 900 μl 
water and the labelled eluted glycans (1800 μl total volume) were then left to dry 
overnight in a vacuum centrifuge (Royle et al., 2008).  
2.2.4.4 Ultra Performance Liquid Chromatography (UPLC) for the 
separation of  the 2-AB labelled glycans 
 
A high throughput platform for the separation of N-glycans from various samples 
using UPLC-HILIC with fluorescence detection with high efficiency was recently 
described, which greatly improves over HPLC based methods (Mariño et al., 
2010a; Saldova et al., 2014a). HILIC separates both neutral and charged glycans in 
a single separation allowing for total glycan characterisation with single-column 
chemistry. Separation is based on the hydrophilic potential of the glycan, which is 
affected by many factors, including:  size, charge, composition, structure, linkage, 
and oligosaccharide branching. Notably, the main advantage of HILIC is the ability 
to separate structural isomers, which is very difficult to achieve with other 
methodologies (Saldova et al., 2014a).  
The 2-AB derivatized N-glycans (section 2.2.3.3) were separated by ULPC with 
fluorescence detection on a Waters Acquity UPLC H-Class instrument consisting of 
a binary solvent manager, sample manager and fluorescence detector under the 
control of Empower 3 chromatography workstation software (Waters). The 
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hydrophilic interaction liquid chromatography (HILIC) separations were performed 
using a Waters Ethylene Bridged Hybrid (BEH) Glycan column, 150 x 2.1 mm i.d., 
1.7 µm BEH particles, with 50 mM ammonium formate, pH 4.4, as solvent A and 
acetonitrile (MeCN) as solvent B. This system allows for separation of N-glycans 
with a decrease in run time and greatly increased resolution due to the sub 2 µm 
stationary phase. The 30 minute method was used with a linear gradient of 30-
47% (v/v) with buffer A at 0.56 mL/minute flow rate for 23 minutes followed by 
47-70% (v/v) A and finally reverting back to 30% (v/v) A to complete the run 
(Saldova et al., 2014).  An injection volume of 10 µL sample prepared in 70% (v/v) 
MeCN was used throughout. Samples were maintained at 5oC prior to injection, 
while separation was carried out at 40oC. For detection the fluorescence 
excitation/emission wavelengths were ex = 330 nm and em = 420 nm, 
respectively. The system was calibrated using an external standard of hydrolyzed 
and 2AB-labeled glucose oligomers to create a dextran ladder, as described 
previously (Royle et al., 2006).  
2.2.4.5 Weak Anion-Exchange High-Performance Liquid Chromatography 
(WAX HPLC) for the determination of sialic acid content of IgY 
 
Weak anion exchange (WAX) HPLC was used to separate the N-glycans by charge 
and was carried out as detailed in Royle et al. (2006), with a fetuin N-glycan 
standard as reference. The principle behind this method involves the application 
of labelled glycans to an anion exchange column and elution with a salt gradient. 
Negatively charged sugars (such as sialic acid) will bind to the anion exchanger, 
while neutral glycans will pass through the column. The separated glycans 
(sialylated glycans) are then compared to a fetuin standard and classified as 
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mono-, di-, tri-, and tetrasialylated glycans (J. J. Kattla et al., 2011).  WAX HPLC 
was performed using a Vydac 301VHP575 7.5 × 50 mm column (Anachem) on a 
2695 Alliance separations module with a 2475 fluorescence detector (Waters), 
which was set with excitation and emission wavelengths of 330 and 420 nm, 
respectively (Royle et al., 2008). Solvent A was 0.5 M formic acid adjusted to pH 
9.0 with ammonia solution and solvent B was 10% (v/v) methanol in water. 
Gradient conditions were as follows: a linear gradient of 0 to 5% (v/v) A over 12 
minutes at a flow rate of 1 mL/minute, followed by 5−21% (v/v) A over 13 minutes 
and then 2−50% (v/v) A over 25 minutes, 80−100% (v/v) A over 5 minutes 
followed by 5 minutes at 100% A. Samples were injected in water. A fetuin N-
glycan standard was used for calibration (Royle et al., 2008).  
2.2.4.6 Exoglycosidase digestion for the determination of 
monosaccharide sequence and linkage of the N-glycans present in the IgY 
 
Exoglycosidase digestions were carried out on aliquots of the total labelled N-
glycan pools in accordance with methods previously described by Royle et al 
.(2006). All exoglycosidase enzymes were obtained from Prozyme, San Leandro, 
CA, USA. The 2AB-labeled glycans were digested in a volume of 10 μL for 18 hours 
at 37 °C in 50 mM sodium acetate buffer, pH 5.5 (except in the case of jack bean 
α-mannosidase (JBM) where the buffer was 100 mM sodium acetate, 2 mM Zn2+, 
pH 5.0), using arrays of the following enzymes: Arthrobacter ureafaciens sialidase 
(ABS), 0.5 U/mL; Streptococcus pneumoniae sialidase (NAN1), 1 U/mL; bovine 
testes β-galactosidase (BTG), 1 U/mL; Streptococcus pneumoniae β-galactosidase 
(SPG), 0.4 U/mL; bovine kidney α-fucosidase (BKF), 1 U/mL; β-N-
acetylglucosaminidase cloned from S. pneumonia, expressed in Escherichia coli 
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(GUH), 8 U/mL and JBM (EC), 50 U/mL. After incubation, enzymes were removed 
by filtration through a 10 kDa protein-binding EZ filters (Millipore Corporation). N-
Glycans were then analyzed by UPLC and WAX HPLC. 
2.2.4.7 Ultra Performance Liquid Chromatography-Fluorescence-Mass 
Spectrometry (UPLC-FLR-MS) 
 
The UPLC-FLR-MS analysis was carried out by Dr. Silvia Millán Martín (NIBRT, 
Dublin, Ireland)  using the following methods.  
For UPLC-FLR-QTOF MS analysis lyophilised IgY samples were reconstituted in 3 µl 
of water and 9 µl acetonitrile. Online coupled fluorescence (FLR)-mass 
spectrometry detection was performed using a Waters Xevo G2 QTof (YCA 219) 
with Acquity® UPLC (Waters Corporation, Milford, MA, USA) and BEH Glycan 
column (1.0 x 150 mm, 1.7 μm particle size).  
For MS acquisition data the instrument was operated in negative-sensitivity mode 
with a capillary voltage of 1.80 kV. The ion source block and nitrogen desolvation 
gas temperatures were set at 120 °C and 400 °C, respectively. The desolvation gas 
was set to a flow rate of 600 L/h. The cone voltage was maintained at 50V. Full-
scan data for glycans were acquired over m/z range of 450 to 2500. Data 
collection and processing were controlled by MassLynx 4.1 software (Waters 
Corporation, Milford, MA, USA). 
The fluorescence detector settings were as follows ex = 330 nm, em = 420 nm; 
data rate was 1pts/second and a PMT gain = 10. Sample injection volume was 10 
μL. The flow rate was 0.150 mL/minute and column temperature was maintained 
at 60 °C; solvent A was 50 mM ammonium formate in water (pH 4.4) and solvent 
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B was acetonitrile. A 40 minute linear gradient was used and was as follows: 28% 
(v/v) A for 1 minute, 28-43% (v/v) A for 30 minutes, 43-70% (v/v) A for 1 minute, 
70% (v/v) A for 3 minutes, 70-28% (v/v) solvent A for 1 minute and finally 28% 
(v/v) A for 4 minutes.  
Samples were diluted in 75% (v/v) acetonitrile prior to analysis. The weak wash 
solvent was 80% (v/v) acetonitrile and the strong wash solvent was 20% (v/v) 
acetonitrile. To avoid contamination of Mass Spec system, flow was sent to waste 
for the first 1.2 minutes and after 32 minutes.   
2.2.4.8 Molecular Modelling of IgY 
Molecular modelling of IgY was carried out by Dr. Mark Wormald (Oxford 
University, England). Modelling was performed on a Silicon Graphics Fuel 
workstation using InsightII and Discover software (Accelrys Inc., San Diego, USA). 
Figures were produced using the program Pymol (Schrodinger, LLC, 2010).  
Protein structures used for modelling were obtained from the Protein Data Bank 
(PDB) database  (Berman et al., 2000). The peptide structure of chicken IgY was 
based on the crystal structures of human IgE domains C2-4 (Wan et al., 2002) 
and human IgG Fab domain (Stanfield et al., 1990)  The N-linked glycans to model 
on IgY were chosen on the basis of the peaks with the largest areas in the glycan 
profile (Appendix Four). 
2.2.5 Differentiation of indolent, significant and aggressive prostate 
cancer by robotic high-throughput N-glycan profiling 
 
To investigate if differential glycosylation patterns could distinguish between 3 
cohorts of PCa patients, namely, indolent, significant and aggressive PCa. Whole 
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serum N-glycan profiling was carried out on 117 prostate cancer patients’ sera 
using a robotised, high-throughput analysis platform for glyco-profiling which 
utilises ultra-performance liquid chromatography (UPLC) to obtain high resolution 
separation of N-linked glycans released from the serum.  
On the basis of the technologies used for N-glycan profiling of IgY (section 2.2.4), 
the UPLC analytical workflow was improved on by developing an automatable 
sample preparation workflow, implemented on a liquid handling platform. The 
system, originally developed for glycoprofiling of immunoglobulin G antibodies 
(IgG) (Figure 2.5) uses a robotic liquid-handling workstation, allowing the 
preparation of 96 samples (or multiples thereof) in 22 hours with excellent 
reproducibility and can greatly facilitate serum biomarker discovery (Stöckmann 
et al., 2013, 2015).  
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Figure 2.5: Automated high-throughput IgG-antibody glyco-profiling platform. The 
sample preparation workflow consists of glycoprotein affinity purification, protein 
denaturation, enzymatic glycan release, glycan immobilisation on solid supports, 
removal of contaminants, glycan release, labelling, and solid-phase extraction (Taken 
from Stöckmann et al., 2013). 
  
2.2.5.1 Serum Samples 
 
Samples were collected with consent from prostate cancer patients following a 
standard operating procedure, which is part of the Prostate Cancer Research 
Consortium BioResource. Ethical consent was granted from respective Hospital 
ethics committees of the consortium. Blood samples (10 mL) were collected into 
anticoagulant-free tubes. Samples were coded and transported on ice to the 
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laboratory. The tubes were centrifuged at 900 x g at 20°C for 10 minutes within a 
30 minute time-frame. Serum from each patient sample was then collected, 
aliquoted and stored at −80°C until time of analysis. Each serum sample 
underwent no more than three freeze/thaw cycles prior to analysis. A total of 117 
patients (indolent [41], significant [32] and aggressive [44]) were included in this 
study. Epstein’s criteria was used to define patients as having indolent, significant 
or aggressive PCa (Epstein et al., 1994). Indolent PCa was defined as tumour 
volume <0.5cm³, organ-confined disease and no Gleason patterns 4 or 5. 
Significant disease was defined as tumour volume >0.5 cm³, organ-confined 
disease and Gleason pattern 4. Aggressive PCa was defined as Gleason patterns 4 
or 5 and non-organ-confined disease.  
2.2.5.2 Glycoprotein denaturation and glycan release 
 
Serum samples (5 µL) were added to a 96-well V-bottom plate (in duplicate) and 
placed in a Hamilton Robotics StarLet liquid-handling platform. Denaturation 
buffer (55 µL per well, 100 mM ammonium bicarbonate, 12 mM dithiothreitol) 
was dispensed into the 96-well V-bottom plate (Greiner Bio-One) containing the 
PCa serum samples, which was placed on a robotic heater shaker, fully covered 
and insulated with an anti-evaporation lid. This assembly was incubated at 65oC 
with agitation at 700 rpm for 30 minutes. After cooling to room temperature for 
10 minutes, a iodoacetamide solution (120 mM, 10 µL per well) was added, the 
plate was covered with an anti-evaporation lid and incubated at room 
temperature with agitation at 700 rpm for 30 minutes. A trypsin solution (40, 000 
U/mL) in water, 10 µL per well) was added, the plate was sealed, placed on the 
robotic heater shaker and fully covered with an anti-evaporation lid. Incubation 
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was performed at 37oC with agitation at 700 rpm for 120 minutes. The 
temperature was increased to 105oC and incubation was continued for a further 
10 minutes. The plate was left to cool to room temperature, centrifuged briefly 
(2,700 x g for 30 seconds) and the seal was removed. PNGase F (Prozyme R Glyco 
N-Glycanase R, 10 µL per well, 0.5 mU in 1 M ammonium bicarbonate, pH 8.0) was 
added and the plate was covered with an anti-evaporation lid and incubated at 
40oC with agitation at 700 rpm for 2 hours. 
2.2.5.3 Hydrazide-mediated glycan ‘clean-up’ 
 
The wells of a 96-well chemically inert filter plate (Millipore Solvinert, 
hydrophobic polytetrafluoroethylene membrane, 0.45 µm pore size) were washed 
with 100 µL methanol (MeOH) and ultralink hydrazide resin (40 µL suspension in 
water, Thermo Scientific) was subsequently dispensed to each well. The resin was 
sequentially washed with (100 µL per well) MeOH, H2O and acetonitrile (MeCN) 
and the plate was placed on a heater (80oC, 8 minutes) to seal the membranes. 
One hundred and eighty microliters MeCN/acetic acid, (98:2) was added to the 
resin, followed by 20 µL of the glycan solution. The filter plate was incubated with 
shaking at 700 rpm at 80oC for 60 minutes. Fifty microlitres MeCN/acetic acid 
(98:2) was then added and shaking was continued at the same temperature for 10 
minutes to disrupt resin aggregates. The resin was washed sequentially with 
MeOH (3 x 200 µL), 2M guanidine (2 x 200 µL), H2O (2 x 200 µL), 
triethylamine/MeOH (1:99, 2 x 200 µL) and MeOH (2 x 200 µL per well). Fresh 
MeOH (180 µL) and acetic anhydride (20 µL) were added and the plate was 
incubated for 30 minutes with agitation at 600 rpm, at 21oC. Excess reagent was 
removed by filtration and the resins were twice washed sequentially with MeOH, 
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H2O and MeCN, Acetic acid/MeCN (2:98, 175 µL) and H2O (25 µL) were 
sequentially added and the plate was incubated at 70oC with agitation at 700 rpm 
for 90 minutes. Fluorescent labeling mix (50µL, 350 mM 2-aminobenzamide, 1 M 
sodium cyanoborohydride in acetic acid/dimethyl sulfoxide (30:70)) was 
dispensed into each well and the plate was incubated at 65 oC with agitation at 
800 rpm for 120 minutes. 
2.2.5.4 Glycan solid phase extraction 
 
The labelling reaction was quenched by the addition of 550 µL MeCN/H2O (95:5). 
The suspension was transferred to a 2 mL collection plate, the beads were left to 
settle, 200 µL of the supernatant was aspirated and dispensed back into the filter 
plate. After extensive mixing the suspension was transferred back into the 
collection plate. This cycle was repeated to ensure a quantitative transfer of the 
resins. HyperSep Diol Solid Phase Extraction (SPE) cartridges (ThermoScientific) 
were washed with 500 µL MeCN/H2O (95:5), 1 mL H2O and 1 mL MeCN/H2O. 
Next, the quenched reaction supernatant was transferred onto the SPE cartridges. 
An incubation period of 5 minutes typically led to complete drainage of the 
solvent by gravity. The SPE cartridges were washed three times with 750 µL 
MeCN/H2O (95:5). A collection plate was placed inside the robotic vacuum 
manifold and the SPE cartridges were washed twice with 200 µL H2O/MeCN 
(80:20), with an incubation period of 5 minutes between each wash step. The 
samples were concentrated to dryness in a vacuum evaporator and then dissolved 
in 30 µL MeCN/H2O (70:30). A portion (33%) of the resuspended sample was then 
analysed by UPLC. 
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2.2.5.5 Ultra Performance Liquid Chromatography (UPLC) of the 2-AB 
labelled glycans 
 
The 2-AB derivatized N-glycans were separated by HILIC-ULPC, as described in 
section 2.2.3.4.   
2.2.5.6 Statistical analysis 
 
Statistical analysis was carried out by Mr. Keefe Murphy (PCRC biostatistician, 
University College Dublin). Briefly, all 50 peaks were examined individually to 
explore baseline differences in expression using one way analysis of variance 
(ANOVA). Tukey’s post-hoc honestly significant difference (HSD) was performed to 
calculate the p-values. Boxplots were used to illustrate the distribution of each 
biomarker by significance.  
The peaks were then considered in combination (in a multivariate predictive 
regression context) to see which panel of variables would yield the best predictive 
performance. This was arrived at using logistic regression analysis and the best 
model fit was ensured by forward and backwards stepwise AIC selection. Model 
diagnostics was then carried out to assess the performance of this biomarker 
panel. The discriminant ability of both the ‘significant peaks’ and the ‘combined 
biomarker panel’ were determined by means of ROC curves and AUC values. 
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Chapter Three 
Screening and analysis of an 
avian anti-fPSA library 
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3.1 Introduction 
 
In this chapter screening of pre-existing scFv and fab clones from an avian fPSA 
library for the isolation of an nM affinity anti-fPSA antibody fragment is detailed.  
Evaluation of the binding characteristics of this avian anti-fPSA scFv fragment by 
surface plasmon resonance using Biacore 3000 instrumentation is described in 
detail. Finally, discovering the unique structural attributes of this avian antibody 
fragment was explored by X-ray crystallographic techniques.  
Antibodies are ideal bio-recognition elements and are likely to remain the affinity 
molecules of choice for wide variety of analytical, biochemical, and medical 
approaches. Our advanced understanding of the factors that contribute to 
antibody specificity arises from the knowledge gained from multiple disciplines 
including; structural biology, immunogenetics, cellular and molecular biology and 
immunoinformatics. Once an antibody fragment is successfully isolated, 
expressed and purified it also needs to be extensively characterised. Binding 
assays of the antibody to the cognate antigen need to be defined, ideally epitope 
mapping should be conducted and most importantly, the affinity (dissociation 
constant) the antibody has for the antigen needs to be determined.  
In the past decade surface plasmon resonance (SPR)-based optical biosensors, 
such as Biacore systems have evolved as standard tools for antibody 
characterisation and binding interaction studies. The Biacore 3000 instrument 
uses SPR technology for biomolecular interaction analysis in real time without the 
need for labels. This instrument provides a comprehensive characterisation of 
binding events and kinetics analysis can also be conducted with relative ease 
(Wilson, 2002; Leonard et al., 2011). 
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Much research is focused on the precise nature of the binding interactions 
between an antibody and its cognate antigen.  There are a numerous different 
methods that are commonly used to map the fine details of these interactions. 
The rules that govern antibody-antigen recognition, including  the molecular 
structures within a target antigen that make specific contacts with an antibody 
(referred to as antibody or B-cell epitopes) and  the molecular determinants 
within the antibody structure that have specific interactions with the antigen 
epitope  (termed paratopes), are only now becoming well characterised due to an 
increase in the availability of three-dimensional structures (Sela-Culang et al., 
2013; Abbott et al., 2014). X-ray crystallography is undoubtedly the method that is 
most commonly used to determine the precise sites of interaction between an 
antibody and its antigen.  
A deep understanding of the role that each structural element plays in antibody-
antigen interactions is crucial both to evolve our understanding of immunity, and 
is essential for successful engineering of unique high affinity binders.  
Developments in structure-based design strategies have aided in vaccine design 
and development of antivirals for the treatment of the human immunodeficiency 
virus (HIV) and the influenza (HA) virus (Lee and Wilson, 2015). The structural 
characterisation of both HIV-1 Envelope protein and influenza HA in complex with 
a variety of diverse antibodies has allowed for the identification of the key sites of 
vulnerability on these viruses. The structural information describing the 
interaction of these antibodies with the antigens is now publically available, 
allowing for rational, structure-guided antibody engineering (Julien et al., 2012).  
Crystal structures enable very accurate determination of key interactions between 
individual amino acids from both side chain and main chain atoms in both the 
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epitope and paratope.  Amino acids that are within 4 Å of each other are generally 
considered to be contacting residues (Abbott et al., 2014). The number of 
residues that are in contact with antigens is thought to differ in antibodies 
recognising peptides, haptens and proteins (Finlay and Almagro, 2012; 
Raghunathan et al., 2012). The  high-quality integrated knowledge resource 
specialising in immunogenetics data of antibodies-The Immunogentic Database 
(IMGT)- provides access to sequence, genome and structural data on antibodies 
and related proteins of the immune system (Lefranc, 2014). Raghunathan and 
colleagues mined this rich source of information along with the three-dimensional 
structures available at the PDB and  analysed 140 unique high-resolution (<3 Å) 
antibody structures, including 55 in complex with proteins, 46 with haptens and 
39 with peptides to develop and deeper insight into the structural architecture of 
the antigen-binding site (Raghunathan et al., 2012). These authors successfully 
determined length variations of the hypervariable loops, number of contacts with 
antigen, frequency and location of antigen-contacting residues and the type of 
amino acid residues interacting with proteins, haptens and peptides 
(Raghunathan et al., 2012).  
Information such as that published by Raghunathan and colleagues enhances our 
understanding of the structure–function relationship in antibodies while providing 
valuable guidance to design libraries for antibody discovery. There is,  however, a 
limited understanding of the structural attributes of avian antibodies. As 
highlighted in Chapter Three of this thesis, chicken antibodies are now receiving 
significant recognition as high-quality, high-affinity antibodies that can be 
generated to a wide range of antigens for a number of therapeutic, diagnostic and 
biotechnological applications. 
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Extensive examination of the amino acid characteristics of the chicken repertoire 
has provided a significant insight into mechanisms employed by the avian immune 
system (Wu et al., 2012; Conroy et al., 2014).The lack of avian antibody crystal 
structures in the PDB has limited our understanding of the structural 
consequences of these uniquely chicken features. To date only three structures 
are available for chicken antibody fragments (Shih et al., 2012; Conroy et al., 
2014). This chapter focuses on the isolation and characterisation of an avian anti-
fPSA scFv in an attempt to further our knowledge of chicken antibody fragments 
and develop antibodies for improved prostate cancer diagnostics.  
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3.2 Results 
3.2.1 Identification of high affinity anti-fPSA scFv 
 
Over 1,000 anti-fPSA scFv and Fab clones from an avian anti-fPSA library 
(generated by Dr. Conor Hayes, in DCU) were screened by monoclonal ELISA 
(section 2.2.2.1) and clones with an absorbance value of greater than 0.3 (Figure 
3.1) were taken forward for kinetic characterisation on the Biacore 4000. These 
clones were screened using a previously immobilised CM5 dextran chip 
functionalised with approximately 6,000 RU of anti-HA epitope by EDC-NHS 
coupling chemistry over spots 1, 2, 4 and 5. Anti-fPSA scFv and Fab lysates were 
diluted 1:3 (in duplicate) in HBPS-EP+ and analysed in a capture approach over the 
anti-HA surface at 25oC. The data was evaluated using the BiaEvaluation software 
using the ‘2 over 2’ template and curves were fitted with a 1:1 Langmuir binding 
equation (Figure 3.2). 
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Figure 3.1: Anti-fPSA scFv monoclonal ELISA’s. Over 1,000 anti-fPSA scFv and Fab 
antibody clones were assessed for reactivity to fPSA by monoclonal ELISA. Expressed 
antibody lysate was diluted 1 in 2 in PBSTM and added to a fPSA-coated plated. 
Specifically bound clones were then detected with an HRP-labelled anti-HA polyclonal 
antibody, TMB was added, the reaction stopped with 10% (v/v) HCl, and the absorbance 
was read at 450 nm. All clones above the 'cut-off' of 0.3 were taken for further 
characterisation on the Biacore 4000.  
 
 
138 
 
 
Figure 3.2: ‘2 over 2’ kinetic analysis of scFv B8. The surface was composed of a 
polyclonal anti-HA antibody on spots 1, 2, 4 and 5.  Anti-fPSA scFv and Fab lysates were 
diluted 1:3 (in duplicate) in HBPS-EP
+
 and analysed in a capture approach over the anti-
HA surface at 25
o
C. The diluted lysates were captured on spots 1, 2, 4 and 5 and two 
concentrations of fPSA (10 nM and 50 nM diluted in HBS-EP
+
) were then passed over the 
captured antibody fragments and referenced against the unmodified surface on spot 3. 
The data was evaluated using the BiaEvaluation software using the '2 over 2' template 
and curves were fitted with 1:1 Langmuir binding equation. Analysis identified scFv B8 
as a single digit nano-molar affinity antibody (KD 1.25 x 10
-9
M). 
3.2.2 Optimisation of expression of scFv B8 
 
Once the clone was identified as having high affinity for fPSA it was necessary to 
express this antibody fragment. An overview of the main conditions that were 
optimised for the expression of scFv B8 is detailed in Table 3.1. 
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Table 3.1: Conditions for optimisation for recombinant antibody expression 
Temperature 
 
  
Lowering the expression temperature routinely improves the 
solubility of recombinant proteins, and can result in a reduction in 
degradation.  Once induced, temperatures of 18-30
o
C should be 
assessed. 
Time At lower temperatures the rate of protein production also decreases 
and, thus, longer induction times are necessary to obtain sufficient 
protein. Time points should be taken at 2- 16 hours. 
Inducer 
Concentration 
In addition to lowering the temperature, a reduction in transcription 
rate can also be achieved by lowering the concentration of the 
induction agent. Lowering the IPTG concentration can enhance the 
production of soluble protein.   
 
Various concentrations of IPTG (0 mM, 0.05 mM and 0.1 mM) were assessed at 
both 25oC and 30oC and samples were taken at time points at 0, 2, 4 and 16 
(overnight) hours for analysis by SDS-PAGE and WB. Once transferred to the 
nitrocellulose membrane the antibody fragment was detected with a HRP tagged 
anti-HA antibody and the reaction developed with liquid TMB for membranes. The 
determination of optimal expression conditions proved very difficult to achieve, as 
can be seen in Figure 3.3. However, optimal conditions of 0.1 mM IPTG for 4 hours 
at 25oC were employed for large-scale expression and subsequent purification.  
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Figure 3.3: Optimisation of expression of scFv B8. Varied conditions were optimised to 
ascertain the optimal expression conditions for anti-fPSA scFv B8. Although expression 
levels are poor, 0.1 mM IPTG for 4 hours at 25
o
C was chosen as the optimal conditions 
(Red box; A and B).  In the SDS (B & D) the presence of extracellular E. coli proteins are 
also expressed at high levels for the overnight sample. Thus, overnight expression was 
not deemed ideal for scFv B8. Low levels of expression were seen for all IPTG 
concentrations at each time point in the 30
o
C study, as there was a very faint band at 
approximately 25kDa. A: Western blot analysis of scFv B8 expression study at 25
o
C, 
probed with anti-HA antibody; B: SDS-PAGE for optimisation at 25
o
C; C: Western blot 
analysis of scFv B8 expression study at 30
o
C , probed with anti-HA antibody; D: SDS-
PAGE for optimisation at 30
o
C. Legend; L: Ladder, 1: Time point = 0 hrs, 0 mM IPTG; 2: 
Time point = 0 hrs , 0.05 mM IPTG; 3: Time point = 0 hrs , 0.1 mM IPTG; 4: Time point = 2 
hrs, 0 mM IPTG; 5: Time point = 2 hrs, 0.05 mM IPTG; 6: Time point = 2 hrs, 0.1 mM IPTG; 
7: Time point = 4 hrs, 0 mM IPTG; 8: Time point = 4 hrs , 0.05 mM IPTG; 9: Time point = 4 
hrs , 0.1 mM IPTG; 10: Time point = o/n, 0 mM IPTG; 11: Time point = o/n, 0.05 mM 
IPTG; 12: Time point = o/n, 0.1 mM IPTG. Red arrow indicates scFv fragment at 28 kDa. 
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3.2.3 Purification of scFv B8 by Immobilised Metal Affinity 
Chromatography  (IMAC) 
 
Using the optimal conditions identified in section 3.2.2 a 1 L culture of scFv B8 was 
prepared and lysed, as detailed in section 2.2.2.3. Ni-NTA resin was applied to a 
10 mL chromatography column and once settled, the resin bed was equilibrated 
with 2 column volumes of PBS followed by one column volume of OSB-A buffer. 
The expressed antibody lysate was filtered and applied to the column (twice). 
Samples were collected at each step of the purification process and analysed by 
SDS-PAGE and WB. The eluted protein was concentrated and buffer exchanged 
against PBS/0.02% (w/v) NaN3 using a 10,000 MWCO vivaspin column. The 
purified concentrated protein was determined to be 1 mg/mL using the NanoDrop 
spectrophotometer.  
 
Figure 3.4: IMAC purification of scFvB8. A 1 L culture was prepared and expressed 
antibody lysate purified by IMAC. Samples were taken throughout the process for 
analysis by SDS-PAGE (left) and WB (right). Specific detection of the scFv fragment was 
performed by probing the WB membrane with a HRP-labelled anti-HA antibody. ScFv B8 
was successfully purified to 1 mg/mL. L: Ladder; FL: Filtered lysate; FT1: Flow through 1; 
FT2: flow through 2; W: Wash; EP: Eluted protein and CP: Concentrated protein.  
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3.2.4 Anti-fPSA scFv B8 Sandwich ELISA Limit of Detection (LOD) Assay 
 
Limit of Detection (LOD) is a well-established parameter used to characterise an 
analytical method. It is defined as the lowest analyte concentration likely to be 
reliably distinguished from the limit of the blank (LOB) and at which detection is 
feasible. Anti fPSA scFv B8 Limit of Detection (LOD) was determined in accordance 
with the Clinical and Laboratory Standards Institute’s (CLSI) published guidelines 
“EP17, Protocols for Determination of Limits of Detection and Limits of 
Quantification” (Armbruster and Pry, 2008). The assay was carried out in 
sandwich ELISA format, with a total of 24 replicates to ensure confidence in the 
result (Table 3.2).  
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Table 3.2: Determination of anti fPSA scFv B8 Limit of Detection (LOD) by indirect ELISA 
PSA 
Concentration 
32 16 8 4 2 1 0.5 0.25 0.12 0.06 0.01 0 
Replicate # 1 2.527 1.884 1.388 0.690 0.258 0.084 0.062 0.054 0.060 0.059 0.000 0.019 
Replicate # 2 2.486 1.954 1.204 0.692 0.264 0.075 0.067 0.054 0.051 0.053 0.011 0.008 
Replicate # 3 2.416 1.948 1.290 0.504 0.253 0.070 0.062 0.047 0.064 0.045 0.008 0.013 
Replicate # 4 2.330 1.941 1.214 0.629 0.253 0.082 0.054 0.048 0.048 0.048 0.004 0.004 
Replicate # 5 2.472 1.927 1.601 0.612 0.256 0.092 0.065 0.056 0.056 0.048 0.006 0.008 
Replicate # 6 2.423 1.974 1.358 0.571 0.257 0.083 0.070 0.056 0.060 0.046 0.021 0.007 
Replicate # 7 2.060 1.991 1.485 0.650 0.207 0.101 0.066 0.051 0.058 0.043 0.008 0.006 
Replicate # 8 2.469 1.802 1.478 0.614 0.259 0.073 0.058 0.048 0.055 0.045 0.026 0.040 
Replicate # 9 2.461 2.049 1.423 0.731 0.234 0.077 0.067 0.043 0.058 0.048 0.009 0.008 
Replicate # 10 2.361 1.912 1.299 0.661 0.228 0.074 0.049 0.060 0.055 0.045 0.017 0.011 
Replicate # 11 2.470 2.000 1.311 0.663 0.218 0.068 0.062 0.054 0.060 0.068 0.009 0.008 
Replicate # 12 2.444 2.003 1.322 0.640 0.208 0.067 0.063 0.054 0.060 0.039 0.008 0.007 
Replicate # 13 2.437 2.028 1.342 0.621 0.201 0.062 0.062 0.040 0.058 0.048 0.005 0.004 
Replicate # 14 2.481 2.030 1.368 0.638 0.207 0.072 0.050 0.059 0.056 0.045 0.004 0.005 
Replicate # 15 2.477 1.997 1.350 0.648 0.218 0.073 0.065 0.044 0.051 0.049 0.007 0.006 
Replicate # 16 2.547 2.112 1.436 0.715 0.238 0.077 0.062 0.060 0.053 0.011 0.017 0.005 
Replicate # 17 2.014 1.774 1.311 0.546 0.242 0.083 0.065 0.058 0.047 0.045 0.018 0.008 
Replicate # 18 2.415 1.921 1.181 0.557 0.228 0.078 0.062 0.056 0.055 0.045 0.014 0.016 
Replicate # 19 2.706 1.943 1.130 0.419 0.114 0.087 0.057 0.050 0.050 0.048 0.009 0.009 
Replicate # 20 2.579 1.969 1.682 0.694 0.296 0.086 0.066 0.049 0.049 0.048 0.009 0.008 
Replicate # 21 2.552 1.804 1.391 0.625 0.214 0.082 0.054 0.047 0.057 0.046 0.005 0.005 
Replicate # 22 2.306 1.365 1.358 0.656 0.211 0.073 0.064 0.057 0.057 0.030 0.005 0.006 
Replicate # 23 2.326 2.021 1.304 0.619 0.211 0.087 0.066 0.040 0.059 0.049 0.006 0.007 
Replicate # 24 2.445 2.032 1.318 0.521 0.234 0.082 0.067 0.059 0.056 0.045 0.007 0.002 
Average 2.425 1.933 1.356 0.621 0.229 0.079 0.062 0.052 0.055 0.046 0.010 0.009 
Std. Dev 0.148 0.145 0.124 0.072 0.034 0.009 0.006 0.006 0.004 0.010 0.006 0.007 
 
 
Determination of LOD 
Limit of Blank (LoB) is the highest apparent analyte concentration expected to be 
found when replicates of a blank sample containing no analyte are tested; 
LoB = mean blank + 1.645(Std. Dev. blank) 
Limit of Detection (LoD) is the lowest analyte concentration likely to be reliably 
distinguished from the LoB and at which detection is feasible. LoD is determined 
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by utilising both the measured LoB and test replicates of a sample known to 
contain a low concentration of analyte; 
LoD = LoB + 1.645(Std. Dev. low concentration sample*) 
LoB = 0.009* + 1.645(0.007*) = 0.021 
LoD = 0.021 + 1.645(0.006*) = 0.03 
LoD of anti-fPSA scFv B8 = 0.03 ng/mL 
*Note: Samples figures used highlighted in red in table 
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Figure 3.5: Limit of Detection (LoD) sandwich ELISA for scFv B8. Varying concentrations of fPSA (30 - 0 ng/mL) were captured on a goat anti-PSA polyclonal coated ELISA 
plate. Binding of anti-fPSA scFv B8 was then detected with the HRP-labelled secondary antibody, anti-HA followed by addition of TMB. The LoD of scFv B8 was 
determined to be 0.03 ng/mL by carrying out 24 replicates of the assay. A: Full graph (PSA concentrations 30 - 0 ng/mL); B: Lower PSA concentrations (0.5 - 0 ng/mL- 
zoom in of red section in A.
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3.2.5 Anti-fPSA scFv B8 cross reactivity assay 
 
To ensure anti-fPSA scFv B8 was specific for fPSA and not cross reactive with cPSA 
a sandwich ELISA was performed, as described in section 2.2.2.4. Varying 
concentrations of cPSA were included in the assay, along with a control antigen (3 
% BSA), to provide confidence in the results obtained. Anti-fPSA scFv B8 is highly 
specific for fPSA and does not cross react with cPSA or the control antigen, as can 
be seen in Figure 3.6. 
 
Figure 3.6: Cross reactive Sandwich ELISA for scFv B8. Varying concentrations of 
fPSA/cPSA (20 - 0 ng/mL) were captured with a polyclonal goat anti-PSA antibody 
coated ELISA plate. Binding of anti-fPSA scFv B8 was then detected with the HRP-
labelled secondary antibody. The absorbance was read at 450nm. scFv B8 did not cross 
react with cPSA.  The negative control was 3% (w/v) BSA which was substituted for PSA 
(Neg Control).  
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3.2.6 Kinetic analysis of scFv B8 using Biacore 3000 
 
Initially a preconcentration study was carried out to identify the optimal buffer 
conditions for subsequent immobilisation, to increase the potential yield of 
immobilised ligand. Preparations of 25 µg/mL anti-HA antibody, diluted in a low 
ionic strength buffer (10 mM NaOAc) over a range of pH values (pH 4.0, 4.2, 4.4, 
4.6, 4.8 and 5.0) was passed over the underivitised chip surface (flow cell 2) and 
the degree of electrostatic binding monitored. 
The principle behind using an array of pH buffers is that the protein carries a ‘net’ 
positive charge at pH values less than its isoelectric point causing an electrostatic 
interaction between the negatively charged dextran surface and the positively 
charged protein. This results in a higher coupling efficiency with a lower 
requirement for protein. The highest pH at which preconcentration of the protein 
onto the underivitised surface is observed should be employed for the 
immobilisation (Leonard et al., 2011).    
Maximum potential binding for anti-HA was observed in NaOAc, pH 4.4 (Figure 
3.7). Hence, this was utilised for immobilisation of 25 µg/mL anti-HA antibody to 
the surface of flow cell 2, using amine coupling chemistry. 
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Figure 3.7: Preconcentration study for anti-HA antibody. Anti-HA antibody diluted in 10 
mM sodium acetate solutions of pH of 4.0, 4.2, 4.4, 4.6, 4.8 and 5.0 was passed over the 
surface of a CM5 dextran chip at a flow rate of 10 μL/minute. During preconcentrations 
studies there is an electrostatic interaction between the positive charged protein (due to 
its charge below the isoelectric point) and the negatively charged surface carboxylated 
groups. The optimal buffer conditions for the immobilisation of anti-HA antibody to the 
CM5 dextran surface was identified as NaOAc, pH 4.4, as the highest levels of binding 
was observed at this pH.  
 
The immobilisation of a ligand to a CM5 dextran chip involves a number of steps 
described in section 2.2.3.4.2. The chip is activated with 400 mM EDC (1-ethyl-3-
(3-dimethylaminopropyl)-carbodiimide hydrochloride) and 100 mM NHS (N-
hydroxysuccinimide), the ligand is subsequently passed over the surface and the 
chip surface is then deactivated with 1 M ethanolamine-hydrochloride to block 
and eliminate any potential non-specific binding (NSB) to the surface.  
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Immobilisation was performed by passing anti-HA polyclonal antibody diluted in 
10 mM NaOAc to 25 μg/mL, pH 4.4, over the activated surface at a flow rate of 10 
μL/minute for 15 minutes. Following capping and deactivation of any unreactive 
NHS groups, the surface was post conditioned with 20 mM NaOH (Figure 3.8). 
Approximately 19,000 RU were successfully immobilised to the surface of flow cell 
2 of the CM5 dextran chip.  
 
 
Figure 3.8: Immobilisation of anti-HA polyclonal antibody. The surface of a CM5 dextran 
chip was activated with an EDC/NHS solution and the anti-HA polyclonal antibody 
passed over the activated carboxyl group surface. The sample was injected for 15 
minutes until the surface was fully saturated. Binding of the ligand occurs via the amino 
groups on the protein with the activated carboxyl groups on the dextran surface chip. 
After sufficient capturing of the ligand was achieved the remaining activated groups 
were deactivated with ethanolamine-HCl solution. The surface was regenerated using a 
20 mM solution of NaOH. The level of anti-HA successfully immobilised to the surface 
was approximately 19,000RU. 
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 ScFv B8 was kinetically characterised using the kinetic wizard functionality on the 
Biacore 3000 and the subsequent data generated was evaluated using 
BIAevaluation software, version 4.1.1. Purified scFv B8 was diluted 1 in 3,000 in 
running buffer and passed over the anti-HA surface at a flow rate of 30 μL/minute 
for 3 minutes. fPSA was then passed over the surface in varying concentrations 
(6.25, 3.12 (in duplicate), 1.6, 0.8, 0.4 and 0 nM) for 3 minutes, and allowed to 
dissociate for 12 minutes.  Regeneration of the surface was carried out by passing 
over 20 mM NaOH for 10 seconds at a flow rate of 30 μL/minute. The dataset 
from the reference flow cell (flow cell 1 - underivatised surface) was subtracted to 
remove any systemic effects, and the 0 nM fPSA concentration binding response 
(buffer only) was subtracted from each antigen response, thus double reference 
subtracting the dataset. The simplest 1:1 Langmuir binding model fit the dataset 
well with a global Rmax. and the curve (Figure 3.9, upper graph) was fitted with a 
Chi2 value of 0.482. This value gives information about the ‘goodness‘ of the curve 
fit and for good qualitative data this value should be as low as possible. The 
residual plot (Figure 3.9, lower graph) shows the data points are distributed 
randomly above and below the zero line but are within acceptable limits. 
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Figure 3.9: Kinetic interaction analyses of fPSA and scFv B8.  Six concentrations of PSA 
(6.25 nM, 3.12 nM (x2) 1.6 nM, 0.8 nM, 0.4 nM and 0 nM) were used to fit the kinetics 
using 1:1 Langmuir binding model (global fit). The following kinetic parameters were 
derived; Ka: 1.36 x 10
6
Ms
-1
 , Kd 1.15 x 10
-3
s
-1
, and KD; 0.8.x 10
-9
 with a Chi
2
 (X
2
) value of 
0.482.  
3.2.7 Crystal Structure of scFv B8 
 
In collaboration with the lab of Prof. James Whisstock, Monash University, Dr. 
Paul Conroy successfully solved the crystal structure of scFv B8 to 1.4 Å. This 
structure revealed unique binding attributes of avian antibodies, including a 
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CDRL1 canonical structure that has hitherto to be observed in mammalian 
repertoires and a rarely captured disulphide constrained CDRH3 (Figure 3.10). 
 
 
Figure 3.10; The crystal structure of anti fPSA scFv B8. (A) Diagrammatic representation 
of the scFv format coloured by chain (V
L
: blue, V
H
: green) with the CDR L1 (red), L2 
(salmon), L3 (brown), H1 (yellow), H2 (orange) and H3 (magenta) shown. The flexible 
linker (black) connects the C-terminus of the V
L
 to the N terminus of the V
H
, but is not 
modelled in the solved structure. (B) The CDR arrangement of scFv B8 is compact 
creating a ‘shelf-like’ arrangement for antigen binding. (C) The antibody binding sites as 
viewed from the antigen perspective. (D) The transparent electrostatic surface view of 
the scFv, from the antigen perspective, with the CDR loops (L1, L2, L3, H1, H2, H3) 
visible. The positively and negatively charged areas are indicated in blue and red, 
respectively. ScFv B8 has a predominantly positively charged surface (Figure adapted 
from Conroy et al., 2014). 
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3.2.8 Expression and purification of scFvB8 Ser MT by Immobilised Metal 
Affinity Chromatography (IMAC) and Gel Filtration (GF) 
 
In order to investigate the structural and binding impact of the conserved cysteine 
pair observed in scFv B8 a mutant variant was generated.  scFv B8 plasmid DNA 
was used as a template to introduce a cysteine to serine double mutant at C97 
and C100 in CDRH3 (C97/100S; scFv B8 Ser MT) (section 2.2.2.7). Successful 
generation of the mutant sequence was confirmed (Appendix two) and the 
mutant clone was subsequently expressed and purified as detailed in section 
2.2.2.8.   
The expressed antibody was purified in a 2-step process. IMAC purification was 
used initially (Figure 3.11 (A), followed by size exclusion chromatography (also 
referred to as gel filtration) (Figure 3.11 (B).  “Structural biology-grade” proteins 
must be produced using a purification process that results in the generation of an 
abundance of highly pure protein in order to determine the structure using X-ray 
crystallography (Kim et al., 2011). Gel filtration is a basic chromatography 
technique that separates proteins with differences in molecular size and shape as 
they pass through gel filtration medium in a packed column, and is often used as a 
final polishing step following IMAC purification (Kim et al., 2011). Gel filtration of 
scFv B8 Ser MT was carried out on an S 75/16/60 column on the AKTA Explorer 
FPLC system (GE Healthcare). The protein was homogenous, soluble, mono-
dispersed, stable and estimated to be greater than 95% pure (as determined by 
SDS-PAGE, Figure 3.11 (B), hence was concentrated to approximately 16 mg/mL to 
take forward to coarse screening for crystallisation conditions. 
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Figure 3.11: Purification of scFv B8 Ser MT by (A) IMAC and (B) Gel Filtration (GF). A 4 L 
culture of scFv B8 Ser MT was prepared and expressed antibody lysate purified by (A) 
IMAC and (B) GF. Eluates 2-6 from the IMAC purification were further polished by 
resolution on a size exclusion column. Fractions 21- 31 (underlined –red) were collected 
and analysed by SDS-PAGE. ScFv B8 Ser MT was successfully purified and concentrated 
to 16.12 mg/mL. L: Ladder; FT: Flow through 1; W1: Wash; W2: Wash 2; E1-9: Eluted 
protein fractions; HP: Histidine (IMAC) purified protein; F21-F31: Gel filtration containing 
protein fractions.   
3.2.9 Determination of the crystal structure of anti fPSA scFv B8 Ser MT 
by X-ray crystallography  
 
Initial crystal-forming conditions were identified by setting up 240 different 
conditions from a variety of commonly employed kits that provide highly effective 
and rapid screening methods for the crystallisation proteins. Each kit provides a 
differing set of crystallants, buffer composition, pH, salts and other additives to 
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comprehensively coarse screen for conditions to promote crystallisation of 
proteins. Within 72 hours, crystals were observed in 14% of the conditions set in 
the initial screen (34 crystal hits). Of these 34 crystals, 2 were notable similar to 
the wild type scFv crystals, that is large hexagonal type crystals (Figure 3.12).  
Refinement of these two conditions (as described in section 2.2.2.9.2) was carried 
out in order to increase the size and number of crystalline outcomes. Common 
refinements include varying the concentrations of all components in the 
crystallisation condition, slight pH changes, using additives and switching to 
similar buffers or precipitants (Luft et al., 2014).  
 
Figure 3.12: Crystals of scFv B8 Ser MT. Hexaganol type crystals were observed from the 
Crystal screen kit (Hampton Research) (A) condition number 5: 2.0 M Ammonium 
sulphate, 5 % (v/v) 2-propanol and (B) condition number 13: 0.2 M Ammonium sulphate, 
0.1 M sodium acetate trihydrate, pH 4.6, and 30 % (w/v) polyethylene glycol 
monomethyl ether (PEG MME) 2,000.   
 
Following the fine screening of these 2 conditions numerous crystals were 
obtained, with condition number 5 providing the largest crystals. Interestingly, 
many of these conditions generated lots of small crystals in clusters; however, as 
the % IPA decreased in the original condition (2.0 M Ammonium sulphate, 5 % 
(v/v) 2-propanol) the crystals were notably more spaced out and quite large in 
comparison to the high % IPA crystals. Individual crystals obtained from the 
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condition 2.0 M Ammonium sulphate, 3 % (v/v) 2-propanol were extracted from 
the drop (collected in a goniometer loop of an appropriate size (decided visually 
under a microscope) and loaded directly into the puck and stored in liquid 
nitrogen, using 25% (v/v) glycerol as the cryoprotectant,  until the synchrotron 
visit.  
X-ray diffraction was carried out at the Australian Synchrotron MX2 beamline at 
100K. The data was merged and processed using XDS , POINTLESS and SCALA. 
Molecular Modelling and replacement was carried as described Conroy et al., 
(2014). scFv B8 Ser MT was solved in the same space group as the wild type 
antibody (P6122), to 1.5Å  and appears to retain the compact conformation 
observed in CDRH3 of scFv B8 (Figure 3.16C).   
3.2.10 Kinetic analysis of scFv B8 Ser MT using Biacore 3000  
 
Kinetic analysis was carried out in a similar manner to the wild type, starting with 
a preconcentration study to identify the optimal buffer conditions for subsequent 
immobilisation. Preparations of 25 µg/mL fPSA, diluted in 10 mM NaOAc over a 
range of pH values (pH, 4.0, 4.2, 4.4, 4.6, 4.8 and 5.0) were passed over the 
underivitised chip surface (flow cell 4) and the degree of electrostatic binding 
monitored. 
Maximum potential binding for fPSA was observed in NaOAc, pH 4.0 (Figure 3.13), 
Hence, this was utilised for immobilisation of 25 µg/mL fPSA to the surface of flow 
cell 4, using amine coupling chemistry. 
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Figure 3.13:  Preconcentration study for fPSA. fPSA was diluted in 10 mM sodium acetate 
solutions of pH, 4.0, 4.2, 4.4, 4.6, 4.8 and 5.0 and  passed over the underivitised surface 
of a CM5 dextran chip at a flow rate of 10 μL/minute. The optimal buffer conditions for 
the immobilisation of fPSA to the CM5 dextran surface was identified as NaOAc, pH 4.0, 
as the highest levels of binding was observed at this pH. 
Once the optimal pH for immobilisation was identified, fPSA was immobilised to 
the surface, as detailed in the methods section (2.2.2.10.1), by passing fPSA 
diluted in 10 mM NaOAc to 25 μg/mL, pH 4.0, over the activated surface at a flow 
rate of 10 μL/min for 15 minutes. Following capping and deactivation of any 
unreactive NHS groups, the surface was post conditioned with 20 mM NaOH. 
Approximately 1000 RU were successfully immobilised to the surface of flow cell 4 
of the CM5 dextran chip (Figure 3.14). 
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Figure 3.14: Immobilisation of fPSA. The surface of a CM5 dextran chip was activated 
with an EDC/NHS solution and fPSA passed over the activated carboxyl group surface. 
The sample was injected for 15 minutes until the surface was fully saturated. Binding of 
the ligand occurs via the amino groups on the protein with the activated carboxyl groups 
on the dextran surface chip. After sufficient capturing of the ligand was achieved the 
remaining activated groups were deactivated with ethanolamine-HCl solution. The 
surface was regenerated using a 20 mM solution of NaOH. The level of anti-HA 
successfully immobilised to the surface was approximately 1,000RU. 
ScFv B8 Ser MT was kinetically characterised using the kinetic wizard functionality 
on the Biacore 3000 and the subsequent data generated was evaluated using 
BIAevaluation software, version 4.1.1.  Purified scFv B8 Ser MT was passed over 
the fPSA surface in varying concentrations (2.5, 1.25, 0.625 (x2), 0.312, and 0 μM) 
for 3 minutes, and allowed to dissociate for 12 minutes.  The dataset from the 
reference flow cell (flow cell 3 - underivatised surface) was subtracted to remove 
any systemic effects, and the 0 nM scFv B8 Ser MT concentration binding 
response (buffer only) was subtracted from each antigen response, thus double 
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reference subtracting the dataset. The simplest 1:1 Langmuir binding model fit the 
dataset well with a global Rmax. and the curve (Figure 3.15, upper graph) was fitted 
with a Chi2 value of 7.25. The Chi2 value is a quantitative measure of the closeness 
of fit, and in an ideal situation will approximate to the square of the noise level. It 
is difficult to recommend absolute values for acceptance limits for Chi2; the values 
need to be considered in combination with assessment of the shape of the 
residuals. The residual plot (Figure 3.15, lower graph) shows the data points are 
distributed randomly above and below the zero line.  
 
Figure 3.15: Kinetic interaction analyses of fPSA and scFv B8 Ser MT.  Five concentrations 
of scFv B8 Ser MT (2.5 μM, 1.25 μM, 0.625 μM (x2) , 0.312 μM, and 0 μM) were used to 
fit the kinetics using 1:1 Langmuir binding model (global fit) The following kinetic 
parameters were derived; Ka: 7.18 x 10
3
Ms
-1
 , Kd 7.38 x 10
-3
s
-1
, and KD; 1.03x 10
-6
 with a 
Chi
2
 (X
2
) value of 7.25.  
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A Loss of binding was observed when the cysteine residues are substituted with 
serine as scFv B8 Ser MT binding drops from sub nM affinity (wild type scFv B8: KD; 
0.8.x 10-9  to μM affinity (scFv B8 Ser MT KD; 1.03x 10
-6).  
3.2.11 Expression and Purification of scFvB8 Ala MT by Immobilised 
Metal Affinity Chromatography (IMAC) and Gel Filtration 
 
Given the structural similarities between scFv B8 and scFv B8 Ser MT yet the huge 
differences in binding kinetics, a second mutant was created to further investigate 
the impact of the cysteine pair in CDRH3.   
ScFv B8 plasmid DNA was used as a template to introduce a cysteine to alanine 
double mutant at C97 and C100 in CHRH3 (C97/100A; scFv B8 Ala MT) (section 
2.2.2.7). Successful generation of the mutant sequence was confirmed (Appendix 
two) and the mutant clone was subsequently expressed and purified by Dr. Paul 
Conroy, as detailed in section 2.2.2.8.   
3.2.12 Determination of the crystal structure of anti fPSA scFv B8 Ala MT 
by X-ray crystallography  
 
Crystal forming conditions for scFv B8 Ala MT were identified from the Crystal 
Screen and Crystal Screen II (Hampton Research) kit by Dr. Paul Conroy. Crystals of 
scFv B8 Ala MT were obtained in 2 M ammonium sulphate. Crystals were also 
obtained in 0.1 M NaOAc, pH 4.6, with 0.2 M ammonium sulphate. These crystals 
were flash-cooled in liquid nitrogen using 25% (v/v) glycerol as the cryoprotectant.  
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Data sets were collected at the Australian Synchrotron MX2 beamline at 100K. 
The data was merged and processed using XDS, POINTLESS, and SCALA. Molecular 
Modelling and replacement was carried as described by Conroy et al., (2014).  
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Figure 3.16: Crystal structures of wild type and mutant variants of anti-fPSA scFv B8. (A) Diagrammatic representation of wild type scFv format with 
each mutant variant overlaid (magenta: wild type, cyan: Ser MT and green/orange: Ala MT). Electron density map of (B) wild-type (C) Ser MT and 
(D) and (E) Ala MT, with each showing the CDRH3 arrangement. All structures were solved in the same space group –P6122, with the exception of 
the second Ala MT (E), which was solved in the P212121 space group. The Ser MT (C) contains the same compact configuration of wild type scFv BB 
due to hydrogen bond formation. The rigid CDRH3 is opened up completely in the Ala MT (D) and in the second Ala structure (E) R100a swings out, 
widening out CDRH3.
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3.2.13 Mammalian Expression of recombinant PSA 
 
The commercial available Invitrogen vector suite, pSecTag2 A, B, and C are 
specifically designed expression vectors for high-level stable and transient 
expression in mammalian hosts. This vector suite also includes pSecTag2/PSA, in 
which PSA is fused to the c-myc epitope and the polyhistidine tag. The resulting 
fusion protein is ~33 kDa which includes the N-terminal secretion signal (Figure 
3.17) 
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Figure 3.17: Vector map of pSecTag2/PSA. Map details the many features of the 
pSecTag2A/PSA vector (Invitrogen). Features include: Human cytomegalovirus (CMV) 
promoter/enhancer, T7 promoter, ATG initiation codon (permits initiation of translation 
of the pSecTag2 fusion protein) Murine Ig κ-chain leader sequence, Multiple cloning site, 
c-myc epitope (allows detection of pSecTag2 fusion protein with widely available anti-
myc antibodies), Polyhistidine tag (for high affinity binding to Ni
2+-
chelating resin easy 
purification by IMAC). In addition, Bovine growth hormone (BGH) reverse priming site 
and BGH polyadenylation signal, f1 origin , SV40 early promoter and origin , Zeocin™ 
resistance gene (for selection of transformants in E. coli and stable transfectants in 
mammalian cells), SV40 polyadenylation signal (permits efficient transcription 
termination and polyadenylation of mRNA), pUC origin and  ampicillin resistance gene. 
Figure adapted from      
http://tools.lifetechnologies.com/content/sfs/manuals/psectag2_man.pdf. 
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HEK293F cells were seeded to 1-2 x 106 cells/mL in Freestyle media; a chemically 
defined, ‘protein-free’ expression medium specifically developed to support the 
growth and transfection of HEK293F cells in suspension without adaptation.  
Polyethylenimine (PEI) was used as a transfection agent and 1 mL samples were 
taken at days 3, 4, 5 and 7 post transfection. Samples were centrifuged at 5,500 x 
g for 30 minutes and the supernatant analysed by SDS-PAGE (Figure 3.18).  
 
Figure 3.18: Recombinant PSA expression. Samples (1 mL) were taken at days 3, 4, 5, and 
7 and the presence of PSA confirmed by resolution on a 15% SDS –PAGE gel. PSA is fused 
to the c-myc epitope and the polyhistidine tag, resulting in a ~33 kDa fusion protein.  
Expression increases over time and 7 days post transfection was determined to be the 
optimal time for expression of recombinant PSA. L: Ladder; 3: PSA sample taken at 3 
days; 4: PSA sample taken at 4 days; 5: PSA sample taken at 5 days and7: PSA sample 
taken at 7 days. 
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3.2.14 Purification of recombinant PSA by Immobilised Metal Affinity 
Chromatography (IMAC) and Gel Filtration  
 
Recombinant PSA was purified in the 2-step process detailed in section 2.2.2.14, 
which yields highly pure, homogenous proteins (Figure 3.19).  
 
Figure 3.19: Purification of recombinant PSA (rPSA) by (A) IMAC and (B) Gel Filtration 
(GF). Secreted media (35 mLs) was collected and lysate purified by (A) IMAC and (B) GF. 
Eluates 2,3 and 4 from the IMAC purification were further polished by resolution on a 
size exclusion column. Fractions 26- 34 (underlined –red) were collected and analysed by 
SDS-PAGE. rPSA was successfully purified and concentrated to 0.4 mg/mL. L: Ladder; FT: 
‘Flow through’ 1; W1: Wash; W2: Wash 2; E1-10: IMAC-eluted protein fractions; HP: 
Histidine (IMAC) purified protein and F24-F34: Gel filtration containing protein fractions.   
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3.2.15 Formation of recombinant PSA-scFv B8 complex 
 
The rPSA-scFv B8 complex was formed by addition of excess scFv B8 (1 mg) to PSA 
(0.4 mg). This protein mixture was left on ice for 2 hours and then concentrated 
before resolution on a S75/16/60 analytical gel filtration column (section 
2.2.2.15). The complex was successfully formed (Figure 3.20) and complex-
containing fractions were isolated and concentrated to 7.3 mg/mL for screening 
for identification of crystal-forming conditions. 
 
Figure 3.20: Formation of rPSA-scFv B8 complex. Protein complex was allowed to form 
by adding excess scFv B8 to rPSA and leaving static for 2 hours. (A) The protein complex 
was confirmed by resolution on a size exclusion column. The first peak contains the 
protein complex while the 2
nd
 peak contains excess scFv B8. (B) Fractions 17- 26 (1
st
 
peak) were collected and analysed by SDS-PAGE to ensure the presence of both PSA (33 
KDa) and scFv B8 (28KDa).  
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3.2.16 Determination of the crystal structure of rPSA-anti-fPSA scFv B8 
complex 
 
Initially, crystals were observed in 0.1 M magnesium acetate, 0.1 M MOPS, pH 7.5, 
with 12% (w/v) PEG 8000. Following fine screeening of this condition, an increase 
in %  (w/v) PEG 8000  yield better crystal formation (0.1 M magnesium acetate, 
0.1 M MOPS, pH 7.5, 15% (w/v) PEG 8000). Polyethylene glycol (PEG) is a high 
molecular weight linear polymer that is frequently used as a precipitating agent 
for generation of protein crystals.  PEG is highly effective both in terms of 
precipitating ability and cost effectiveness and is particularly well suited for 
macromolecular crystallisation (McPherson, 1985). 
Crystals were flash-cooled in liquid nitrogen using 25% (v/v) glycerol as a 
cryoprotectant. X-ray diffraction data-sets were collected at the Australian 
Synchrotron MX2 beamline. The data was merged and processed using XDS, 
POINTLESS, and SCALA. Molecular Modelling and replacement was carried as 
described by Conroy et al.(2014). The resultant anti-fPSA scFv B8-rPSA complex 
structure was solved to 1.95 Å in the P1 21 1 space group (Figure 3.21).  
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Figure 3.21: Crystal structure of anti-fPSA scFvB8-rPSA complex. ScFv B8 light (blue) and 
heavy (green) chains with the CDRs shown: L1 (red), L2 (brown), L3 (salmon), H1 
(yellow), H2 (orange) and H3 (magenta) in contact with rPSA. Expanded view of the 
interaction (black dashed box) with residues contributing to the interaction with the Y-
axis rotate by 90
o 
to view from the heavy (top) and light (bottom) chain. 
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3.3 Discussion 
 
This chapter describes the screening of a pre-existing scFv and fab anti-fPSA 
library for identification of a highly sensitive anti-fPSA-specific antibody fragment 
and its subsequent characterisation.  
An anti-fPSA library was constructed from the spleens of female Leghorn chickens 
immunised with fPSA was readily available for screening and isolation of an fPSA 
specific antibody fragment. These antibody fragments were previously isolated 
from a large library (3.10 x 108 cfu/mL) following three rounds of selection from 
the antibody repertoire displayed on the surface of filamentous phage by 
immobilised panning using phage display (carried out by Dr. Conor Hayes).  
Here, approximately 800 anti-fPSA fab clones and 280 anti-fPSA scFv clones were 
screened by monoclonal ELISA and evaluated for binding affinity using the Biacore 
4000 and a nanomolar affinity anti-fPSA scFv was identified. Various optimisation 
steps were taken with this fragment with the aim of expressing and purifying 
sufficient amounts of antibody for extensive kinetic characterisation with the 
Biacore 3000. Expression of scFv B8 was optimised and although proving difficult, 
1 mg/mL protein was purified by IMAC (Figure 3.4).  
One point to note from the optimisation of expression (Figure 3.3) is that the 
antibody fragment appears to be expressing in the absence of IPTG. Typically, in 
the absence of the inducer, the target gene will not be transcribed in lac 
controlled vectors, as pComb3 is under control of the lac operon, scFv B8 should 
not express without IPTG. This issue of uninduced expression is sometimes 
observed in E. coil systems that utilise the lac operon and is often referred to as 
‘leaky’ expression (Grossman et al., 1998). Some strains of E. coli such as 
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BL21(DE3)pLysS and Rosetta(DE3)pLysS are specifically developed to assist in the 
reduction of leaky expression in lac controlled systems. These strains contain a 
plasmid encoding T7 lysozyme, which binds and inhibits T7 polymerase (Moffatt 
and Studier, 1987). The concentration of T7 lysozyme produced in these strains 
results in low basal transcription activity. The use of these strains of E. coli could 
be used in future experiments to reduce the observed levels of uninduced 
expression. 
The anti-HA tag integrated into the pComb3x vector not only facilitates 
purification but also assisted in the kinetic evaluation of scFv B8. A polyclonal anti-
HA antibody was immobilised to the surface of a CM5 dextran chip via amine 
coupling chemistry and a kinetic program using the capture binding assay format 
was custom developed for interaction analysis between anti-fPSA scFv B8 and 
fPSA. The affinity for fPSA was determined to be 0.8 x 10-9M from the data 
generated. Each kinetic evaluation study was carried out 3 times (inter-day and 
intra-day) to provide confidence in the results obtained.  
‘Limit of detection’ (LoD) is a term used to describe the smallest concentration of 
a measurand that can be reliably measured by an analytical procedure. It can be 
defined as the lowest analyte concentration likely to be reliably distinguished 
from the limit of the blank (LOB) and at which detection is feasible. An approach 
for determining the LoD was described by Armbruster and Pry (2008) and was 
employed in this study to determine the LoD of anti-fPSA scFv B8.  This method 
utilises analysis of samples containing small but known concentrations of the 
substance of interest. The advantage of this empirical approach is that objective 
data is used to compare the analytical response of blank and low concentration 
samples to determine conclusively what concentration of analyte is necessary to 
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distinguish its presence from its absence (Armbruster and Pry, 2008). A total of 24 
replicates were carried out (Table 3.2) and the LoD of anti-fPSA scFv B8 was 
identified as 0.03 ng/mL.  The ability to detect (repeatedly) low levels of fPSA is 
essential for patients in the ‘diagnostic grey zone’ of 4-10 ng/mL as clinicians use a 
measure of percentage fPSA (free:total PSA ratio) to determine the percent 
probability of finding prostate cancer on a needle biopsy by age in years, as 
detailed in Table 3.3. 
Table 3.3: Relative risk of prostate cancer as determined by free:total PSA ratio (Taken 
from:http://www.mayomedicallaboratories.com/testcatalog/Clinical+and+Interpretive/
81944). 
Free:total PSA ratio 50-59 years 60-69 years > or =70 years 
< or =0.10 49.2% 57.5% 64.5% 
0.11-0.18 26.9% 33.9% 40.8% 
0.19-0.25 18.3% 23.9% 29.7% 
>0.25 9.1% 12.2% 15.8% 
 
Järås and colleagues developed an assay technology platform on which a large 
number of plasma samples as well as a large number of analytes could be 
measured. The author’s effectively show quantitative duplex detection of free and 
total PSA on the same porous silicon chip in an antibody microarray. The 
microarray format was chosen to allow multiplex detection of biomarkers related 
to prostate cancer. The fPSA antibody used in this assay was a recombinant Fab 
(rFab 5A10)(Eriksson et al., 2000) measured free PSA with a dynamic range of 
0.40-74.9 ng/mL and a LOD: 0.47 ng/mL (Järås et al., 2012) . Anti-fPSA scFv B8 has 
an LoD of 0.03 ng/mL, significantly lower than the antibody employed by the 
assay developed by Järås and colleagues. This antibody fragment is also highly 
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specific to fPSA (Figure 3.6) and was not show to cross-react with the other major 
component of total PSA, complex PSA (cPSA). Incorporation of anti-fPSA scFv B8, 
alongside other prostate cancer specific markers, into a multiplex assay such as 
that developed by Järås and colleagues could greatly enhance PCa diagnosis.  
Sequence analysis of anti-fPSA scFv B8 carried out by Source Bioscience Ltd, 
Dublin, Ireland. The DNA sequences obtained were translated using the translate 
tool from Expasy (http://web.expasy.org/translate/) and the amino acid 
sequences were then exported to PowerPoint and the significant regions 
highlighted (appendix two). 
Sequencing exposed an unusual cysteine pair in CDRH3. In a recent study, the VH 
repertoire of IgY was characterised and compared with VH CDR diversity of 
humans, mice and camelids (Wu et al., 2012). Here, the authors show that the 
chicken CDRH3 repertoire has higher cysteine content than other species (chicken 
9.4%, human 1.6% and mice 0.25%). Data from this study suggests that 
noncanonical disulphides are a structural diversification strategy in the restricted 
V gene germline repertoire of chickens, and are favourable as they potentially aid 
in stability and affinity for its target (Shih et al., 2012; Wu et al., 2012).  
Following this observation, the crystal structure of scFv B8 was resolved to 1.4 Å 
(work carried out by Dr. Paul Conroy, Monash University, Melbourne). To 
precisely understand the molecular mechanisms of proteins high resolution of 2 Å 
is required. We successfully resolved scFv B8 to 1.4 Å, providing confidence in the 
level of accuracy of this structure, and exposed a unique shelf-like structure within 
CDRH3. Until recently, these types of bonds in CDR have never been seen in a 
crystal structure in chicken antibodies (Shih et al., 2012). Mutational hotspots and 
structure-guided mutation strategies can maximise the diagnostic performance of 
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recombinant antibody fragments (Muller et al., 2011; Stura et al., 2011). Muller 
and colleagues specifically mutated an anti-fPSA antibody (Fab – 5D3D11) and the 
results from this study, showed improvement to the diagnostic performance for 
patients in the ‘diagnostic grey zone’, allow better discrimination between 
prostate cancer and BPH (Muller et al., 2011).  
The solved structure revealed a number of interesting canonical structural 
grouping deviations that are likely distinctly ‘chicken’. At present the lack of 
chicken structures in the PDB impedes a rational, focused appraisal of the 
consequences of novel CDRL1 canonical structures or the non-canonical 
disulphide bonded CDRH3, for the classical modes of protein-, peptide- or hapten-
binding. The CDRL1 of scFv B8 mirrors the chicken canonical cluster described by 
Shih and co-workers (Shih et al., 2012) and its presence is also concurrent with a 
long, non-canonical disulphide constrained CDRH3, which exhibits a distinct bias 
towards small amino acids (G/S/A/C/T) (Finlay and Almagro, 2012; Wu et al., 
2012; Conroy et al., 2014). 
This may suggest that such a binding site arrangement is not antigen binding 
mode specific, but raises the possibility that it is necessary to have a short CDL1 to 
facilitate the elongated and disulphide constrained CDRH3. These descriptive 
structures further support the increasing genetic, functional and now structural 
evidence that such constrained CDRH3 are an active diversification strategy in the 
restricted germline repertoire of chicken (Shih et al., 2012; Wu et al., 2012; 
Conroy et al., 2014). This CDRL1-CDRH3 arrangement forms a common structure 
in chicken antibodies (2 of the 3 available chicken structures), which is distinctly 
different from the structures described in mammals to date (North et al., 2011; 
Chailyan et al., 2011; Shih et al., 2012; Conroy et al., 2014). 
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Following these observations, mutant variants of scFv B8 were generated by site-
directed mutagenesis to assess the impact the two intra-CDRH3 cysteine residues 
their structural impact played in antigen binding. Mutation of these cysteine 
residues to serine did not change the ‘shelf-like’ structure in CDRH3 (Figure 3.17-
B) however, it dramatically reduced binding affinity (sub-nanomolar to 
micromolar) (Figure 3.16).  Given that the presence of charged surfaces can often 
encourage protein-protein interactions (Boswell et al., 2010), it is unsurprising 
that there is a noticeable reduction of positive charge in the Ser-MT antibody 
fragment (Figure 3.23-B) in CDRH3 compared to the wild type (Figure 3.23-A). The 
deliberate modification of antibody charge through direct chemical modification 
of amino acid side chains with positive, negative  or neutral chemical groups is 
often carried out to permit exploratory study of the relationships between the net 
molecular charge and binding kinetics, and are also carried out to improve the 
pharmacokinetic properties of antibodies for the diagnosis or treatment of 
disease (Boswell et al., 2010).  
A second mutant variant of wild type scFv B8, with a double alanine substitution 
at C97 and C100 was also created.  Two crystals were diffracted and the structures 
were solved in different space groups.  One structure diffracted to 1.7 Å in the 
same space group as wild type and Ser MT (P61 2 2) (Figure 3.17 C) and the 
second was solved to 1.9 Å in the P 21 21 21 space group (Figure 3.17 D). In both 
cases there was a single molecule in the asymmetric unit (Appendix two lists full 
refinement statistics for all structures).  
The rigid formation seen in the wild type and Ser MT was disrupted and CDRH3 is 
disordered in the Ala MT. Kinetics analysis was carried out (data not shown). 
However, the Ala MT lost all binding capabilities and no interaction was observed 
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with PSA. On the basis of these results, it is believed this disulfide bond in CDRH3 
of scFv B8 is critical for its ultra-specific recognition of fPSA.  Selection of 
antibodies from chicken antibody libraries that contain intra-CDR disulfide bridges 
is highly favourable and can ultimately lead to identification of high affinity 
antibodies with unique binding profiles. 
 
Figure 3.23: Diagrammatic representation of the surface charge of wild type and mutant 
variants of anti-fPSA scFv B8. Transparent electrostatic surface view of the WT (A) and 
Ser MT (B) and Ala MT (C, D) from the antigen perspective, with the CDR loops visible. 
Positively and negatively charged areas are indicated in blue and red, respectively. 
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While determination of the crystal structure and kinetics analysis of anti-fPSA scFv 
B8 and its mutant variations strengthened the hypothesis that conserved 
disulphides in Aves play an important role in creating paratopes of great 
complexity, to truly understand the binding mechanisms of this antibody-antigen 
interaction, the crystal structure of anti-fPSA scFv B8 and recombinantly 
expressed PSA was determined. The high resolution co-complex structure was 
solved to 1.95 Å in the P1 space group following diffraction of one crystal at the 
Australian Synchrotron. This is the first example of a protein antigen-avian 
antibody structure to our knowledge. 
The kinetics studies on the mutant variants clearly showed that the disulphide 
bridge was essential for antigen recognition; however it is possible that the 
disulphides do not actually make contact with recombinant PSA (Figure 3.24).  
Recombinant PSA forms contact with scFv B8 directly between the disulphide 
bond at S98, R100a and N100b (Kabat numbering) in CDRH3. It is likely that the 
disulfide bond stabilizes the domain creating a rigid scaffold for interaction with 
recombinant PSA. Each of the hypervariable loops in the heavy chain form contact 
with recombinant PSA, whilst two of the light chain CDRs forms part of the 
paratope. Binding in CDRH1 occurs with Y56 and negatively charged amino acid 
aspartic acid at D52a and D52b.  Interestingly, human and mice antibodies both 
show a strong preference for the use of Tyrosine residues whereas the amino acid 
content in the chicken shows very different paratope chemical composition, 
including an unusually low representation of Y (Finlay and Almagro, 2012; Wu et 
al., 2012).  
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Figure 3.24: Anti-fPSA scFv B8-recombinat PSA binding contacts. The conformational 
epitope is comprised of 2 major binding segments on recombinant PSA (N172, D173, 
Q177 and P180, K182, V183), with single residue contacts (G105 and E229) at each end 
of the major contact segments. Each of the hypervariable regions of the heavy chain of 
scFv B8 comprises the majority of binding residues with the paratope.  
 
There is a distinct bias toward small amino acids G/S/A/C/T in chicken antibodies 
(Wu et al., 2012). The prevalence of these small residues in the CDR loops implies 
that they are important for conformational flexibility  (Birtalan, Zhang, Frederic A. 
Fellouse, et al., 2008). Serine accounts for 40% of the residues in contact with 
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recombinant PSA, suggesting this flexibility is essential for scFv B8’s highly affinity 
recognition of PSA. 
A noteworthy observation of this antibody-antigen complex is that there is a 
contact residue (K66) in the framework region between CDRL1 and L2.  The less 
variable framework regions form the β sheets and generally provides structural 
support for the antigen binding site, rather than making contact with the antigen 
(Finlay and Almagro, 2012). Sequence variability in the framework regions can 
directly affect CDR loop conformation and the orientation of VH–VL pairing. Albeit 
rarely, binding contacts have been previously observed in the framework region, 
particularly the heavy chain FR3- the framework region between CDR H2 and H3, 
which accounts for 1.3% of human antibody-antigen contacts (Sela-Culang et al., 
2013). Framework residues in the light chain rarely make contact with the 
antigen, as was observed with anti-fPSA scFv B8 and recombinant PSA. It is likely 
that K66 plays a role in maintaining the stability of the overall structure of the 
antibody-antigen complex.  
 
Chapter conclusions 
Overall screening of the anti-fPSA library was successful and a highly specific 
antibody fragment was isolated, expressed, purified and extensively 
characterised. The crystal structure of this antibody fragment revealed that the 
restricted germline repertoires of chicken antibodies can produce antibodies with 
unique binding mechanisms. The co-complex of this avian antibody fragment in 
contact recombinant PSA was also solved. 
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Chapter Four 
Generation of recombinant  
anti-PSA antibody fragments 
and N-glycan characterisation 
of polylconal antibodies from 
an avian immune system 
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4.1 Introduction 
 
This chapter describes the development of avian recombinant antibody fragments 
to complex prostate specific antigen (cPSA) by phage display, the process of 
library building and the selection processes involved in identifying cPSA-specific 
antibodies.  The isolation and N-glycan characterisation of the avian IgY molecule 
is also detailed. 
The use of PSA as a biomarker of prostate cancer (PCa) remains highly 
controversial as it lacks cancer specificity. There is a nominal level of PSA in serum 
in healthy males hence the presence of PSA in serum does not necessarily mean a 
man has prostate cancer.  Circulating levels of the protein can fluctuate in 
response to a variety of circumstances including sexual activity, BPH and chronic 
prostatitis (Botchorishvili et al., 2009). A PubMed search of ‘prostate cancer 
diagnosis’ returns over 80,000 articles (as of July 2015) but, in the 25 years since 
the FDA first approved the serum PSA test for clinical use, no other biomarkers 
have gained FDA approval that surpass the PSA gold standard. PSA is still the 
primary tool for detection, risk stratification and monitoring of PCa. A greater 
understanding of the molecular isoforms of PSA has led to improvements in the 
cancer-related specificity of the test.   
While advances are being made in improving the PSA test, there is an unmet need 
to clearly distinguish between significant and insignificant PCa. However, it is 
unlikely—in the near future, at least—that any single biomarker will be capable of 
definitively distinguishing between significant and insignificant disease. Combining 
panels of markers (Oon et al., 2011)—for example, serum protein markers (Fan et 
al., 2011), miRNA expression profiles (Hassan et al., 2012) , and epigenetic 
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modifications such as DNA methylation (Jerónimo et al., 2011)—with novel glycan 
expression patterns could improve the accuracy of diagnosing and screening for 
prostate cancer (Gilgunn et al., 2013). The primary aim of this chapter is to 
develop isoform-specific recombinant antibody fragments to incorporate into a 
microfluidic-based platform with multiple PCa-specific markers for improved PCa 
diagnosis.  
Phage display is the predominant technique employed in recombinant antibody 
selection. Random segments of DNA can be readily inserted into the phage coat 
particle and amplified in bacterial cells. Antibody fragments are frequently 
inserted into the coat protein of the phage and subsequently expressed on the 
surface of the phage following superinfection with helper phage. The phage-scFv 
particle can then be selectively enriched for the cognate antigen using solid phase 
selection screening of the phage library. The major advantage of phage display is 
the link between phenotype and the corresponding genotype (Barbas et al., 
2001).  
Polyclonal and recombinant antibodies are commonly developed in many 
different species provided the immunoglobulin gene sequences are known 
(Andris-Widhopf et al., 2000). However, a large number of protein targets are 
highly conserved in mammalian evolution, thus commonly used mammalian 
species such as rabbits and mice are inclined to generate a limited immune 
response due to immunological tolerance invoked during foetal development 
(Andris-Widhopf et al., 2000).  The use of a species more phylogenetically distant 
from humans such as chickens, who diverged from mammalian genomes some 
310 million years ago (International chicken Genome Sequencing Consortium, 
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2004), are ideal alternatives for immunisation and selection of recombinant 
antibodies (Andris-Widhopf et al., 2000; Narat et al., 2003).   
Recent exploitation of the avian immune system has highlighted its use for the 
generation of high-quality, high-affinity antibodies to a wide range of antigens for 
a number of therapeutic and diagnostic applications (Spillner et al., 2012; Wu et 
al., 2012). 
The mechanism in which chickens generate antibody diversity was extensively 
characterised at the genomic level and is considerably simpler in comparison to 
the v-gene repertoire of mice and humans, which involves a large set of 
sequences that are highly diverse in both sequence and structure (Wu et al., 
2012). The avian v-gene germline repertoire utilises single functional V-genes for 
the heavy (VH3 family) and light chains (exclusively λ light chains) that contain 
unique VL-JL and VH-D-JH segments (Finlay and Almagro, 2012). Despite this 
simplified system, chickens have a broadly adaptable repertoire capable of 
generating unique, high affinity antibodies to proteins, peptides and hapten 
antigens. The v-genes are rearranged using conventional V(D)J recombination 
mechanisms, however in order to generate a large, diverse antibody repertoire, 
chickens employ a complex V-gene diversification mechanism known as ‘gene 
conversion’. This is a process in which upstream pseudogenes, that lack a 
recombination signal, are incorporated into the expressed rearranged V-region 
gene (Wu et al., 2012).  Chickens also only have 15 function D-genes, all of which 
are highly homologous. Some are in fact identical in amino acid content (e.g. 
D9/12/13 and D4/8/11) (Reynaud et al., 1991; Wu et al., 2012). The limited CDR3 
VH repertoire is hyper-diversified by the use of D-D junctions, somatic mutation 
and gene conversion. These D-like sequences may replace the entire D segment or 
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only a small section; this leads to the creation of “mosaic CDRs (Shih et al., 2012; 
Wu et al., 2012). These D-segments contain cysteine residues at a far higher 
frequency than humans or mice. This prevalence results in >50% of the chicken 
repertoire containing non-canonical CDRH3 cysteine residues and potentially 
plays an important role in functional diversity (Figure 4.1) 
 
Figure 4.1: The process of gene conversion in chicken is illustrated for both the heavy and 
light chain. In the H germline, a functional VH domain is comprised of unique VH and Jμ 
gene segments with one of a family of Dμ elements (~15 D-family members). In the L 
germline, a single light chain exists (λ) and each light chain is composed of the same Vλ-Jλ 
arrangement, which in itself generates minimal diversity. A process known as ‘gene 
conversion’ which occurs in immature B-cells gives rise to diversity by translocation of 
pseudogene sequences into the V-genes. Typically the closest pseudogene is used more 
frequently in gene conversion; however, in the light chain the pseudogenes are 
distributed across a 20kb region preceding the VL gene (Taken from Conroy et al., 2014). 
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Chickens are an ideal immunological host for the generation of recombinant 
antibodies for a number of reasons (i) they can produce  antibodies against highly 
conserved human proteins (ii) their relatively high core body temperature (41oC) 
which results in very stable antibodies in terms of half-life and (iii) there is 
considerably less germ-line diversity in chickens than in mice and rabbits thus 
fewer primers are required for amplification of the heavy and light chains (Andris-
Widhopf et al., 2000; Barbas et al., 2001; Narat et al., 2003).   
To further understand uniquely chicken attributes, the N-glycan content of IgY 
was also investigated in this body of work, using a fully quantitative high-
throughput N-glycan analysis-based on ultra-performance liquid chromatographic 
(UPLC) separation of released glycans. IgY is more heavily glycosylated than its 
mammalian counterpart as it contains two potential N-glycosylation sites. One is 
located in Cv3 domain, that is absent in the mammalian IgG, and the other is 
located in the Cv2 domain which corresponds to the CH2 (Cγ2) domain of 
mammalian IgG (Figure 4.2) (Narat, 2003; Suzuki and Lee, 2004).  
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Figure 4.2: Structures of Immunoglobulin G and Y and their N-glycosylation sites. (A) IgG (left) is composed of four constant heavy domains with a single carbohydrate 
site (purple star) on each heavy chain. In contrast, the additional constant domain introduces a second carbohydrate site (right). The flexible hinge region in the 
evolutionary ancestor (IgY) is absent and thus restricts flexibility in comparison to IgG. (B) Comparison of amino acid sequences around potential N-glycosylation sites 
on chicken, duck and human heavy chains. Potential N-glycosylation sites are indicated in red.  
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Structural characterisation of N-glycans present on antibody therapeutics is 
required under regulatory guidelines as the nature of these glycans can decisively 
influence the therapeutic performance of an antibody (Millán Martín et al., 2015). 
The linked carbohydrate moieties of antibodies affect both their thermal stability 
and physicochemical properties, along with other crucial features like receptor-
binding activity, circulating half-life and immunogenicity (Szekrényes et al., 2015). 
N-glycan profiling of therapeutic antibodies with good reproducibility is vital to 
fulfil the needs of the both the biopharmaceutical industry and with national 
regulatory agency requirements (Hristodorov et al., 2013).  
4.2 Results 
4.2.1 Immunisation of chickens cPSA antigen 
 
An adult female Leghorn chicken was immunised with cPSA over a period of 3 
months and the serum extracted and the development of the antibody response 
to the antigen was evaluated using an indirect ELISA (section 2.2.2.2). The serum 
was also assessed for a response to free PSA (fPSA) and ACT (protease inhibitor 
bound to cPSA).  Evaluation of the animal’s response is essential to ensure cPSA-
specific antibodies were being generated and the titre was sufficiently high for 
recombinant antibody generation. The specific titres were determined as twice 
the background (control antigen) and are illustrated in Figure 4.3 and Table 4.1. 
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Table 4.1: Specific antibody titres obtained for cPSA immunised chickens 
Antigen cPSA immunised chicken 
cPSA 1 in 1,000,000 
fPSA 1 in 64, 000 
ACT 1 in 256, 000 
 
Figure 4.3: cPSA immunised chicken serum titrations. Serum was harvested from the 
immunised chickens and an antibody serum titre determined by ELISA. Bound avian 
antibodies were detected using an HRP-labelled anti-IgY-fab antibody followed by 
addition of the liquid substrate, TMB. The absorbance was read at 450nm. High serum 
responses for fPSA, cPSA and ACT can be seen, while the predominant response is 
specific for cPSA with the signal at twice the background at 1 in 1,000,000, there is also a 
significant response for fPSA (signal is twice the background at 1 in 64,000) and ACT 
(signal is twice the background at 1 in 256,000). Signal for the chicken was deemed 
sufficiently high for recombinant antibody library generation for cPSA-specific 
antibodies. 
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4.2.2 Optimisation and amplification of chicken heavy and light chain genes 
As the chicken exhibited a sufficient response to cPSA for library building, the 
recombinant antibody library was built using the cDNA generated form RNA 
isolated and reverse transcribed to cDNA following extraction of the spleen and 
bone marrow using the methods described in sections 2.2.2.3 and 2.2.2.4.  
The primers used for the amplification of the VH and VL chain domains with a long 
linker are listed in section 2.2.2.5. Initially, the MgCl2 concentration was optimised 
for both the bone marrow (BM) and spleen (SP) for amplification of both the VH 
and VL in order to identify the optimal conditions for the PCR reaction that will 
give the optimal yield. The PCR products were resolved on 1.5% (w/v) agarose gels 
and visualised using the Gel Doc™ EZ system and Image Lab™, as illustrated in 
Figure 4.4. 
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Figure 4.4: MgCl2 optimisation for spleen (SP) and bone marrow (BM) for both for (A)  VL 
and (B) VH amplifications. These reactions were carried out small-scale (1x) and the 
results revealed that (A) 1.5 mM MgCl2 was optimal for both the SP and BM for the VL 
amplifications, and (B) while 1.5 mM MgCl2 was also optimal for the SP VH amplification, 
2.0 mM MgCl2 provided the optimal yield for the BM VH reaction. Negative reactions 
(Control –C) in the absence of cDNA showed no contaminating bands.  
 
Large-scale (10x) reactions were then carried out using the optimal conditions 
obtained and the correct size amplicons were isolated by gel extraction and 
subsequent clean up (Figure 4.5).  
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Figure 4.5: Optimised large-scale amplifications of VL for BM and SP (A) and VH for BM 
and SP (B) of cPSA immunised chicken. In both cases successful amplification of VL 
(bands at ~350bp) and VH (bands at ~450bp) were observed. The negative control 
showed no contaminating non-specific bands. The 1Kb DNA Hyperladder
TM
 allowed 
approximation of fragment size following resolution on a 1.5% (w/v) agarose gel.  
 
4.2.3 SOE-PCR of variable heavy and light chains 
The avian scFv fragment was constructed by fusing equimolar concentrations of 
the purified variable light and variable heavy chains using the overlap primers, 
CSC-F and CSC-B, listed in section 2.2.2.5. These primers amplified the fusion 
product with incorporation of a long serine-glycine linker 
(GGSSRSSSSGGGGSGGGG). Platinum Taq DNA Polymerase enzyme was used for 
this step in the library building process as it is a robust system, providing highly 
specific amplification and a high yield. Platinum Taq requires the inclusion of 
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MgSO4, which was initially optimised on a small-scale (1x) (Figure 4.6) to ensure 
the correct scFv fragment was amplified in a sufficient amount for digestion and 
subsequent ligation. The optimised reactions identified 2 mM as the best MgSO4 
concentration for both the BM and SP and thus was utilised for the large-scale 
(10x) reactions (Figure 4.7)  
 
Figure 4.6: MgSO4 optimisation for SOE-PCR. An equimolar mix of VL and VH was 
overlapped successfully as shown by the formation of a specific band at ~800bp, 
corresponding to the scFv SOE construct for both the spleen (A) and bone marrow (B). 
The optimal MgSO4 concentration was identified as 2 mM for both the BM and SP. 
Negative control reactions show that no non-specific bands were amplified.  
 
Figure 4.7: Large-scale amplification of (A) SP SOE and (B) BM SOE. The BM and SP scFv 
constructs were successfully amplified for the large-scale reaction using the optimised 
MgSO4 concentrations in sufficient quantities necessary for the next stage of library 
construction. The negative control reactions show no contaminating bands.  
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4.2.4 Construction of scFv library in the pComb3xSS vector  
Both the BM SOE and SP SOE constructs were cloned into the pComb3xSS by 
digestion with the restriction enzyme SfiI. A culture of the pComb3xSS vector was 
prepared (section 2.2.2.8) and plasmid DNA was purified using the Nuncleospin 
Xtra midi kit. The pComb3xSS vector contains a double stuffer fragment between 
the two SfiI sites (Figure 4.8), and digestion with SfiI alone can result in a 
significant amount of intact stuffer fragment or undigested vector, which can 
ultimately lead to library contamination. To overcome this issue, following 
digestion with SfiI, the pComb3xSS vector was further degraded with XbaI and 
XhoI. Post triple digestion, the vector was de-phosphorylated via antarctic 
phosphatase treatment (Figure 4.9A). Antarctic phosphatase catalyses the 
removal of 5´ phosphate from DNA.  Phosphatase-treated fragments lack the 5´ 
phosphoryl termini required by ligases, and, thus, cannot self-ligate. The fully 
digested and treated vector yield a single band at approximately 3,000 bp, which 
was resolved in a 0.7% (w/v) agarose gel (2.2.2.9). The scFv inserts were SfiI 
digested (Figure 4.9B) and following ethanol precipitation, were gel-purified, as 
previously described. 
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Figure 4.8: Schematic representation of the pComb3xSS vector. The pComb3xSS vector 
contains both E. coli and f1 bacteriophage origins of replication. The stuffer fragment is 
located between the sfiI restriction enzyme sites. The amber stop codon (TAG) inserted 
between the 3’ sfiI site and the 5’ end of gIII allows for soluble protein expression in 
non-suppressor strains of E. coil. The vector also contains a hexa-histidine (H6) tag and a 
haemagglutinin (HA) tag to aid purification and detection.  
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Figure 4.9: Restriction digests of (A) pComb3xSS vector and (B) scFv inserts.  (A) The 
vector was digested initially with the enzyme SfiI and then XbaI and XhoI. This triple 
digestion ensures the stuffer fragment is fully degraded, reducing the risk of 
contamination in the later stages of the library building process. The vector was then 
antarctic phosphatase treated and the fully treated and digested fragment was resolved 
on a 0.7% (w/v) agarose gel and compared to the 1kb DNA ladder. (B) The BM and SP 
were successfully digested with sfiI and resolved on a 1.5% (w/v) agarose gel. Each 
digest was carried out four times to ensure there was sufficient product for the library 
ligation.   
 
Following ligation of the purified digested inserts and vector, the antibody library 
was transformed into electrocompetent E. coil, generating a library size of 1 x 108 
cfu/mL. The background (test for self-ligation/contamination) was less than 5%, 
which was assessed by control ligation (vector-no insert). The library was rescued 
with helper phage for panning and subsequently enriched for an anti-cPSA specific 
antibody.  
Three rounds of panning were carried out. A negative selection step 
(subtractive/depletion panning against ACT) was introduced before panning 
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against the actual target, i.e. cPSA, to further minimise the retention of off-target 
binders.  
Table 4.2: Panning input and output titres for avian anti-cPSA scFv library 
Round Input Output 
1 1.5 x 1013 3.04 x 106 
2 4.1 x 1011 1.6 x107 
3 1.1 x 1013 1.3 x 107 
 
4.2.5 Polyclonal phage ELISA  
 
Following three successive rounds of panning the scFv displaying phage from each 
round were analysed by polyclonal phage ELISA for enrichment against cPSA, as 
fully described in section 2.2.3.12. To monitor the selection process, phage pools 
acquired in each round of selection were tested in parallel with phage from the 
unpanned library. To increase confidence in the result, negative controls such as 
BSA and helper phage were included to observe the degree of non-specific 
binding. The phage pools were also assessed for possible enrichment against ACT, 
as an ACT-depletion step was employed in this panning strategy to enhance the 
selection of a highly specific cPSA clone. 
The scFv-displaying phage particles were detected by an anti-M13 HRP-labelled 
antibody. Figure 4.10 shows an increase in absorbance from the first round 
onwards suggesting the presence of cPSA-specific scFv harbouring phage within 
the panned library. It is possible the library was highly biased towards ACT, as 
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there was no dramatic enrichment between the rounds. However, cPSA-specific 
antibodies are evidently present in abundance when compared to ACT. There was 
minimal or no background binding to any of the included controls.  
 
 
 
Figure 4.10: Polyclonal phage ELISA. Phage pools from the unpanned library (RO) and 
phage pools obtained after each round of panning were evaluated for reactivity to both 
cPSA and ACT by indirect ELISA. Bound phage was detected with a HRP-labelled anti-
M13 conjugated antibody and the absorbance read at 450nm. Negative controls were 
also used including BSA and Helper Phage. No enrichment was observed between each 
round of panning.  
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4.2.6 Solube monoclonal ELISA  
 
Phage from each round was infected into mid-exponential Top 10F' E. coli for the 
soluble expression of scFv fragments and spread over the surface of agar LB agar 
plates supplemented with carbenicillin. Thirty clones were picked from each 
round and assessed for binding reactivity with cPSA by monoclonal ELISA. Colonies 
were randomly picked, cultured in deep-well 96-well sterile culture plates, and 
lysed as detailed in section 2.2.3.13. The soluble expressed antibody culture lysate 
was analysed for binding to a cPSA-coated ELISA plate (100nM cPSA). Bound cPSA-
specific scFv antibody fragments were detected with a HRP tagged anti-IgY (H+L) 
antibody (Figure 4.11). Over 95% of the soluble-expressed scFv clones positively 
bound cPSA, highlighting the success of the panning experiment.  
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Figure 4.11: Soluble monoclonal ELISA of scFv clones from each round of panning. Sixty clones picked from each round of panning were randomly selected and assessed 
for binding to cPSA by indirect ELISA. Over 95% of the clones showed significant binding to the cPSA-coated plate, showing that the panning was highly successful.  A 
selected cut-off of 0.2 was used (greater than three times the background- red dotted line). 
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4.2.7 Expression and purification of anti-cPSA scFv 2D2SG 
 
Sequence analysis was carried out on two anti-cPSA scFv clones randomly selected (2D2SG and 
2D8SG) by Source Bioscience Ltd, Dublin, Ireland. The DNA sequences obtained were 
translated using the translate tool from Expasy (http://web.expasy.org/translate/) and the 
amino acid sequences were then exported to PowerPoint and the significant regions 
highlighted (Appendix Three). Anti-cPSA clone 2D2SG was taken forward for small-scale 
expression and purification by Immobilised Metal Affinity Chromatography (IMAC). 
A 100 mL culture of scFv 2D2SG was prepared and lysed, as detailed in section 2.2.2.14 
(chapter two). Ni-NTA resin was applied to a 10mL chromatography column and once settled, 
the resin bed was equilibrated with 2 column volumes of PBS followed. The expressed antibody 
lysate was then applied to the column (twice). Samples were collected at each step of the 
purification process and analysed by SDS-PAGE and WB (Figure 4.12). The eluted protein was 
concentrated and buffer exchanged against PBS/0.02% (w/v) NaN3 using a 10,000 molecular 
weight 'cut-off' vivaspin column. The purified concentrated protein was determined to be 0.6 
mg/mL using the NanoDrop spectrophotometer. 
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Figure 4.12: IMAC purification of anti-cPSA 2D2SG. A 100 mL culture was prepared and expressed 
antibody lysate purified by IMAC. Samples were taken throughout the process for analysis by SDS-
PAGE (left) and WB (right) Specific detection of the scFv fragment was performed by probing the WB 
membrane with a HRP-tagged anti-HA antibody. The presence of 2 bands was observed in the SDS-
PAGE gel (left), indicating that scFv 2D2SG possibly formed as a dimer. ScFv 2D2SG was successfully 
purified to 0.6 mg/mL. L: Ladder, FL: Filtered lysate, FT1: ‘Flow-through’ 1, FT2: ‘Flow-through’ 2, W1: 
Wash 1, W2: Wash 2, EP: Eluted protein, CP: Concentrated protein.  
 
4.2.8 Cross-reactivity assay 
 
To ensure anti-cPSA 2D2SG was specific for cPSA and not cross reactive with ACT or fPSA an 
indirect ELISA was performed, as described in section 2.2.2.15. Varying concentrations 
(doubling dilution; 100 nM, 50 nM, 25 nM 12.5 nM and 0 nM) of cPSA, ACT and fPSA were 
coated to the plate and a 1:10 dilution of IMAC-purified scFv 2D2SG was added. Bound 
antibody was detected using a HRP-labelled anti-HA antibody. From Figure 4.13 it can be seen 
that anti-cPSA is highly specific for cPSA and binds at low concentrations of 12.5 nM. There is 
no cross-reactivity with fPSA whatsoever; however there is some cross-reactivity to ACT.    
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Figure 4.13: Cross reactive indirect ELISA for scFv 2D2SG. Varying concentrations of cPSA/ACT/fPSA 
(100 - 0 nM) were coated an ELISA plate. Binding of anti-cPSA scFv 2D2SG was then detected with 
HRP-labelled anti-HA, followed by addition of the liquid substrate TMB. The absorbance was read at 
450nm. scFv 2D2G does not cross react with fPSA, however does cross-react with ACT; scFv 2D2SG 
binds approximately 2-fold less to ACT compared to cPSA.   
 
4.2.9.1 IgY Purification 
 
Immunoglobulin Y differs from most of the other immunoglobulins as it does not bind protein 
A or protein G (Constantinoiu et al., 2007). IgY was successfully recovered from the serum of 
chickens using thiophilic adsorption. Total protein concentration was determined to be 11.5 
mg/mL by spectrophotometry at 280 nm (NanoDrop 1000). The heavy and light chains of the 
purified IgY were visualized by reducing SDS-PAGE and Western Blot analysis (Figure 4.14). 
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The SDS-PAGE analysis revealed the presence of some contaminating bands (above 70kDa) 
indicating the presence of non-specific avian serum proteins. The IgY was estimated to be 
approximately 70% pure, which is in line with that expected from use of the Pierce Thiophilic 
adsorption KitTM. Constantinoiu  and colleagues (2007) showed that IgY purity can be increased, 
without comprising recovery by reduction of the potassium salt from 0.5 M (as used in Pierce 
Thiophilic adsorption KitTM) to 0.2 M (Constantinoiu et al., 2007). 
 
 
Figure 4.14: SDS-PAGE and Western Blot analysis of IgY purified from serum. Approximately 500 μg of 
purified IgY was resolved on 12% SDS-PAGE gels and visualised by staining with InstantBlue (left). The 
resolved proteins were also transferred to nitrocellulose membranes and the presence of the heavy 
chains at approximately 65-68 kDa and the light chains at 25 kDa can be seen after probing with an 
anti-IgY H+L-HRP-tagged antibody (right). L: PageRuler Plus Prestained protein ladder. 
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4.2.9 N-glycan profiling of avian polyclonal IgY antibodies 
 
This study describes the detailed N-glycan profile of IgY polyclonal antibodies from the serum 
of leghorn chickens using a fully quantitative high-throughput N-glycan analysis approach, 
based on ultra-performance liquid chromatography (UPLC) separation of released glycans. 
4.2.9.2 IgY N-glycan profiling 
 
The N-glycans released from the IgY purified from avian serum (Figure 4.14) were analysed by 
WAX-HPLC and UPLC-HILIC in combination with exoglycosidase digestions and structural 
assignments using established methods (Royle, Campbell, Radcliffe, White, Harvey, Abrahams, 
Kim, Henry, N. A. Shadick, et al., 2008) and the software tool GlycoBase 
(https://glycobase.nibrt.ie). UPLC-FLR-QTOF MS analysis was also carried out for comparative 
analysis. Annotation of the N-glycans present in each chromatographic peak was based upon 
the oligosaccharide composition as derived from the m/z value.  
Over 80 different glycans structures were assigned to 40 peaks (Figure 4.15 and Appendix 
Four). N-glycan structures annotated include high mannose, hybrid and complex glycans with 
variable degrees of core fucosylation, galactosylation and sialylation. The presence of highly 
complex glycans that contain more sialic acids than branches (known as polysialic acids) was 
also observed.  
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Figure 4.15: HILIC-UPLC profile of undigested N-glycans from serum IgY. Profiles are standardised 
against a dextran hydrolysate (GU). The HILIC-chromatogram was separated into 40 peaks. (Final IgY 
structural assignments are listed in Appendix Four). 
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Figure 4.16: Unfractionated IgY profile was subjected to exoglycosidase digestions. In order to confirm 
the structures, the sequence of particular glycan moieties can be elucidated by sequential 
exoglycosidase digestion. The GU for each glycan is directly related to the number and linkage of its 
constituent monosaccharides; the larger the glycan, the higher its GU. Therefore, the removal of 
terminal sugars by exoglycosidase digestion results in a movement of the peak to a lower GU. (Final 
IgY structural assignments are listed in Appendix Four). 
 
 
 
 
 
207 
 
 
 
 
 
 
Figure 4.17: IgY glycans separated according sialic acid content by WAX−HPLC. Where a sample 
contains a large number of structures with varying degrees of sialylation, it is helpful to first separate 
the pool into fractions by charge (i.e., containing zero, one, two, . . . sialic acids) using WAX-HPLC 
because several peaks may co-elute on UPLC-HILIC. The WAX-chromatogram was separated into 5 
peaks: S1, S2, S3, S3j and S4. (Final IgY structural assignments are listed in Appendix Four). 
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Figure 4.18: WAX fraction’s separated by HILIC-UPLC. The differently charged fractions are analysed by 
UPLC-HILIC following WAX-HPLC to determine all of the structures present in each charged fraction. 
(Final IgY structural assignments are listed in Appendix Four). 
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4.2.9.2 Molecular Modelling of IgY  
Molecular Modelling of IgY was carried out by Dr. Mark Wormald (Oxford Univeristy). The 
precise glycans chosen for sites N390 (M9Glc/peak 31 and A2G2S1/peak 20) were based on the 
site specific glycan analysis of IgY (Suzuki and Lee, 2004). The glycans chosen for sites N292 
(A2G2S2/peak 27 and FA3G3/peak 24) were representatives from the other largest peaks. 
Glycan structures were generated using the database of glycosidic linkage conformations 
(Wormald et al., 2002) and in vacuo energy minimisation to relieve unfavourable steric 
interactions. The Asn-GlcNAc linkage conformations were based on the observed range of 
crystallographic values (Petrescu et al., 2004), the torsion angles around the Asn C-C and C-
C bonds then being adjusted to eliminate unfavourable steric interactions between the 
glycans and the protein surface (Figure 4.19).  
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Figure 4.19: Molecular model of glycosylated IgY. Magenta – heavy chain; pink – light chain; yellow– 
stick representation of cysteine residues; blue – glycans. The glycans are labelled according to the 
nomenclature in Appendix Four. 
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4.3 Discussion 
 
This chapter describes the generation of polyclonal and recombinant avian antibodies, and the 
subsequent characterisation of the glycan content of the avian polyclonal antibodies.  
Initially, the construction of a chicken anti-PSA scFv library and subsequent screening of the 
library for identification of a cPSA-specific antibody was described. Sufficient quantities of VH 
and VL were amplified and the desired single chain Fv fragment was successfully assembled 
with a flexible glycine-serine linker in the VL-(Gly4Ser)4-VH orientation.  A scFv phage library with 
a combined (bone marrow and spleen) size of 1 x 108 cfu/mL was generated. The generated 
library size indicates the number of possible clones which could potentially bind cPSA. A library 
size of 107 after electroporation is deemed sufficient for identification of the target antigen. 
The library size is dependent on both the concentration and quality of the DNA and the 
efficiency of the E. coli cells (Andris-Widhofp et al., 2000; Barbas et al., 2001).  
When developing the panning strategy, a negative selection step (i.e., subtractive panning 
against ACT) was introduced before the positive one (panning against cPSA) to further 
minimize the retention of ACT-specific binders. After three rounds of subtractive-based 
panning against cPSA immobilised on a solid support, polyclonal ELISA confirmed the presence 
of cPSA-specific antibodies (Figure 4.10). The negative selection step was highly successful in 
depleting the library of ACT-specific antibody fragments, hence no enrichment for cPSA was 
observed.  Individual clones were analysed by monoclonal ELISA and over 95% of the clones 
successfully bound to the cPSA-coated wells.  
Two clones from pan 2, 2D2SG and 2D8SG (Figure 4.11), showed a high degree of antibody 
expression when grown in small-scale (96-well plates) and an exceptionally high degree of 
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binding to immobilised cPSA (in comparison to the other clones analysed in the monoclonal 
ELISA). These two clones were sent for sequencing to check for inter-clone sequence diversity. 
The DNA sequences were translated using the translate tool from ExPASY and the acquired 
amino acid sequences were then aligned and the complementary determining binding (CDR) 
regions of the antibody evaluated using ClustalW2 software. The CDR regions of the antibodies 
were highlighted according to the Kabat scheme (Figure 4.20) 
 
Figure 4.20: Sequence alignment of anti-cPSA 2D2SG and 2D8SG. The CDRs are highlighted using the 
Kabat numbering system. Conserved CDR flanking regions are highlighted (bold and underlined). Light 
chain CDRs are indicated in blue with the heavy chain CDRs in green. Other highlighted regions: linker; 
pink, hexahistidine tag; purple and HA-tag; gold. Sequences translated using ExPASY tool 
(http://web.expasy.org/translate/) and aligned using ClustalW 
(http://www.ebi.ac.uk/Tools/psa/emboss_needle/) 
 
The diversity between the clones is evident from the sequence variation between the heavy 
and light chains, in particular CDRH3, which is unsurprising given that highly diverse CDR3 loops 
are the key determinant of specificity in antigen recognition. The CDRH3 of anti-cPSA 2D2SG is 
quite long (19 residues) with over 40% comprised of small amino acids (A/G/S), the prevalence 
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of small residues  in the CDR loops confers conformational flexibility which is crucial for 
effective antigen recognition. This CDRH3 notably also contains a single tryptophan and two 
tyrosine residues.  Tyrosine, tryptophan and arginine residues are capable of mediating a wide-
array of intermolecular interactions which are desirable in the composition of the CDRs 
(Birtalan et al., 2008). 
Following sequence alignment, it was evident that the linker in scFv 2D2SG is significantly 
shorter than expected, being only 7 residues in length and contains a serine to glutamine point 
mutation at the start (GQSSRS-----------S). The presence of this linker is highly unusual given 
that the primers used to generate the overlapping of the VL and the VH domains encoded for a 
long linker, 18 residues in length (GGSSRSSSSGGGGSGGGG). Anti-cPSA 2D2SG was expressed 
on a small-scale and purified to 0.6 mg/mL by IMAC and, interestingly, the presence of two 
bands can be seen in the SDS, both at approximately 28kDa (Figure 4.12). Linkers of different 
lengths can result in levels of oligomerisation and may alter the interface of the VH and VL 
domains (Barbas et al., 2001). scFv fragments can be expressed as a monomer, dimer or 
multimers depending on the length of the linker. Connections of the light and heavy variable 
regions with long linkers appear to favour monomeric molecules whereas short linkers tend to 
express as non-covalent dimers. A scFv molecule with a linker of 3 to 12 residues cannot fold 
into a functional Fv domain and instead associates with a second scFv molecule to form a 
bivalent dimer (referred to as a diabody, approximately 60 kDa). Diabodies, have several 
advantages over monomeric antibody fragments including  high binding avidity, which can lead 
to an increase in affinity constants (higher ‘off-rates’)(Hudson and Kortt, 1999; Holliger and 
Hudson, 2005; Wang et al., 2008). 
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In a diabody, the two pairs of domains can pack together with the antigen-binding sites 
pointing in opposite directions, resulting in bivalent or bispecific interactions. In figure 4.13, we 
can see that 2D2SG binds to both ACT and cPSA. This bivalent binding favours the concept that 
2D2SG could potentially have formed as a dimer. However, significant further analysis would 
need to be carried out to confirm this.  The comparative avidity of a multivalent format 
depends on numerous factors, such as the density and accessibility of adjacent epitopes as well 
as the conformational flexibility of both target antigens (Holliger and Hudson, 2005).  
Ideally, non-reducing SDS-PAGE analysis would confirm dimerisation. A bivalent antibody 
fragment contains a cross-paired scFv resulting in a fragment of ∼55 kDa in size. The majority 
of SDS-PAGE gels run under reducing conditions which incorporates agents to break bonds that 
potentially exist between multimeric proteins. Thus, the use of non-reducing (non-denaturing) 
SDS-PAGE conditions maintains the proteins’ secondary structure and native charge density 
(Corley, 2005). The presence of a protein band at approximately 55 kDa would indicate that 
scFv 2D2SG has formed a dimeric structure and is indeed a diabody. Also, size-exclusion 
chromatography (SEC) would aid in determining the presence of a dimeric format. SEC is a 
separation technique based on the molecular size of the components. Separation is achieved 
by the differential exclusion of the sample molecules from the pores of the packing material as 
they pass through a bed of porous particles. Molecules of small size will enter the pores 
whereas larger molecules will flow quickly though the matrix and exit the column first (Corley, 
2005). Hence, a dimeric scFv (55 kDa) will elute from the column before a monomeric scFv. 
Additionally, structural analysis of this antibody fragment alone, and in contact with cPSA 
and/or ACT would provide the greatest insight into its multivalent binding capabilities.  
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Avian serum IgY is functionally equivalent to mammalian IgG, as detailed in the introduction to 
this chapter.  However, it contains an additional constant region and is significantly more 
glycosylated. To clarify the particular structural glycan characteristics of the IgY molecule 
detailed analysis of the N-glycan profile of IgY polyclonal antibodies from the serum of leghorn 
chickens was also investigated.  
Structural assignments revealed that serum IgY to contains mainly high mannose, bi-, tri- and 
tetraantennary glycans with or without core fucose and bisects, all with varying levels of 
galactosylation and sialylation (See appendix two for full list of structural assignments).  
In investigating the site-specific N-glycosylation of IgY, Suzuki and Lee (2004) noted the Fc 
portion of IgY possesses a N-glycosylation site which is structurally equivalent to conserved 
glycosylation sites of other Ig classes in mammals and is composed of predominantly high-
mannose type oligosaccharides (Suzuki and Lee, 2004). High-mannose glycans observed in this 
study are rarely found in mammalian glycoproteins (Kondo et al., 2012). This uniquely avian 
glycosylation pattern at the conserved N-glycosylation site is thought to be attributed to the 
structural differences between IgG and IgY (IgY lacks the hinge region seen in IgG) (Kondo et 
al., 2012).  The additional N-glycosylation site, located in Cv2 domain, was previously shown to 
contain exclusively complex-type oligosaccharides (Suzuki and Lee, 2004; Kondo et al., 2012). 
These distinct avian glycosylation patterns and structural differences provide IgY with distinct 
biochemical properties and behaviour. A model of IgY with the glycans identified from this 
study was generated following glycan assignment (Figure 4.19). Characterisation of the 
individual glycans decorated on a protein is essential for detailed understanding of 
structure/function relationships and the design of potential therapeutic agents. The model 
generated from this study aims to enhance our understanding of the therapeutic potential of 
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IgY. Computational modelling methods are universally accepted as central tools in the 
invention process for many biopharmaceuticals, facilitating drug development areas, such as 
optimising affinity for a target while minimising cross reactive effects, alongside optimising 
pharmacokinetic properties (Kuroda et al., 2012). 
The oligosaccharide content of therapeutic immunoglobulins plays a significant role in its 
bioactivity and pharmacokinetic (PK) activity.  Raju and colleagues (2000) examined at 
variations between the glycan content of IgG across several species. These authors highlighted 
the importance of choosing the right host in generating therapeutic IgG as the terminal 
sialylation of IgG is species-specific (Raju et al., 2000). In this study, MALDI-TOF-MS analysis of 
chicken IgY suggested the N-linked glycosylation of chicken IgY is considerably more 
heterogeneous than its human counterpart, IgG.  
These results correlate with previous studies (Suzuki and Lee, 2004; Kondo et al., 2012; Raju et 
al., 2000) and also highlight several previously unidentified structures. A high sialic acid content 
was observed with many sialic acid isomers (same composition but different sialic acid linkage 
arrangements resulting is different GU from the original structure). The presence of unusual 
sialic acids was also noted, and these are likely to be polysialic acids or sialic acid (Sia) is linked 
on N acetylgalactosamine (GalNAc) as well as on Galactose. Sias are most commonly α2-3 or 
α2-6 linked to galactose (Gal) or α 2–6 linked to GalNAc. However, Sia can also be found linked 
to N-acetylglucosamine (GlcNAc) or to another Sia in α2–8 or α2–9 linkages (Cohen and Varki, 
2010). Polysialic acids occupy internal positions within glycans, the most common being one Sia 
residue attached to another, often at the C-8 position (Varki et al., 2009b).  
The high sialic acid content of IgY is very important when considering IgY as a therapeutic agent 
as the level of sialic acid can have a significant impact on the PK of therapeutic antibodies. A 
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lower content of total sialic acids can significantly reduce half-life (Liu, 2015). Hence, the high 
sialic acid content of IgY that was observed suggests IgY-based biotherapeutics could have 
potentially extended circulating half-lives and are promising candidates for use against a 
variety of pathogens.  
Certain glycan structures have a direct impact on the immunogenicity of therapeutic proteins 
i.e., their presence can affect protein structure in such a way that the protein becomes 
immunogenic. However the glycan structure itself can also induce an immune response. The 
sialic acid N-glycolylneuraminic acid (Neu5Gc) and terminal galactose-α-1,3-galactose are 
examples of such structures that are not naturally present in humans and are known to be 
immunogenic when used as therapeutics (Van Beers and Bardor, 2012). These non-human 
antigenic structures could promote clearance of a biopharmaceutical preparation from 
circulation (Tangvoranuntakul et al., 2003; Chung et al., 2008; Padler-Karavani et al., 2008). 
 The chimeric mouse–human IgG1 monoclonal antibody, Cetuximab, is an anti-human 
epidermal growth factor receptor (EGFR) antibody used for the treatment several cancers 
(Chung et al., 2008). High incidences of hypersensitivity reactions to Cetuximab were reported 
and a study by Chung and colleagues showed that the majority of patients who had a 
hypersensitivity reaction to Cetuximab also had circulating IgE antibodies against Cetuximab 
before therapy was initiated. These antibodies were specific for the glycan structure galactose-
α-1, 3-galactose, which is present on the Fab portion of the Cetuximab heavy chain (Chung et 
al., 2008). In order to overcome these severe hypersensitivity reactions which are observed 
with many immunoglobulin-based biotherapeutic agents it is of primordial importance to 
ensure the oligosaccharide content will not elicit such reactions. Recently, a glyco-engineered 
anti-EGFR monoclonal antibody with a lower α-Gal content than Cetuximab was developed (Yi 
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et al., 2014), highlighting the importance of these structures to the biopharma industry in the 
development of novel biotherapeutics.  
While IgY is heavily decorated with complex glycans, no non-human immunogenic structures 
were identified. The results from this study, combined with other known advantages of chicken 
antibodies, such as increased stability over IgG and phylogenetic distance from man (Spillner et 
al., 2012), makes chickens ideal hosts for the generation of novel oral therapeutic interventions 
for the treatment of numerous infectious diseases. 
 
Chapter conclusions 
Overall, in this chapter, antigen-specific recombinant antibody fragments were successfully 
selected from the generated immune libraries by phage display. Uniquely, chicken antibody N-
glycan features were also investigated and it was concluded that IgY is heavily decorated with 
complex glycans. However, no known non-human or immunogenic glycans were identified. 
 
Future work 
Extensive characteriation of the anti-cPSA antibodies generated from the cPSA immunised 
chicken needs to be carried out including optimisation of the expression and purification 
conditions to generate high yields of pure protein. Determination of the Limit of Detection 
(LoD) of these antibodies should be performed to define their limits for use in a working assay.  
Kinetic characterisation using the Biacore 3000 should also be carried out to determine the 
on/off rates of these antibodies so they can be effectively incorporated into microfluidic-based 
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platform for PCa detection. It is anticipated that anti-fPSA scFv B8 (Chapter 3) and anti cPSA 
2D2SG and 2D8SG will be utilised, along with other PCa –specific antibodies, in a mutilplex 
assay for improved PCa diagnosis.  
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Chapter Five 
Differentiation of indolent, 
significant and aggressive prostate 
cancer by robotic high-throughput 
N-glycan profiling 
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5.1 Introduction 
 
In this chapter, differential glycosylation patterns of PCa serum was investigated to see if it 
could distinguish between 3 cohorts of PCa patients, namely, indolent, significant and 
aggressive PCa. A total of 117 patients (indolent [41], significant [32] and aggressive [44]) were 
included in this study (Figure 5.2) (Patient clinical data in Appendix Five). With respect to 
patient enrolment in the study, all men going for a radical prostatectomy in Ireland were 
eligible and there were no exclusion criteria as long as they were suitable for surgery.  No 
patients withdraw from the study following their surgery or during their follow up. Pateint data 
was collected, including medical history, current medication and family cancer history but it 
was not included in the analysis. 
Here, whole serum N-glycan profiling was carried out on all 117 prostate cancer patients’ sera 
using a highly efficient robotised, high-throughput analysis platform for glyco-profiling with 
UPLC (Stöckmann et al., 2013, 2015). 
The decoration of the vast majority of secreted eukaryotic proteins with glycan structures is 
one of the most common post translational modifications (Dube and Bertozzi, 2005). The 
glycome can change dramatically in response to a subtle change in the cellular environment 
and it is now universally accepted that glycan expression patterns change with the cellular 
condition modifications that accompany the onset of tumourigenesis (Varki et al., 2009; 
Freeze, 2006). 
The size, diversity and complexity of glycans found in mammalian systems provides a wealth of 
information and a significant analytical challenge scientists are faced with is to understand in 
detail which glycans contribute to specific biological functions (Stöckmann et al., 2013). 
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However, within the past decade, advances in the field of proteomics and glycomics has helped 
glycobiologists decipher the link between glycan structures and disease progression (Dube and 
Bertozzi, 2005).  
The high throughput methods devised by Professor Pauline Rudd’s group in The National 
Institute for Bioprocessing Research and Training (NIBRT) provide a superbly reliable and 
robust method that allows for detailed analysis of femtomolar quantities of N-linked sugars 
released from glycoproteins. This approach was designed specifically for the identification and 
high-throughput screening for disease biomarkers (Figure 1.3) (Campbell et al., 2008b; Royle, 
Campbell, Radcliffe, White, Harvey, Abrahams, Kim, Henry, N. A. Shadick, et al., 2008). 
An automated workflow for sample preparation implemented on a robotic liquid handling 
platform was developed to improve on the time and efficiency of the methods previously 
developed by Royle and colleagues (Royle et al., 2008). This system allows for the preparation 
of 96 samples (or multiples thereof) in 22 hours with excellent reproducibility. It also improves 
on the HPLC technique by use of hydrophilic interaction chromatography ultra-performance 
liquid chromatography (HILIC-UPLC) which allows for shorter run times and greatly increased 
resolution (Figure 5.1). 
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Figure 5.1:  Robotic automated sample preparation workflow for UPLC-based glycan analysis on a 
liquid handling platform. The sample preparation workflow consists of protein denaturation, 
enzymatic glycan release, glycan immobilization on solid supports, removal of contaminants, glycan 
release, labelling, and solid-phase extraction (Stöckmann et al., 2013). 
HILIC glycan analysis is continuously advancing and has many advantages over other methods 
such as high-performance anion-exchange chromatography (HPAEC) reversed-phase liquid 
chromatography (RP−LC) and capillary electrophoresis (CE) (Saldova et al., 2014b). 
HILIC separates charged glycan and neutral glycans within a single separation enabling total 
glycan characterisation in single-column chemistry. In HILIC, separation is based on the 
hydrophilicity of the glycan, which is affected by its, composition, size, charge structure, 
linkage, and branching.  The separation of structural isomers is difficult to achieve with other 
methodologies, which is one of main advantages of HILIC (Mariño et al., 2010; Saldova et al., 
2014). Saldova and co-workers showed that using HILIC-UPLC greatly improved separation of 
human serum N-glycans as compared with HPLC (Saldova et al., 2014b).  
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5.2 Results 
5.2.1 PCRC patient cohort 
 
A total of 117 patients (indolent [41], significant [32] and aggressive [44]) were included in this 
study (Figure 5.2). Epstein’s criteria was used to define patients as having indolent, significant 
or aggressive PCa (Epstein et al., 1994).  
 
 
Figure 5.2: Prostate cancer patients sera sourced from the Prostate Cancer Research Consortium 
(PCRC) BioResource. Indolent PCa was defined as tumour volume <0.5cm³, organ-confined disease and 
no Gleason patterns 4 or 5. Significant disease was defined as tumour volume >0.5 cm³, organ-
confined disease and Gleason pattern 4. Aggressive PCa was defined as Gleason patterns 4 or 5 and 
non-organ-confined disease (Patient clinical data available in Appendix Five). 
 
225 
 
5.2.2 UPLC-HILIC profiling of PCa patients serum 
 
A high-throughput platform, automated in a robotic 96-well plate format, for N-glycan analysis 
of human serum using ultra-performance liquid chromatography (UPLC)−HILIC with 
fluorescence detection was recently described (Saldova et al., 2014). This high resolution UPLC-
HILIC method allows potential biomarkers to be separated without the need for exoglycosidase 
digestion or pre-separation on WAX-HPLC (Saldova et al., 2014).  
The serum N-glycome of all 117 PCa patients was analysed in duplicate. The profiles were 
separated into 50 peaks and each peak was examined individually to see if there was any 
significantly different expression between indolent, significant and aggressive PCa patients 
(Figure 5.3). The amounts of total core-, outer-arm fucose, and high-mannosylated glycans 
were calculated based on composition of these 50 peaks, and the glycans were then 
summarized into five groups according to sialylation (S0−S4), five groups according to 
galactosylation (G0−G4), and four groups according to branching (A1−A4) (See glycan features 
in Table 5.1). 
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Figure 5.3:  Typical HILIC-UPLC profile of undigested serum N-glycome from prostate cancer patients. 
Profiles were standardised against a dextran hydrolysate (GU). The HILIC-chromatogram was 
separated into 50 peaks. Structural assignments are listed in Table 5.1.  
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Table 5.1: Summary of identified N-Glycans from prostate cancer sera a,b,c 
 
Glycan label GU Glycans S0 S1 S2 S3 S4 G0 G1 G2 G3 G4 A1 A2 A3 A4 high M CoreF Outer arm F
GP1 4.85 A1
5.34 M4
5.41 FA1
5.41 A2
GP3 5.61 A1[6]G1
5.78 A2B
5.78 A1[3]G1
GP5 5.88 FA2
6.18 M5
6.24 FA2B
6.24 FA1[6]G1
6.24 A2[6]G1
6.38 FA1[3]G1
6.38 A2[3]G1
GP7 6.55 A2[6]BG1
6.71 A2[3]BG1
6.71 FA2[6]G1
6.71 M4A1G1
GP9 6.84 FA2[3]G1
GP10 6.95 FA2[6]BG1
7.08 FA2[3]BG1
7.08 M6 D1,D2
7.08 M6 D3
7.20 A1[3]G1S[3]1
7.20 A2G2
GP13 7.38 A1[3]G1S[6]1
GP14 7.38 A2BG2
7.62 A2[3]G1S[3]1
7.62 A2[3]G1S[6]1
7.62 FA1G1S[3]1
7.62 FA1G1S[6]1
7.62 M5A1G1
7.62 FA2G2
7.76 FA2BG2
7.76 M7 D3
7.76 A2[6]BG1S[3]1
7.76 A2[6]BG1S[6]1
7.92 A2[3]BG1S[3]1
7.92 A2[3]BG1S[6]1
7.92 FA2[6]G1S[3]1
7.92 FA2[6]G1S[6]1
7.92 M4A1G1S[3]1
7.92 M4A1G1S[6]1
7.92 M7 D1
8.03 FA2[3]G1S[3]1
8.03 FA2[3]G1S[6]1
8.03 FA2[6]BG1S[3]1
8.03 FA2[6]BG1S[6]1
8.20 FA2[3]BG1S[3]1
8.20 FA2[3]BG1S[6]1
8.38 A2G2S[3]1
8.38 A2G2S[6]1
8.38 A3G3
8.53 A2BG2S[3]1
8.53 A2BG2S[6]1
8.63 M5A1G1S[3]1
8.63 M5A1G1S[6]1
8.63 FA3G3
8.63 M8 D2,D3
8.63 *A2G2S[3]1
8.80 FA2G2S[3]1
8.80 FA2G2S[6]1
GP24 8.80 M8 D1,D3
9.02 FA2BG2S[3]1
9.02 FA2BG2S[6]1
9.21 *A2G2S[3,3]2
9.21 *A2G2S[3,6]2
9.21 *FA2G2S[3,3]2
9.21 A2F1G2S[3]1
9.21 A2F1G2S[6]1
9.43 A3G3S[3]1
9.43 A3G3S[6]1
9.43 M9
9.62 A3BG3S[3]1
9.62 A3BG3S[6]1
9.62 A2G2S[3,3]2
9.62 A2G2S[3,6]2
9.62 A2G2S[6,6]2
9.79 FA3G3S[3]1
9.79 FA3G3S[6]1
9.79 FA3BG3S[3]1
9.79 A2BG2S[3,3]2
9.79 A2BG2S[3,6]2
9.79 A2BG2S[6,6]2
GP29
GP28
GP26
GP27
GP25
GP23
50% 50%50% 50%GP22
GP21
GP20
GP19
GP18
GP17
GP16
50% 50%50%GP15
50%50% 50% 50%GP12 50% 50%
GP11
GP8
50% 50% 50%GP6 50%
GP4
GP2
 N -glycans Total Features
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Glycan label GU Glycans S0 S1 S2 S3 S4 G0 G1 G2 G3 G4 A1 A2 A3 A4 high M CoreF Outer arm F
10.04 A3F1G3S[3]1
10.04 FA2G2S[3,3]2
10.04 FA2G2S[3,6]2
10.04 FA2G2S[6,6]2
10.17 FA2BG2S[3,3]2
10.17 FA2BG2S[3,6]2
10.17 FA2BG2S[6,6]2
10.17 A2F1G2S[3,3]2
10.17 A2F1G2S[3,6]2
10.17 A2F1G2S[6,6]2
10.17 M9Glc
10.31 A3G3S[3,3]2
10.31 A3G3S[3,6]2
10.31 A3G3S[6,6]2
10.43 A3BG3S[3,3]2
10.43 A3BG3S[3,6]2
10.43 A3BG3S[6,6]2
GP34 10.60 A4G4S[3]1
10.77 FA3G3S[3,3]2
10.77 FA3G3S[3,6]2
10.77 FA3G3S[6,6]2
10.77 *A3G3S[3,3]2
10.96 *A3G3S[3,3,3]3
10.96 A3F1G3S[3,3]2
10.96 A4G4S[6]1
11.14 *A3G3S[3,3,6]3
11.14 *A3G3S[3,6,6]3
11.14 *A3BG3S[3,3,3]3
11.14 *A3BG3S[3,3,6]3
11.14 *A3BG3S[3,6,6]3
11.28 *FA3G3S[3,3,3]3
11.28 *FA3BG3S[3,3,3]3
11.54 A4G4S[3,6]2
11.54 A3G3S[3,3,3]3
11.54 A3G3S[3,3,6]3
11.54 A3G3S[3,6,6]3
11.54 A3G3S[6,6,6]3
11.72 A3BG3S[3,3,3]3
11.72 A3BG3S[3,3,6]3
11.72 A3BG3S[6,6,6]3
11.89 FA3G3S[3,3,3]3
11.89 FA3G3S[3,3,6]3
11.89 FA3G3S[3,6,6]3
11.89 FA3G3S[6,6,6]3
12.03 *A3G3S[3,3,3]3
12.03 *A3G3S[3,3,6]3
12.03 *A3G3S[3,6,6]3
12.03 A3F1G3S[3,3,3]3
12.03 A3F1G3S[3,3,6]3
12.03 FA3BG3S[3,3,3]3
12.03 FA3BG3S[6,6,6]3
12.15 A4G4S[3,3,3]3
12.15 A3F1G3S[3,6,6]3
12.33 A4G4S[3,3,6]3
12.33 A4G4S[3,6,6]3
12.48 A4F1G3S[3,3,3]3
12.48 A3F2G3S[3,3,3]3
12.48 A4F1G3S[3,3,6]3
12.48 A4F1G3S[3,6,6]3
12.67 A3F2G3S[3,3,6]3
12.67 A4F2G3S[3,3,3]3
12.67 A4F2G3S[3,3,6]3
12.67 *A4G4S[3,3,3,3]4
12.78 A4G4S[3,3,3,3]4
GP46 12.96 A4G4S[3,3,3,6]4
13.27 *A4G4S[3,3,3,6]4
13.27 A4G4S[3,3,6,6]4
13.27 A4G4S[3,6,6,6]4
13.47 *A4G4S[3,3,3,3]4
13.47 FA4G4S[3,3,3,3]4
13.47 FA4G4S[3,3,3,6]4
13.47 A4BG4S[3,3,6,6]4
13.82 A4F1G4S[3,3,3,3]4
13.82 A4F1G4S[3,3,3,6]4
13.82 A4F1G4S[3,3,6,6]4
13.82 A4F1G4S[3,6,6,6]4
13.99 A4G4LacS[3,3,3,3]4
13.99 A4G4LacS[3,3,3,6]4
13.99 A4F2G4S[3,3,3,3]4
13.99 A4F2G4S[3,3,6,6]4
14.43 A4F3G4S[3,3,3,3]4
GP50 33%
50%GP48
GP49
GP47
33%GP45
GP44
GP43
GP42
GP41
GP40
GP39
GP38
GP37
GP36
GP35
GP33
GP32
GP31
GP30
 N -glycans Total Features
 
229 
 
a
 The HILIC-chromatogram was separated into 50 peaks and structural assignment carried out 
according to Saldova et al., 2014. 
b 
*Sialic acids isomers (same composition but different sialic acid 
linkage arrangements resulting in different GUs from the original structures). 
c 
Peaks calculated into 
specific features are highlighted in grey (where there is 33 or 50%; the glycans with the given feature 
are approximately that abundant in the given peak): Sialylation: S0 (neutral, GP1−11+ 
(GP12/2)+14+16+17+24); S1 (monosialylated, (GP12/2)+GP13+GP15+GP18−23+GP25+GP27+GP34); S2 
(disialylated, GP26+28−33+GP35) ;S3 (trisialylated, GP36−44); S4 (tetrasialylated, GP45−50); 
Galactosylation: G0 (agalactosylated, GP1−2+GP4−5+(GP6/2)+(GP12/2)); G1 (monogalactosylated, 
GP3+GP7−10+(GP12/2)+GP13+GP15+GP18-19+(GP22/2)); G2 (digalactosylated, GP14+GP16−17+GP20-
21+(GP22/2)+GP23+GP25−31); G3 (trigalactosylated, GP32-33+GP35−41); G4 (tetragalactosylated, 
GP34+GP42−50); Branching: A1 (monoantennary, GP1−3+ (GP12/2) +13+ (GP15/2) + (GP22/2)); A2 
(biantennary, GP4-5+(GP6/2)+GP7-10+(GP12/2)+GP14+(GP15/2)+GP16-21+(GP22/2)+GP23+ 
GP25−31); A3 (triantennary, GP32-33+GP35−41); A4 (tetraantennary, GP34+GP42−50); High mannose: 
(GP6/2) +GP11 ; Fucosylation: Core-fucose: GP2+GP5+ (GP6/2) +GP8−10+ (GP15/2) +GP16-
17+GP19+GP23+GP25+GP30-31+GP40+ (GP48/2) ; Outer-arm fucose: 
GP41+GP44+(GP45/3)+GP49+(GP50/3).Structure abbreviations: all N-glycans have two core GlcNAcs; F 
at the start of the abbreviation indicates a core-fucose α1,6-linked to the inner GlcNAc; Mx, number 
(x) of mannose on core GlcNAcs;D1 indicates that the α1-2 mannose is on the Manα1-6Manα1-6 arm, 
D2 on the Manα1-3Manα1-6 arm, D3 on the Manα1-3 arm of M6 and on the Manα1-2Manα1-3 arm of 
M7 and M8; Ax, number of antenna (GlcNAc) on trimannosyl core; A2, biantennary with both GlcNAcs 
as β1,2-linked; A3, triantennary with a GlcNAc linked β1,2 to both mannose and the third GlcNAc 
linked β1,4 to the α1,3 linked mannose; A4, GlcNAcs linked as A3 with additional GlcNAc β1,6 linked to 
α1,6 mannose; B, bisecting GlcNAc linked β1,4 to β1,3 mannose; Gx, number (x) of β1,4 linked 
galactose on antenna; F(x), number (x) of fucose linked α1,3 to antenna GlcNAc; Sx, number (x) of 
sialic acids linked to galactose; Lac(x), number (x) of lactosamine (Galβ1-4GlcNAc) extensions. 
 
5.2.2 Statistical analysis 
 
Statistical analysis was carried out by Mr. Keefe Murphy (PCRC biostatistician, University 
College Dublin). Initially, all 50 peaks were examined individually to explore baseline 
differences in expression using one way analysis of variance (ANOVA). Tukey’s post-hoc 
honestly significant difference (HSD) was performed to calculate the p-values and boxplots 
were used to illustrate the distribution of each biomarker by significance. From this analysis a 
panel of 13 peaks were identified as significant, as follows;  
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Peak 4 + Peak13 + Peak 14 + Peak15 + Peak17 + Peak 18 + Peak 22 + Peak 27 + Peak 33 + Peak 
34 + Peak 37 + Peak38 + Peak40 
 
All 50 peaks were then considered in combination (in a multivariate predictive regression 
context) to see which panel of variables would yield the best predictive performance, the 
following panel was identified: 
 
Peak15 + Peak22 + Peak1 + Peak29 + Peak44 + Peak11 +Peak21 + Peak7 + Peak45 + Peak17 + 
Peak37 + Peak10 + Peak30 
5.2.3 Significant changes in whole serum N-glycome in prostate cancer 
 
When considered individually, 13 peaks showed statistically significantly different expression 
levels across the 3 patient cohorts. Of these 13 peaks, 4 peaks showed statistically significantly 
different expression levels as disease progresses from indolent to aggressive (Figure 5.4) and 
will be further discussed. 
Peak 4, containing mostly biantennary bisected glycans (A2B) and peak 22 containing mostly 
biantennary digalactosylated monosialylated glycans (A2G2S1) and high mannose structures 
(M5A1G1S1, M8) were significantly increased as disease progresses in this study. 
Notable decreases were also observed, particularly in triantennary trigalactosylated 
trisialylated glycans with and without core-fucosylation (Peak 37- A3G3S3, Peak 40-FA3G3S3), 
as PCa progresses from indolent to aggressive.  
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Figure 5.4: Boxplots of 4 glycosylation peaks which exhibited significant differences across 3 patient 
groups (indolent, significant and aggressive) from the Irish PCRC cohort. A box plot is a simple way of 
representing statistical data based on the minimum, first quartile, median, third quartile, and 
maximum. Here, boxes represent the 25th and 75th percentiles with the median indicated. The lower 
and upper quartiles are shown as horizontal lines either side of the rectangle. (A) Peaks that 
significantly increase as disease progresses and (B) peaks that significantly decrease as disease 
progresses. 
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Model diagnostics was then carried out to assess the predictive performance of these 4 peaks. 
The discriminant ability was determined by means of ROC curves and AUC values. 
 
Figure 5.5: ROC curves of the 4 significantly changed peaks as prostate cancer progresses. A ROC curve 
is a fundamental tool for diagnostic test evaluation where the true positive rate (Sensitivity) is plotted 
in function of the false positive rate (100-Specificity) for different cut-off points of a parameter. The 
AUC value indicates how each peak can predict indolent, significant or aggressive PCa. A perfect 
diagnostic test has an AUC 1.0 whereas a non-discriminating test has an area 0.5. The AUC values for 
all peaks very close to or less than 0.5, which indicates the glycans in these peaks, alone, have poor 
discriminatory ability. 
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5.2.4 N-glycome biomarker panel  
 
Within this combination of glycans there are notable increases and decreases in certain glycan 
structures as disease progresses from the indolent cohort to the more advanced cohort as 
demonstrated in Figure 5.6. 
There is an increase biantennary bisected monogalactosylated glycans (Peak 7-A2[6]BG1) and 
biantennary digalactosylated monosialylated and high mannose (Peak 22 – mostly A2G2S1, 
M5A1G1S1)  glycans as disease progresses. We also observed increases in core fucosylated 
biantennary disialylated glycans (Peak 30 – mostly FA2G2S2) and tetraantennary tetrasialylated 
glycans in peak 45 (predominately A4G4S4).  
With disease progression we also identified decreases in bisected biantennary disialylated 
glycans (mostly A2BG2S2 - peak 29) and certain high mannose glycans (mostly M6 isomers – 
Peak 11). Peak 37, which is comprised mostly of triantennary trigalactosylated trisialylated 
glycans (A3G3S3) was also included in this biomarker panel and was significantly decreased 
with disease progression.  
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Figure 5.6: Plotted peaks form part of the PCa whole serum N-glycome biomarker panel that show 
altered expression in indolent, significant and aggressive PCa from the Irish PCRC cohort. Figure 
Legend on Page 230 
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Figure 5.6: Plotted peaks form part of the PCa whole serum N-glycome biomarker panel that show 
altered expression in indolent, significant and aggressive PCa from the Irish PCRC cohort. A box plot is 
a simple way of representing statistical data based on the minimum, first quartile, median, third 
quartile, and maximum. Here, boxes represent the 25th and 75th percentiles with the median 
indicated. The lower and upper quartiles are shown as horizontal lines either side of the rectangle (A) 
Four peaks that increase as disease progresses and (B) three peaks that decrease as disease 
progresses. 
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As for the significant biomarker panel, model diagnostics was then carried out to assess the 
performance of this biomarker panel (Peak15 + Peak22 + Peak1 + Peak29 + Peak44 + Peak11 
+Peak21 + Peak7 + Peak45 + Peak17 + Peak37 + Peak10 + Peak30). The discriminant ability was 
determined by means of ROC curves and AUC values (Figure 5.7). To further assess the net 
benefit of this prediction model calibration curves (Figure 5.8) were prepared.  
 
Figure 5.7: ROC curves are plotted with AUC values of the peaks in the biomarker panel in indolent, 
significant and aggressive PCa. A ROC curve is a fundamental tool for diagnostic test evaluation where 
the true positive rate (Sensitivity) is plotted in function of the false positive rate (100-Specificity) for 
different cut-off points of a parameter. The AUC value indicates how each peak can predict indolent, 
significant or aggressive PCa. A perfect diagnostic test has an AUC 1.0 whereas a non-discriminating 
test has an area 0.5. The glycans present in N-glycome biomarker panel can predict PCa cohorts with 
high sensitivity and specificity (multiple AUC 0.81). This biomarker has high discriminant ability and 
can predict indolent cancer to 77%, significant to 84% and aggressive disease to 83%.  
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Figure 5.8: Calibration curves of the N-glycome biomarker panel in indolent, significant and aggressive 
PCa. A calibration curve is a measure of the agreement between observed outcomes and predictions. 
The resulting curve shows whether the model underestimates or overestimates PCa classification. A 
perfect prediction should be on the 45° line (Steyerberg et al., 2010). The glycosylation biomarker 
panel is close to the 45° line for the indolent and significant and is almost equal to the 45° line for 
aggressive cohort. This result illustrates that the N-glycan biomarker panel is not grossly misclassifying 
PCa patients i.e. there is strong agreement between the observed (PCRC classified) and predicted (by 
N-glycome biomarker) results.  
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5.3 Discussion  
 
Recently, the over-diagnosis of PCa has become one of the major clinical dilemmas faced by 
urologists. PCa is slow growing in most men, presenting no clinical symptoms during the life-
time of the patient, and in many cases, men die with the disease rather than from the disease 
(Vickers et al., 2012). 
For this reason, urologists have had to identify new treatment strategies for men diagnosed 
with low risk ‘indolent’ PCa, namely, active surveillance and watchful waiting. Prostate cancer-
specific mortality under active surveillance is very low and trials of active surveillance report 
encouraging results (Venderbos et al., 2013).  
The Epstein criteria can be used to determine PCa significance, and thereby identify indolent 
PCa’s which may be eligible for active surveillance. However, the Epstein criteria depends 
largely on Gleason score, and changes to the Gleason scoring system (Epstein, 2010) have 
resulted in a major shift in Gleason classification standards and have raised questions as to 
what Gleason score now constitutes indolent disease. 
It is increasingly obvious that there is an unmet need to develop a biomarker that can 
differentiate between indolent and aggressive prostate cancer, ultimately, maximising the 
benefits of cancer screening while limiting harm.  
In this chapter, whole serum N-glycan profiling was carried out on 117 prostate cancer 
patients’ serum using a highly efficient robotised, high-throughput analysis platform for glyco-
profiling with UPLC. The aim of this study was to investigate if differential glycosylation 
patterns could distinguish between the 3 cohorts of PCa patients. 
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The current clinical model used for determining PCa classification in Ireland focus on 4 
variables; serum PSA (ng/mL), clinical stage (DRE), age, biopsy Gleason Score and has limited 
sensitivity, specificity, and predictability as detailed in Table 5.2. 
Table 5.2: Current clinical model predictability  
 
 
Initially, statistical analysis was performed to determine if significant peaks could differentiate 
between indolent, significant and aggressive PCa. From these results, 2 peaks significantly 
increased and 2 peaks significantly decreased as disease progresses. Model diagnostics was 
carried out for these 4 peaks to determine their predictive performance (Figure 5.5).  
A receiver operating characteristic (ROC) curve was generated for each peak (by Mr. Keefe 
Murphy), which plots the sensitivity (true positive rate) against 1 – (false positive rate) for a 
range of values for the ability to predict an outcome (Steyerberg et al., 2010). Overall accuracy 
is sometimes expressed as area under the ROC curve (AUC). The closer the curve is located to 
upper-left hand corner and the larger the area under the curve, the better the test will be at 
discriminating between the 3 cohorts (Eusebi, 2013). In Figure 5.5, the AUC values are all very 
Type Specificity Sensitivity AUCs 95% C.I. Multi AUC ORC 
Indolent 0.929 0.548 0.776 {0.703, 
0.849} 
 
 
0.668 
{0.618, 
0.706} 
 
 
0.724 
{0.667, 
0.781} 
Significant 0.667 0.452 0.471 {0.372, 
0.570} 
Aggressive 0.788 0.623 0.779 {0.702, 
0.855} 
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close to or less than 0.5, indicating the glycans in these peaks, alone, have poor discriminatory 
ability. A perfect diagnostic test has an AUC 1.0 whereas a non-discriminating test has an area 
0.5 (Eusebi, 2013). The ability of these peaks alone to predict between indolent, significant and 
aggressive PCa, is worse than the current clinical model (Table 5.2). 
Given the poor predictability of these peaks alone for discriminating between indolent, 
significant and aggressive PCa, further statistical analysis was carried out where the peaks were 
then considered in combination (in a multivariate predictive regression context) to see which 
panel of variables would yield the best predictive performance.  
From this biomarker panel there are noticed increases and decreases in expression patterns of 
glycosylation in several peaks (Figure 5.6),  of which  2 peaks are statistically significantly 
altered (Peak 22 and Peak 37).  The glycans present in these peaks correlate with the most 
common serum glycome alterations observed in prostate cancer, and are well documented, 
including sialylation, branching and fucosylation (Saldova et al., 2011). 
Increases in core-fucosylation 
The ageing process is known to effect serum N-glycans and differential patterns between age 
groups were detected in various studies (Marino et al., 2012), notably, core-fucosylation is 
known to decrease with age (Knezevic et al., 2009).  In this study patient groups were matched 
for age when they were selected for inclusion in the cohort so there should be no difference in 
age between the groups. 
The observed increase in core-fucosylation (FA2G2S2, Peak 30) in significant and aggressive 
patients compared to indolent patients is unsurprising as altered fucosylation is now 
considered a common feature of many cancers (Marino et al., 2012) and has been previously 
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observed in prostate cancer studies (Kyselova et al., 2007, Saldova et al., 2011). In comparing 
24 PCa patients with 10 healthy controls Kyselova et al. (2007) noted that the fucosylation of 
glycan structures was significantly higher in the serum of the PCa patients.  Changes in 
fucosylation pathways could affect the level of core fucosylation. An increase in 
fucosyltransferases increases the core fucosylation of Epidermal Growth Factor Receptor 
(EGFR), which is commonly overexpressed in many carcinomas (Masumoto et al., 2008). In 
an earlier study (Saldova et al., 2011), an increase in core-fucosylation in PCa sera in a study of 
13 patients with Benign Prostate Hyperplasia (BPH) and 34 PCa patients was shown. In this 
study it can be seen that increases in core-fucosylated glycans in this biomarker panel helps 
distinguish indolent PCa from clinically insignificant and aggressive PCa.  
Alterations in high mannose glycans 
Complex high mannose structures (M5A1G1S[3]1, M5A1G1S[6]1 and M8 D2,D3; Peak 22) 
increase as disease progress. N-glycans with high mannose, hybrid, or complex type sugar 
chains contribute in a multitude of cellular processes including cell-cell/cell-matrix/receptor-
ligand interaction, cell signalling/growth and differentiation (Banerjee, 2012).  Given that high 
mannose structures participate both in cell survival and cell death this could be an indication 
for the observed increased abundance of high mannose structures in significant and aggressive 
disease compared to indolent disease.  
An abundance of high mannose structures were observed when the N-glycan profiles of 
membrane proteins across 3 different colorectal cancer cell lines (LIM1215, LIM1899, and 
LIM2405) was investigated (Sethi et al, 2014). The authors of this study suggest incomplete N-
glycan processing led to the accumulation of high mannose type structures in the colorectal 
cancer cell lines. In another recent colorectal cancer study the authors showed high-mannose 
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N-glycan structures were more common in carcinomas than in adenomas (Kaprio et al., 2015). 
We did however observe a decrease in isomers of the high mannose glycan-M6 (predominant 
glycans in peak 11); therefore it is likely that only certain high mannose structures are 
increased in PCa patients. 
A3G3S3/A4G4S4 
Alterations in certain glycan structures were noted in a previous prostate cancer study that 
correlate with the glycans in this biomarker panel (Saldova et al., 2011), in which significant 
decreases in triantennary trigalactosylated trisialylated glycans (A3G3S3) and increases in 
tetraantennary tetragalactosylated tetrasialylated (A4G4S4) are observed in advanced 
aggressive PCa.  
Certain glycan structures are well-known markers for tumour progression and through decades 
of glycomic studies one of the more typical features of disease progression that is consistently 
observed is increased expression of sialic acid sugars on the surface of cancer cells (Büll et al., 
2014).  While we can see an increase in tetraantennary tetrasialylated glycans (A4G4S4, peak 
45) in aggressive PCa we also observed a significant decrease in triantennary trisialylated 
glycans (A3G3S3, peak 37).  
Patients with a Gleason score of 7 are generally positive for perineural invasion (PNI), found to 
be at a more advanced stage of metastasis and have an increased chance of re-occurrence. PNI 
is an important pre-operative indicator of the pathological stage of the tumor. In our initial 
study we showed that increases in tetraantennary tetragalactosylated tetrasialylated (A4G4S4) 
correlate with PNI and can help diagnose tumor spread (Saldova et al., 2011) 
 
243 
 
This study supports previous serum PCa glycomics analysis (Saldova et al., 2011) as our 
aggressive patients are defined as Gleason patterns greater than 4 and non-organ-confined 
disease. Differentiation between the more challenging significant and aggressive prostate 
cancer over clinically insignificant disease could potentially be identified by measurement of 
increases in tetraantennary tetragalactosylated tetrasialylated in patient’s sera.  
Various studies have noted excessively high expression of sialic acids and aberrant sialylation 
in cancer. One reason this is thought to occur is that factors such as oncogenes, hormones, 
and/or chemotherapy can aid in the increased expression of sialyltransferases and 
downregulate the expression of sialidases in cancerous cells. Ultimately, this leads to 
accumulation of uncharacteristic hyper-sialylated structures on the cell membrane (Büll et al., 
2014). The tumour microenvironment alters key elements of glycan biosynthesis apparatus, 
such as glycotransferases and glycosidases, and aberrant glycosylation is now widely accepted 
as a characteristic of cancer. The altered expression of these enzymes results in the production 
of glycoproteins with modified glycans (Drake et al., 2010).  There is now a common 
acceptance that increases in branching and sialylation correlate with more advanced cancers, 
which we have discussed and observed in this study.   
However, interestingly it was noticed that there was a decrease in the highly branched and 
sialylated triantennary trigalactosylated trisialylated glycans (A3G3S3) in peak 37. This 
structure was also decreased in previous studies, where decreases in A3G3S3 could distinguish 
between patients with Gleason score 5 and Gleason score 7 significantly better than the 
currently used PSA assay (Saldova et al., 2011). In this body of work, significant decreases in 
this structure was observed in the significant and aggressive patient groups compared to the 
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indolent group. It can be hypothesised that decreases in triantennary trigalactosylated 
trisialylated glycans could have good predictability in monitoring PCa disease progression.   
 
Table 5.3: Sensitivity, specificity and predictability of glycosylation biomarker panel 
Type Specificity Sensitivity AUCs 95% C.I. Multi AUC ORC 
Indolent 0.811 0.628 0.771 {0.678, 
0.864} 
 
 
0.810 
{0.759, 0.861} 
 
 
0.845 
{0.793, 
0.898} 
Significant 0.844 0.667 0.836 {0.753, 
0.919} 
Aggressive 0.857 0.723 0.827 {0.745, 
0.909} 
 
Within this panel we have observed increases in certain high mannose structures (M5A1G1S1 
and M8) and tetraantennary tetrasialylated glycans (A4G4S4) and significant decreases in 
triantennary trigalactosylated trisialylated glycans (A3G3S3). These glycans are highly specific 
in predicting the outcome of PCa patients and can provide a novel approach to diagnosing PCa. 
The AUC values for this biomarker panel (Figure 5.7) are considerably better than the current 
clinical model and further model diagnostics (Figure 5.8) to confirm the predictive ability of this 
combination of glycans was also carried out (by Mr. Keefe Murphy). Traditionally used 
performance measures in medicine include, but are not limited to ROC curves, calibration 
curves and decision curves. A calibration curve refers to the agreement between observed 
outcomes and predictions (Steyerberg et al., 2010). A graphical assessment of calibration curve 
for this biomarker panel is shown in Figure 5.8, with predictions on the x-axis, and the outcome 
on the y-axis. A perfect prediction should be on the 45° line (Steyerberg et al., 2010), and we 
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can see the glycosylation biomarker panel is quite close to this, particularly for the aggressive 
cohort.  
This biomarker panel can predict between indolent, significant and aggressive PCa with better 
sensitivity and specificity than the current clinical methods (Tables 5.2 and 5.3).  
The glycosylation biomarker identified from this body of work was also included in analysis 
which showed that a panel of biomarkers attains significantly higher predictive ability than 
each of the biomarkers alone. DNA methylation, miRNA expression, proteomic analysis and 
serum N-glycosylation data were pooled and variables analysed using stepwise AIC and multi-
block aggregation methods (by Mr. Keefe Murphy).  This integrated biomarker panel can 
predict PCa with exceptionally high sensitivity and specificity; indolent disease with 94%, 
significant (87%) and aggressive PCa with 92% accuracy.    
Chapter Conclusions 
In conclusion, whole serum N-glycan analysis was successfully carried out on 117 prostate 
cancer patients, in a high-throughput fashion, using a novel robotized platform for rapid 
serum-based N-glycan sample preparation and quantitation. From the high-quality glycomics 
data generated, a clinically valuable, novel, glyco-biomarker panel was identified that is 
considerably better than the current clinical model. Significant changes between three cohorts 
of PCa were observed, notably, alterations in high mannose structures (M5A1G1S1, M6 and 
M8) and highly branched glycan structures including increases in tetraantennary 
tetragalactosylated tetrasialylated glycans (A4G4S4) and decreases in triantennary trisialylated 
glycans(A3G3S3), and also increases in core-fucosylated glycans. These changes are consistent 
with altered fucosylation and sialylation pathways observed in prostate cancer (Saldova et al., 
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2011). The glycans identified in this biomarker panel have better predictability than the current 
clinical model and therefore may provide a novel, non-invasive approach to diagnosing 
prostate cancer. Development of an effective diagnostic method for prostate cancer is of 
primordial clinical importance as it can aid the effectiveness of treatment and increase a 
patient's chance of survival and quality of life.    
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Chapter Six 
Overall Conclusions 
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6.1 Overall Conclusions 
 
The aims identified at the outset of this project were to develop an in-depth understanding of 
avian antibodies in order to produce highly sensitive antibodies for improving prostate cancer 
diagnostics. It is hoped that antibodies generated from this research will provide clinicians with 
the highly sought after, enhanced tools for detecting the disease and determining the most 
effective intervention plan. In addition, investigation of alterations to the serum glycome 
across different forms of prostate cancer led to the identification of a highly specific, novel 
glyco-marker.  
Here, the strategies employed involved the generation and characterisation of recombinant 
antibody fragments (scFv) to fPSA and cPSA. An anti-cPSA library was generated and antibody 
fragments isolated and characterised by ELISA, SDS-PAGE and Western Blotting. An anti-fPSA 
scFv was also isolated from a fPSA immune repertoire and extensively kinetically and 
structurally evaluated. Both of these antibody fragments are currently being optimised for 
incorporation into a multiplexed microfluidics-based assay, in our laboratory.  
Anti-fPSA scFv B8 was also reformatted to a single chain antibody fragment (scAb) for 
improved expression (results not shown). Reformatting antibody fragments can produce more 
stable, rigid protein structures. Hayhurst and colleagues overcame issues of poor soluble 
expression of a scFv fragment by converting the scFv into a scAb format and introduced co-
expression of the periplasmic chaperone skp, to alleviate protein aggregation in the bacterial 
periplasm (Hayhurst et al., 2003). A modified version of the vector developed by Hayhurst and 
colleagues for the soluble expression of scAb fragments was used to generate an avian anti-
fPSA scAb antibody. This vector was re-engineered by Dr. B. Vijayalakshmi Ayyar (designed by 
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Dr. Stephen Hearty) by replacing the existing HuCκ (human constant domain) with a chicken 
constant domain (Cλ). This scAb fragment retained full binding capabilities of scFv B8 (nM 
affinity for fPSA) and was used for the development of an amperometric magneto-
immunosensor.  
Optimisation of the physicochemical properties of an antibody without perturbing the affinity 
and specificity for its cognate antigen is a challenging endeavour. However, progress in the 
field of structural biology is rapidly accelerating knowledge in this area. In this research, the 
structural binding attributes of chicken antibodies were determined through X-ray 
crystallographic techniques. The interaction surface of antibody-antigen complexes can involve 
a large number of residues and, thus, knowledge of these interactions can provide a wealth of 
knowledge for structure-guided design. It is hoped that the research described in this thesis 
will aid scientists in a rational design-based approach for the development of avian antibodies 
for therapeutic and diagnostics purposes.  
In addition to antibody-based methods for improving PCa diagnostics, glycomic-based analysis 
was also investigated. Recently, rapid screening methods have been used to analyse 
glycosylation patterns on glycoproteins in large cohorts of patients, enabling the identification 
of a new generation of disease biomarkers. In a healthy organism, glycosylation systems 
produce numerous variants of glycans, but the sequences of glycoforms are relatively stable. 
The glycosylation pathway is, however, sensitive to even subtle changes of the surrounding 
intracellular environment. This leads to interruptions in glycosyltransferase activities. Hence in 
pathological conditions, the final structure of synthesised glycans may be significantly altered. 
Aberrant glycosylation patterns are a fundamental characteristic of tumorigenesis, suggesting 
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that modified glycoproteins with tumour-specific glycan moieties are viable diagnostic targets 
for cancer (Ferens-Sieczkowska et al., 2012; Gilgunn et al., 2013).  
At the outset of this project, it was hypothesised that altered glycosylation patterns of PSA 
isoforms will help distinguish between indolent and aggressive forms of prostate cancer 
(Saldova et al., 2011).  It was initially envisaged that antibodies generated from this research 
would be transferred to a platform for selective isolation of PSA isoforms and subsequent 
glycoanalysis.  Proof of concept studies were carried out with anti-PSA polyclonal antibodies 
and anti-fPSA scFv B8 (results not shown), however, a minimum of 30 μg of glycoprotein was 
needed for the associated glycan analysis. Irrespective of the high affinity anti-fPSA scFv B8 had 
for fPSA, there was not enough PSA protein in the patient’s samples to carry out the analysis. 
Hence, whole serum N-glycan profiling was carried out in an attempt to develop a novel glyco-
marker.  The methods used to generate this data were specifically designed for the discovery 
of clinical glyco-biomarkers from human serum.  
A combination of glycans was identified that can distinguish between indolent, significant and 
aggressive prostate cancer with better sensitivity and specificity than current clinical models. 
This combination of glycans, in particular, increase in A4G4S4 and decreases in A3G3S3 are 
highly specific in predicting the outcome of PCa patients and can provide a novel, non-invasive 
approach to diagnosing PCa. There are currently no effective systems which have been 
clinically proven to decipher clinically insignificant prostate cancer and aggressive prostate 
cancer that can be successfully applied for improved patient welfare. This novel-glyco-
biomarker panel should aid in the reduction of ‘over-diagnosis’ of clinically insignificant PCa 
and help stratify patients into the most appropriate treatment option for their individual 
prostatic disease.  
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In conclusion, this body of research has the potential to provide clinicians with novel tools for 
improving PCa diagnostics. It is hoped that the findings presented can be translated into new 
approaches to greatly improve patient outcomes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
252 
 
 
 
 
 
 
 
 
Appendices 
 
 
 
 
 
 
 
 
253 
 
Appendix One 
Glossary of important X-ray crystallographic terms for determining quality of diffracted data 
(Acharya and Lloyd, 2005; Wlodawer et al., 2008) 
Parameter Description 
B-factor Also referred to as temperature factor or thermal vibration factor. This is 
a measure of the thermal mobility, i.e. much an atom oscillates or 
vibrates around the position specified in the model. The majority of 
structures are defined using isotropic B-factors (equal in all directions) 
but can also be anisotropic (not equal in all directions). Diagrams of the 
model are depicted by colour where red ("hot") indicates high values of B 
and blue ("cold") indicates low values of B. 
Completeness The number of observed reflections measured in a data set, expressed as 
a percentage of the total number of reflections present at the specified 
resolution. Structures approaching 100% are good quality structures.  
Ramachandran 
Plot 
This is a plot of the conformational angles around the polypeptide 
backbone compared with those most favoured for various protein 
structural elements 
Resolution Resolution is measured in Å and defines the level of detail, or the 
minimum distance between structural features that can be distinguished 
in an electron-density map. The mean resolution for X-ray 
crystallographic results in the Protein Data Bank is 2.21 Å (June, 2015). 
R-factor  A global reliability, usually expressed as percent that measures the 
goodness-of-fit between the refined structure model and the actual X-ray 
diffraction data. Well defined biological structures are expected to have 
an R-factor < 20%. 
Rmerge A statistical measure of how well the X-ray diffracted data scale together. 
This is often represented for data from the highest-resolution shell, 
allowing the model user to evaluate the reliability of data at the highest 
resolution used. 
Signal-to-noise 
ratio 
This is the X-ray diffraction signal-to-noise ratio, denoted (I/σ). Generally 
values of > 2 are required for good-quality structures.  
 
 
 
 
254 
 
Appendix Two 
X-ray crystallography statistics for each mutant fragment and anti-fPSA scFv B8-rPSA 
complex. 
 C97/100S C97/100A C97/100A* Complex 
Resolution Range (Å) 45.14  - 1.5 
(1.554  - 1.5) 
36.77  - 1.7 
(1.761  - 1.7) 
41.66  - 1.8 
(1.864  - 1.8) 
38.62  - 1.95 
(2.02  - 1.95) 
Space Group P61 2 2 P61 2 2 P 21 21 21 P1 21 1 
a, b, c (Å) 52.702, 
52.702, 
304.053 
52.789, 52.789, 
309.381 
51.994, 66.79, 
69.632 
107.051, 52.053, 
111.943 
 α, β, γ (o) 90, 90, 120 90, 90, 120 90, 90, 90 90, 116.496, 90 
Number of molecules 
in ASU 
1 1 1 4 
Unique Reflections 41690 (4040) 26107 (2518) 23098 (2273) 80772 (7788) 
Completeness 100.00 
(100.00) 
88.27 (87.64) 100.00 (100.00) 99.68 (96.76) 
I/σI 16.68 (5.15) 12.86 (2.01) 13.70 (1.76) 16.63 (2.87) 
Wilson β-Factor 14.11 21.30 22.96 22.35 
Rwork 0.1728 
(0.2120) 
0.1726 (0.2487) 0.1852 (0.2799) 0.1568 (0.2121) 
Rfee 0.2023 
(0.2727) 
0.2083 (0.3103) 0.2037 (0.3325) 0.2041 (0.2699) 
RMS (Bonds) 0.010 0.014 0.007 0.007 
RMS (Angles) 1.30 1.44 1.21 1.00 
Ramachandran 
Favoured (%) 
98 98 96 98 
Ramachandran 
Outliers (%) 
0 0 0 0 
Average β-factor 19.80 29.10 29.60 29.40 
         Macromolecule 16.90 27.90 28.00 28.30 
         Ligands 16.50 40.10 46.20 - 
         Solvent 33.10 36.90 41.10 37.30 
Mol probity score 
(percentile) 
1.20 (97th) 1.50 (91st) - 0.99 (100th)  
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Appendix Three 
 
Sequencing analysis of antibody clones 
Highlighted in yellow: start and end of complementary determining regions (CDR- light 1, 2, 3 
and heavy 1, 2, 3); Highlighted in red: linker; Highlighted in green; Histidine tag (6xHis Tag) and 
hemagglutinin (HA-Tag).   
 
Anti-cPSA scFv 2D2SG 
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Anti-cPSA scFv 2D8SG 
 
 
Anti-fPSA scFv B8 
 
 
 
 
 
257 
 
Anti-fPSA scFvB8_Ser MT 
 
 
 
 
Anti-fPSA scFv B8 _Ala MT 
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Appendix Four 
 
Summary table of N-glycans released from IgY purified from serum (Saldova et al., 2014). 
The Hydrophilic interaction liquid chromatography (HILIC)-chromatogram was separated into 
40 peaks and structural assignment carried out using established methods (Royle et al., 2008) 
and the software tool GlycoBase (https://glycobase.nibrt.ie). * indicates sialic acid linkages; 
Weak Anion Exchange (WAX) fractions were separated out into 5 fractions; S1: Monosialylated, 
S2: disialylated, S3: Trisialylated, S3J: Trisialylated and S4: Tetrasialylated.   All monosialylated 
glycans are linked by α2-3 and α2-6; Disialylated glycans have all combinations of α2-3 and α2-
6 linkages [i.e. (3, 3), (3, 6) and (6, 6)]; Trisialylated glycans have all combinations of α2-3 and 
α2-6 linkages except (6, 6, 6) [i.e. (3, 3, 3), (3, 3, 6) and (3, 6, 6)]; and Tetrasialylated glycans 
have all combinations of α2-3 and α2-6 linkages [i.e. (3,3,3,3), (3,3,3,6) , (3,3,6,6) and (6,6,6,6)]. 
Structure abbreviations: all N-glycans have two core GlcNAcs; F at the start of the abbreviation 
indicates a core-fucose α1,6-linked to the inner GlcNAc; Mx, number (x) of mannose on core 
GlcNAcs; Ax, number of antenna (GlcNAc) on trimannosyl core; A2, biantennary with both 
GlcNAcs as β1,2-linked; A3, triantennary with a GlcNAc linked β1,2 to both mannose and the 
third GlcNAc linked β1,4 to the α1,3 linked mannose; A3’ , isomer with the third GlcNAc linked 
β1-6 to the α1-6 linked mannose; A4, GlcNAcs linked as A3 with additional GlcNAc β1,6 linked 
to α1,6 mannose; B, bisecting GlcNAc linked β1,4 to β1,3 mannose; Gx, number (x) of β1,4 
linked galactose on antenna; F(x), number (x) of fucose linked α1,3 to antenna GlcNAc; Sx, 
number (x) of sialic acids linked mostly to galactose (Structures with more sialic acids then 
galactoses may have some sialic acids linked to GlcNAc or another sialic acid in form of 
polysialic acid.); GU: Glucose unit. 
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Peak Structure Peak 
area 
(%) 
GU Experimental 
mass (m/z) 
Theoretical 
mass (m/z) 
Ion 
 
5 M4 
 
 
 
0.02 5.34 --- 1191.4421 [M-H]
-
 
9 
M5 
 
 
 
2.17 6.14 
1353.514 
676.2448 
1353.4949 
676.2438 
[M-H]
-
 
[M-2H]
-2
 
FA2B 
 
 
 891.8257 
 
891.8390 
 
[M-2H]
-2
 
 
FA3 
 
 
 
A2[6]G1 
 
 
 
798.2899 798.2968 [M-2H]
-2
 
10 
A2[3]G1 
 
 
 
0.22 6.51 
798.2899 798.2968 [M-2H]
-2
 
A3G1 
 
 
 
 
 
 
 
 
899.8270 
 
 
 
 
 
 
899.8365 
 
 
 
 
 
[M-2H]
-2
 
 
A2BG1 
 
 
 
11 
M5A1 
 
 
 
0.17 6.61 
 
777.7769 
 
 
777.7835 
 
 
[M-2H]
-2
 
 
M4A1G1 
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Peak Structure Peak 
area 
(%) 
GU Experimental 
mass (m/z) 
Theoretical 
mass (m/z) 
Ion 
 
12 
FA3G1 
 
 
 
2.26 6.90 
972.8573 
 
972.8654 
 
[M-2H]
-2
 
 
FA2BG1 
 
 
 
13 
FA3G1 
 
 
 
1.22 7.04 
972.8509 
 
972.8654 
 
[M-2H]
-2
 
 
FA2BG1 
 
 
 
14 
M6 
 
 
 
0.44 7.14 
757.2596 757.2702 [M-2H]
-2
 
A2G2 
 
 
 
879.3184 879.3232 [M-2H]
-2
 
15 
A2BG2 
 
 
 
0.92 7.32 
 
 
980.8661 
 
 
 
980.8629 
 
 
 
[M-2H]
-2
 
 
A2[6]G1S1* 
 
 
 
943.8293 943.8445 [M-2H]
-2
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Peak Structure Peak 
area 
(%) 
GU Experimental 
mass (m/z) 
Theoretical 
mass (m/z) 
Ion 
 
16 
FA2G2 
 
 
 
0.59 7.52 
952.3262 952.3521 [M-2H]
-2
 
M5A1G1 
 
 
 
858.7934 858.8099 [M-2H]
-2
 
A2[3]G1S1* 
 
 
 
943.8293 943.8445 [M-2H]
-2
 
17 
FA2BG2 
 
 
 
5.14 7.69 
1053.8828 
 
1053.8918 
 
[M-2H]
-2
 
 
FA3G2 
 
 
 
A3G1S1* 
 
 
 
--- 1045.3842 [M-2H]
-2
 
A2BG1S1* 
 
 
 
--- 
 
 
1045.3842 
 
 
[M-2H]
-2
 
M4A1G1S1* 
 
 
 
923.3214 923.3312 [M-2H]
-2
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Peak Structure Peak 
area 
(%) 
GU Experimental 
mass (m/z) 
Theoretical 
mass (m/z) 
Ion 
 
18 
FA3’G2 
 
 
 
1.60 7.93 
1053.8828 1053.8918 [M-2H]
-2
 
FA2BG1S1* 
 
 
 1118.4037 
 
1118.4131 
 
[M-2H]
-2
 
 
FA3G1S1* 
 
 
 
19 
M7 
 
 
 
0.51 8.02 
838.2908 838.2966 [M-2H]
-2
 
FA2BG1S1* 
 
 
 1118.4243 
 
1118.4131 
 
[M-2H]
-2
 
 
FA3G1S1* 
 
 
 
20 
A3G3 
 
 
 
16.38 8.36 
--- 1061.8893 [M-2H]
-2
 
A2G2S1* 
 
 
 
1024.8506 1024.8709 [M-2H]
-2
 
A2G2S3* 
 
 
 
--- 1315.9663 [M-2H]
-2
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Peak Structure Peak 
area 
(%) 
GU Experimental 
mass (m/z) 
Theoretical 
mass (m/z) 
Ion 
 
 
21 
A3BG3 
 
 
 
0.65 8.51 
--- 1163.4290 [M-2H]
-2
 
A2G2S3* 
 
 
 
--- 1315.9663 [M-2H]
-2
 
A2BG2S3* 
 
 
 
--- 1417.5060 [M-2H]
-2
 
 
22 
FA3G3 
 
 
 
2.12 8.64 
 
1134.9095 
 
1134.9182 
 
[M-2H]
-2
 
A2BG2S1* 
 
 
 
1126.4175 1126.4106 [M-2H]
-2
 
A3’G3 
 
 
 
--- 1061.8893 [M-2H]
-2
 
23 
M8 
 
 
 
4.00 8.78 
919.3203 919.3230 [M-2H]
-2
 
FA2G2S1* 
 
 
 
1097.8785 1097.8998 [M-2H]
-2
 
 
M5A1G1S1* 
 
 
 
 
1004.3476 
 
1004.3576 
 
[M-2H]
-2
 
FA2G2S3* 
 
 
 
--- 1388.9953 [M-2H]
-2
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Peak Structure Peak 
area 
(%) 
GU Experimental 
mass (m/z) 
Theoretical 
mass (m/z) 
Ion 
 
24 
FA3’G3 
 
 
 
8.68 9.00 
1134.9095 
 
1134.9182 
 
[M-2H]
-2
 
 
FA2BG2S1* 
 
 
 1199.4524 
 
1199.4395 
 
[M-2H]
-2
 
 
FA3G2S1* 
 
 
 
25 
FA4G3 
 
 
 
3.93 9.23 
--- 1236.4579 [M-2H]
-2
 
FA3’G2S1* 
 
 
 
1199.4240 1199.4395 [M-2H]
-2
 
A2G2S2* 
 
 
 
1170.4113 1170.4186 [M-2H]
-2
 
FA2BG2S3* 
 
 
 
--- 
1490.5349 
993.3542 
[M-2H]
-2 
[M-3H]
-3
 
M5A1G1S3* 
 
 
 
--- 
1295.4530 
863.2996 
[M-2H]
-2 
[M-3H]
-3
 
FA3G2S3* 
 
 
 
--- 
1490.5349 
993.3542 
[M-2H]
-2 
[M-3H]
-3
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Peak Structure Peak 
area 
(%) 
GU Experimental 
mass (m/z) 
Theoretical 
mass (m/z) 
Ion 
 
26 
M9 
 
 
 
5.11 9.51 
1000.3368 1000.3495 [M-2H]
-2
 
A3G3S1* 
 
 
 
1207.4227 1207.4370 [M-2H]
-2
 
 
27 
A3BG3S1* 
 
 
 
24.92 9.65 
--- 1308.9767 [M-2H]
-2
 
FA3’G2S3* 
 
 
 
--- 
1490.5349 
993.3542 
[M-2H]
-2 
[M-3H]
-3
 
FA2BG1S4* 
 
 
 
--- 
1555.0562 
1036.3684 
[M-2H]
-2 
[M-3H]
-3
 
FA3G1S4* 
 
 
 
--- 
1555.0562 
1036.3684 
[M-2H]
-2 
[M-3H]
-3
 
A2G2S2* 
 
 
 
1170.4043 1170.4186 [M-2H]
-2
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Peak Structure Peak 
area 
(%) 
GU Experimental 
mass (m/z) 
Theoretical 
mass (m/z) 
Ion 
 
28 
FA3G3S1* 
 
 
 
0.67 9.82 
--- 1280.4659 [M-2H]
-2
 
A4G4 
 
 
 
1244.4453 1244.4554 [M-2H]
-2
 
A3’G3S1* 
 
 
 
 
1207.4299 
 
 
1207.4370 
 
 
 
[M-2H]
-2
 
 
A2BG2S2* 
 
 
 
--- 1271.9583 [M-2H]
-2
 
A4G4S4* 
 
 
 
--- 
1826.6462 
1217.4284 
[M-2H]
-2 
[M-3H]
-3
 
29 
FA3’G3S1* 
 
 
 
0.24 9.90 
--- 1280.4659 [M-2H]
-2
 
FA2G2S2* 
 
 
 
1243.4315 1243.4476 [M-2H]
-2
 
30 
FA4G4 
 
 
 
1.19 10.06 
--- 1317.4843 [M-2H]
-2
 
FA2BG2S2* 
 
 
 
 
 
 
 
 
1344.9840 
 
 
 
 
 
 
1344.9872 
 
 
 
 
 
[M-2H]
-2
 
 
FA3G2S2* 
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Peak Structure Peak 
area 
(%) 
GU Experimental 
mass (m/z) 
Theoretical 
mass (m/z) 
Ion 
 
31 
M9Glc 
 
 
 
10.11 10.24 
1081.3684 1081.3759 [M-2H]
-2
 
FA3’G2S2* 
 
 
 
1344.9840 1344.9872 [M-2H]
-2
 
FA2G2S4* 
 
 
 
--- 
1534.5430 
1022.6929 
[M-2H]
-2 
[M-3H]
-3
 
A3G3S2* 
 
 
 
1352.9702 1352.9847 [M-2H]
-2
 
32 A3BG3S2* 
 
 
 
0.97 10.67 --- 1454.5244 [M-2H]
-2 
33 A3’G3S2* 
 
 
 
1.11 10.80 1352.9626 1352.9847 [M-2H]
-2
 
 
 
 
 
34 
 
 
 
FA3G3S2* 
 
 
 
0.65 11.17 
--- 1426.0137 [M-2H]
-2 
A3G3S3* 
 
 
 
1498.5284 
998.6880 
1498.5324 
998.6858 
[M-2H]
-2
 
[M-3H]
-3
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Peak Structure Peak 
area 
(%) 
GU Experimental 
mass (m/z) 
Theoretical 
mass (m/z) 
Ion 
 
35 
FA3’G3S2* 
 
 
 
0.06 
 
11.33 
 
--- 1426.0137 [M-2H]
-2
 
FA4G3S2* 
 
 
 
--- 1527.5533 [M-2H]
-2
 
A3G3S3* 
 
 
 
1498.5126 
998.6880 
1498.5324 
998.6858 
[M-2H]
-2
 
[M-3H]
-3
 
A3BG3S3* 
 
 
 
--- 
1673.1010 
1115.0649 
[M-2H]
-2
 
[M-3H]
-3
 
36 
A3G3S3* 
 
 
 
0.10 11.46 
1498.5284 
998.6880 
1498.5324 
998.6858 
[M-2H]
-2
 
[M-3H]
-3
 
 
A4G4S2* 
 
 
 
1535.5466 1535.5508 [M-2H]
-2
 
A2G2S3* 
 
 
 
--- 
1315.9663 
876.9757 
[M-2H]
-2
 
[M-3H]
-3
 
37 
 
A2G2S3* 
 
 
 2.81 11.59 
--- 
1315.9663 
876.9757 
[M-2H]
-2
 
[M-3H]
-3
 
A3G3S3* 
 
 
 
1498.5284 
998.6880 
1498.5324 
998.6858 
[M-2H]
-2
 
[M-3H]
-3
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Peak Structure Peak 
area 
(%) 
GU Experimental 
mass (m/z) 
Theoretical 
mass (m/z) 
Ion 
 
38 
A3’G3S3* 
 
 
 
0.13 
 
11.92 
 
--- 
1498.5324 
998.6858 
[M-2H]
-2
 
[M-3H]
-3
 
A3BG3S3* 
 
 
 
--- 
1600.0721 
1066.3790 
[M-2H]
-2
 
[M-3H]
-3
 
A2BG2S3* 
 
 
 
--- 
1417.5060 
944.6682 
[M-2H]
-2
 
[M-3H]
-3
 
FA3G3S3* 
 
 
 
--- 
1571.5614 
1047.3718 
[M-2H]
-2
 
[M-3H]
-3
 
39 
FA2G2S3* 
 
 
 0.52 12.09 
--- 
1388.9953 
925.6611 
[M-2H]
-2
 
[M-3H]
-3
 
FA3G3S3* 
 
 
 
--- 
1571.5614 
1047.3718 
[M-2H]
-2
 
[M-3H]
-3
 
40 
M5A1G1S3* 
 
 
 
0.10 12.66 
--- 
1295.4530 
863.2996 
[M-2H]
-2
 
[M-3H]
-3
 
A3'G3S3* 
 
 
 
 
1498.5284 
998.6880 
 
1498.5324 
998.6858 
[M-2H]
-2
 
[M-3H]
-3
 
A4G4S3* 
 
 
 
--- 
1681.0985 
1120.3966 
[M-2H]
-2
 
[M-3H]
-3
 
FA2BG2S3* 
 
 
 
--- 
1490.5349 
993.3542 
[M-2H]
-2
 
[M-3H]
-3
 
A3G3S4* 
 
 
 
--- 
1644.0801 
1095.7177 
[M-2H]
-2
 
[M-3H]
-3
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Appendix Five 
 
Clinical data for prostate cancer patient cohort; serum samples for whole serum N-glycome analysis 
Source: Prostate Cancer Research Consortium (PCRC) BioResource 
RP: Radical Prostatectomy, PSA: Prostate Specific Antigen, DRE: Digital Rectal Examination 
 
PCRC 
NUMBER 
Cohort Biopsy 
Gleason A 
Biopsy 
Gleason B 
Biopsy 
Gleason 
Score 
RP 
Gleason A 
RP 
Gleason B 
RP 
Gleason 
Score 
PSA 
(ng/mL) 
Age at 
RP 
DRE 
 
 
81 Indolent 2 3 5 3 2 5 9.5 64  
92 Indolent 3 2 5 3 2 5 8.45 66  
93 Indolent    2 3 5 4.4 65 Negative 
97 Aggressive    4 3 7 6.1 65 Positive 
104 Aggressive 4 4 8 4 3 7 6.5 55  
114 Indolent    3 2 5 4.5 52  
117 Aggressive 3 3 6 3 4 7 6.5 69 Negative 
121 Aggressive 4 3 7 3 4 7 11.3 60 Negative 
122 Aggressive 4 5 9 4 3 7 8.82 63 Negative 
124 Aggressive 3 4 7 4 3 7 6.2 69 Negative 
151 Indolent 2 3 5 3 2 5 10.7 55 Positive 
161 Indolent 2 3 5 3 2 5 5.3 61 Negative 
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PCRC 
NUMBER 
Cohort Biopsy 
Gleason 
A 
Biopsy 
Gleason B 
Biopsy 
Gleason 
Score 
RP 
Gleason A 
RP 
Gleason B 
RP 
Gleason 
Score 
PSA 
(ng/mL) 
Age at 
RP 
DRE 
 
 
181 Significant 3 4 7 3 4 7 8.8 64 Negative 
168 Indolent 3 4 7 3 3 6 5.3 49 Positive 
185 Indolent 2 3 5 3 3 6 8.3 59  
189 Aggressive 4 3 7 4 3 7 6.3 59 Positive 
198 Indolent 2 3 5 2 3 5 10.4 68 Negative 
220 Aggressive 3 4 7 4 3 7 7.3 67  
223 Indolent 3 2 5 2 3 5 6.5 62  
233 Indolent 2 3 5 2 3 5 4.5 59 Negative 
234 Indolent 2 3 5 2 3 5 0.7 54 Positive 
242 Aggressive 4 3 7 4 4 8 8.7 65  
246 Indolent 2 3 5 3 2 5 7.7 58 Negative 
258 Significant 3 4 7 3 4 7 7.8 52 Negative 
260 Significant 3 4 7 4 4 8 8.1 66 Positive 
261 Aggressive 3 3 6 4 4 8 8.1 67 Negative 
278 Indolent 3 3 6 3 3 6 8.3 64 Negative 
288 Aggressive 4 5 9 4 3 7 5.3 58  
298 Indolent 3 3 6 3 3 6 9.2 55  
303 Indolent 3 3 6 3 3 6 12 59 Negative 
311 Indolent 3 3 6 3 3 6  54 Negative 
314 Indolent 3 3 6 3 3 6 2.27 51 Negative 
315 Indolent 3 3 6 3 2 5 10.4 56 Negative 
317 Indolent 3 3 6 3 3 6 3.9 49 Negative 
318 Aggressive  3  3 4 7 4 66 Positive 
321 Indolent 3 3 6 3 3 6 7.45 61  
335 Aggressive 3   3 4 7 8.2 62 Negative 
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PCRC 
NUMBER 
Cohort Biopsy 
Gleason 
A 
Biopsy 
Gleason B 
Biopsy 
Gleason 
Score 
RP 
Gleason A 
RP 
Gleason B 
RP 
Gleason 
Score 
PSA 
(ng/mL) 
Age at 
RP 
DRE 
 
 
338 Aggressive 3 4 7 4 4 8 8 56  
341 Indolent 2 3 5 3 2 5 1.2 60 Negative 
344 Aggressive 3 3 6 4 3 7 17 54  
363 Indolent 2 3 5 3 2 5 6 52 Negative 
365 Significant 3 4  4 3 7 13.4 64 Positive 
383 Aggressive 4 3 7 4 3 7 9.4 71 Negative 
387 Significant 3 3 6 3 4 7 6.9 52  
391 Aggressive 4 4 8 4 3 7 18.7 60 Negative 
396 Aggressive 3 4 7 3 4 7 4.2 52 Negative 
405 Indolent 3 3 6 3 3 6 1.3 60  
407 Indolent 3 3 6 3 3 6 5.93 64  
411 Significant 3 3 6 3 4 7 6.1 55  
416 Significant 4 4 8 3 4 7 6.39 67  
419 Significant 3 3 6 4 4 8 6.3 73 Negative 
421 Indolent 3 3 6 3 3 6 7.01 56 Negative 
424 Indolent 3 4 7 3 3 6 5.92 58 Negative 
427 Indolent 3 3 6 3 3 6 12.3 58 Negative 
446 Indolent 3 3 6 3 3 6 6.2 63  
447 Significant 3 4 7 3 4 7 5.71 68 Negative 
450 Significant 3 3 6 3 4 7 12.3 57  
451 Aggressive    3 4 7 10.2 66  
452 Significant 4 3 7 3 4 7 3.5 59 Negative 
464 Indolent 3 3 6 3 3 6 9.8 62 Negative 
467 Aggressive 4 4 8 4 3 7 15.6 55 Positive 
471 Significant 3 3 6 3 4 7 4.8 60 Positive 
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PCRC 
NUMBER 
Cohort Biopsy 
Gleason 
A 
Biopsy 
Gleason B 
Biopsy 
Gleason 
Score 
RP 
Gleason A 
RP 
Gleason B 
RP 
Gleason 
Score 
PSA 
(ng/mL) 
Age at 
RP 
DRE 
 
 
472 Indolent 3 3 6 3 3 6 3.69 54 Negative 
483 Indolent 3 3 6 3 3 6 0.9 61 Positive 
479 Aggressive 3 4 7 4 3 7 7.9 63 Positive 
487 Indolent 2 3 5 3 3 6  70  
493 Significant 3 3 6 3 4 7 2.8 56 Negative 
497 Aggressive 3 4 7 4 3 7 5.5 69 Positive 
502 Aggressive 3 4 7 4 3 7  57  
503 Significant 4 3 7 4 4 8 13.1 68 Positive 
504 Significant 3 4 7 3 4 7 5.3 65 Negative 
514 Significant 3 3 6 3 4 7 11.9 58 Negative 
524 Significant 3 4 7 3 4 7 14.7 56 Negative 
528 Aggressive 3 3 6 3 4 7 3.6 60 Negative 
555 Indolent 3 3 6 3 3 6 4.8 67 Negative 
576 Significant 4 3 7 3 4 7 8.3 55 Negative 
577 Indolent 3 3 6 3 3 6 9.6 66  
592 Aggressive 4 5 9 3 4 7 7.3 67 Negative 
602 Significant 3 3 6 4 3 7 6.79 68 Negative 
604 Aggressive 3 4 7 4 4 8 7 63 Negative 
605 Significant 3 3 6 3 4 7 5.66 63  
607 Aggressive 4 4 8 3 4 7 13.2 62 Negative 
610 Aggressive 4 5 9 4 4 8 4.1 73 Positive 
611 Aggressive 4 3 7 4 3 7 8.58 65 Negative 
612 Significant 3 4 7 3 4 7 6.3 61 Negative 
615 Indolent 3 3 6 3 3 6 5 59  
616 Aggressive 3 4 7 4 4 8 5.2 55 Negative 
 
275 
 
PCRC 
NUMBER 
Cohort Biopsy 
Gleason 
A 
Biopsy 
Gleason B 
Biopsy 
Gleason 
Score 
RP 
Gleason A 
RP 
Gleason B 
RP 
Gleason 
Score 
PSA 
(ng/mL) 
Age at 
RP 
DRE 
 
 
619 Indolent 3 4 7 3 2 5 9.5 56 Negative 
621 Significant 3 3 6 3 4 7 5.88 56 Positive 
628 Significant 3 4 7 3 4 7 4.8 61 Negative 
630 Significant 3 4 7 3 4 7 2.8 51  
635 Aggressive 3 3 3 6 3 4 7 60  
641 Significant 3 4 7 3 4 7 5.7 58 Negative 
642 Aggressive 4 3 7 4 3 7 5.1 64 Positive 
643 Significant 3 4 7 3 4 7 11.9 59 Negative 
644 Aggressive 3 4 7 3 4 7 6.7 62  
647 Significant 4 3 7 3 4 7 3.7 61 Positive 
654 Significant 3 4 7 3 4 7 7.2 62  
655 Aggressive 4 3 7 3 4 7 6.5 64 Positive 
659 Significant 3 4 7 3 4 7 3.3 49 Negative 
664 Indolent 3 3 6 3 3 6 5 60 Negative 
665 Aggressive 3 4 7 3 4 7 5 59  
673 Significant 3 4 7 3 4 7 5.2 59 Negative 
679 Aggressive 3 3 6 3 4 7 7.2 58  
680 Aggressive 3 3 6 4 3 7 11.2 56  
681 Aggressive 4 4 8 4 3 7 6.6 69 Positive 
685 Significant 3 4 7 3 4 7 4.9 55 Negative 
704 Significant 3 3 6 3 4 7 7.1 60 Negative 
705 Indolent 3 3 6 3 3 6 3.8 57 Negative 
706 Aggressive 3 4 7 4 3 7 3.6 68  
713 Aggressive 3 4 7 3 4 7 5.3 67 Negative 
717 Aggressive 4 4 8 3 4 7 5.6 59 Negative 
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724 Aggressive    4 4 8 3.1 62  
732 Aggressive 3 4 7 3 4 7 8.4 74 Negative 
735 Aggressive 4 3 7 3 4 7 3.2 61 Positive 
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